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GENERAL ASPECTS OF NON-HODGKIN’S LYMPHOMA 
Non-Hodgkin’s lymphoma’s (NHLs) are a heterogeneous group of  hematological 
malignancies with a large variation in clinical presentation, morphological appearance 
and prognosis. The NHLs make up the largest group (40-50%) of  all hematological 
malignancies. In 2007, 17.700 people in the Netherlands had a non-Hodgkin’s lymphoma. 
Of  these cases, 1.2/1000 was male and 1.2/1000 was female. The number of  newly 
diagnosed NHL was 2800. In the same year, 1061 succumbed to the disease (585 male, 
476 female)1. 
 NHLs almost always arise from cells of  the immune system resulting, in either 
B-cell or T-cell lymphomas. Most (approximately 85%) NHLs arise from their normal 
B-cell counterparts whereas a minority (approximately 15%) is derived from T-cells. Of  
the NHLs, approximately 65% arise in lymph nodes (nodal type), whereas the remaining 
35% can arise in any organ (extra-nodal type). The most recent WHO classifi cation 
contains about 50 different (clinico-pathological) entities. Each entity is considered to 
have a normal physiological counterpart refl ecting the various differentiation stages in the 
lymphoid organs or bone marrow1. 
 Diffuse large B-cell lymphoma (DLBCL) as defi ned by the World Health 
Organization (WHO) 2008 classifi cation is the most frequent lymphoma subtype 
comprising approximately 40% of  the aggressive NHL. More than 50% of  the patients 
are at least 60 years of  age. The addition of  the anti-CD20 antibody rituximab to 
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or other CHOP-
like regimens (R-CHOP) has improved the clinical outcome signifi cantly, the 3 year 
overall survival (OS) being approximately 30 – 40% without rituximab, and 60 – 80% 
with rituximab. Nevertheless, the survival of  both elderly and young patients with NHL 
still remains unsatisfactory, making improvement of  the current therapeutic strategies 
necessary2,3,4,5,6,7,8,9.
 In DLBCL, the international prognostic index (IPI) is one of  the most useful tools 
to distinguish patients with a good from those with a poor prognosis10,11. However, it is 
a clinical classifi cation system insuffi cient in itself  to fully encompass the widely variable 
biological aspects of  this malignancy. Therefore, biological classifi cation systems have 
been developed in order to improve outcome prediction. The most recently described 
for this purpose employs DNA micro-array techniques. Using gene expression profi ling 
(GEP), two subtypes of  DLBCL have been identifi ed: a germinal center B-cell (GCB) 
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subtype with a relatively favorable clinical outcome and a ABC (activated B-cell) subtype 
with a relatively unfavorable clinical outcome12,13,14. 
 GEP is still not a readily accessible technique in daily clinical practice. Therefore, 
histological subclassifi cation systems using immunohistochemistry were subsequently 
designed as a substitute. Hans et al published the proof  of  principle demonstrating 
the possibilities by using only 3 antibodies (CD10, BCL6 and MUM1) in an algorithm 
which could identify patients with a favorable GCB or a non-favorable ABC phenotype. 
The outcome correlated highly with the GEP results on the very same tissue samples15. 
However, these fi ndings could not always be confi rmed by other investigators, indicating 
the need for either (additional) novel prognostic markers and/or improvement of  the 
technique16,17. 
GENERAL ASPECTS OF ACUTE MYELOID LEUKEMIA 
In Western Europe, the mean incidence of  acute myeloid leukemia (AML) is approximately 
2-3/100000. In the Netherlands, approximately 450 new cases of  AML are being 
diagnosed each year. AML occurs in all age groups, but the incidence rises with higher 
age. It is the most common type of  acute leukemia in adults. Two-thirds of  the people 
diagnosed with AML cases are 60 years or older. The 5-year overall survival of  patients 
younger than 60 years old is approximately 35 – 40%, but this drops dramatically to 
only 10% when patients are older than 60 years. Thus, age is an important parameter 
predicting the clinical outcome of  AML. In addition, intrinsic cell biological factors such 
as cytogenetic and molecular determinants are also important in predicting a favorable or 
non-favorable outcome of  AMLs10. 
 The disease is characterized by a large variation in clinical, morphologic, 
cytogenetic, immunophenotypic and molecular features. Analogous to NHL, maturation 
and differentiation arrest at various stages of  myelopoiesis is seen in this disease with 
accumulation of  immature cell types in the bone marrow. Up till now, it is the predominant 
immature myeloid cell which determines the AML subtype, but this is expected to 
change in the near future, as the molecular pathogenesis is being unraveled10. To classify 
myeloid leukemias, various methods to determine the characteristics of  the malignant 
immature myeloid cell are being used. These include morphology, cytochemistry, 
immunophenotyping, cytogenetic and molecular genetic studies. 
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The type and percentage of  blasts which still forms the basis for diagnosis and 
classifi cation of  myeloid neoplasms are determined with morphological analysis, 
including the study of  peripheral blood, bone marrow aspirates and/or trephine biopsies. 
Cytochemistry and other special stains are used to further determine the lineage of  the 
blasts. This characterization process is refi ned using multi parameter fl owcytometry or 
immunohistochemistry, resulting in a more specifi c classifi cation. Immunophenotypic 
characteristics of  AML sub types are commonly quite heterogeneous, probably due to 
genetic diversity. Expression of  markers such as CD7, CD9, CD11b, CD14, CD56 and 
CD34 have been reported to be associated with adverse prognosis, although controversial 
results have been reported regarding the clinical relevance of  these antigens10. 
 Additional genetic studies, such as gene rearrangement analysis by RT-PCR or 
FISH and mutation detection by gene sequencing or allelic PCR, may be performed 
in order to further characterize (defi ne) AML subtypes. This is illustrated by the fact 
that mutation analysis has revealed novel important diagnostic and prognostic subtypes. 
Examples of  mutations in AML which have a diagnostic and prognostic impact are RAS, 
JAK2, PTPN11, NMP1, CEBPA, RUNX1, KIT and FLT3. Nevertheless, as in NHL, 
ongoing research is still necessary to defi ne novel genes or their products to enable more 
patient-tailored treatment modalities2,3. 
THE DISCOVERY OF THE CANNABINOID RECEPTOR 2 (CB2) 
GENE AS A POTENTIAL ONCOGENE
The heterogenic prognoses of  both NHL and AML are based on host-related factors and 
specifi c genetic or biologic alterations. Many approaches have been tried to unravel the 
genetic basis of  the cell biological processes which determine the clinical outcome. Based 
on the results of  these attempts, several clinical or biological classifi cation systems have 
been designed to improve the prediction of  outcome in these malignancies10.
 Retroviral insertional mutagenesis (RIM) is one of  the more effective approaches 
to identify biologic/genetic factors i.e. transforming genes in leukemia and lymphoma. By 
means of  RIM, several proto-oncogenes involved in leukemia and lymphoma have been 
identifi ed18,19,20. Mice injected with a retrovirus develop leukemias and lymphomas within 
a few months. The ability of  these retroviruses to cause malignancy is based on the fact 
that they integrate into the host genome and interfere with normal transcription and or 
translation of  their target genes. This process in turn may lead to gene over-expression or, 
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in case of  tumor suppressor genes, gene inactivation, both having a transforming effect 
which in a number of  cases ultimately lead to cancer. 
 The identifi cation of  the target proto-oncogenes and tumor suppressor genes is 
done by identifying the same genomic locus in independent tumors, i.e. the common virus 
integration sites (cVIS). Using this technique, well-known proto-oncogenes and tumor 
suppressor genes such as EVI1 and P53 respectively, have been found21,22,23. Using RIM, 
the group of  Delwel has identifi ed a cVIS, EVI11 (ecotropic virus integration 11) in mice. 
Further research has demonstrated that viral insertions also occurred in the gene encoding 
the peripheral cannabinoid receptor Cb2, resulting in aberrant mRNA expression, which 
in turn leads to over-production of  the protein24. 
CANNABINOID RECEPTORS AND THEIR LIGANDS
The cannabinoid receptors are members of  the family of  seven trans membrane 
G-protein-coupled receptors (GPCR) (Figure 1). Two cannabinoid receptors have been 
identifi ed using radiolabelled ligand binding assays, RT-PCR and immunohistochemistry. 
Experiments with mainly rodents have uncovered that the central cannabinoid receptor 
Cb1, is mainly located in the central and peripheral nervous system25,26,27. More 
specifi cally, Cb1 was identifi ed by radio-labeling assays with the synthetic cannabinoid 
compound CP55,940. This compound showed specifi c binding sites in rat brain tissue28. 
Further research has lead to the identifi cation and cloning of  the receptor responsible 
for this binding29. Since this receptor was only present in brain tissues, it was named 
the central cannabinoid receptor (Cb1). Subsequently, another cannabinoid receptor was 
also identifi ed and cloned in the human promyelocytic cell-line HL6030. Further research 
indicated the peripheral cannabinoid receptor Cb2 to be mainly found on cells of  the 
immune system. Thus, it was called the peripheral cannabinoid receptor (Cb2). The 
human gene encoding CB1 is located on chromosome 6q14-15 and the gene encoding 
CB2 is located on chromosome 1p36. 
 The main known/identifi ed endogenous ligands of  these receptors, the so called 
endocannabinoids are anandamide, which is found in brain 31 and 2-arachidonoylglycerol 
(2-AG), which is found in canine gut and brain32,33. Also natural ligands such as delta9-
THC extracted from the plant Cannabis sativa and synthetic ligands such as CP55,940 
have been identifi ed34. These ligands have different binding affi nities for the receptors 
and this may result in different downstream effects. The cannabinoid ligands can function 
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as an agonist, an antagonist or an inverse agonist of  the Cb1/Cb2 receptors and may exert 
several functions with neuromodulatory, cardiovascular and reproductive effects35,36,37. 
Modulation of  immune and infl ammatory response and last but not least inhibition of  
cancer cell growth have also been reported38,39,40,41,42,43,44,45,46,47,48,49,50. 
Figure 1 | Schematic overview of  the peripheral cannabinoid receptor: a seven trans-membrane 
receptor with an intracellular C-terminal part (COO-) and an extracellular N-terminal part (NH3+). 
The antibodies used were directed against these C-and N-terminal parts of  this receptor.
EXPRESSION AND FUNCTIONS OF THE PERIPHERAL 
CANNABINOID RECEPTOR IN IMMUNE CELLS 
Cb2 mRNA has been detected in the spleen, thymus, tonsils and bone marrow51,52,53. 
Moreover, mRNA expression analysis in human hematopoietic cells showed that B-cells 
express CB2 abundantly, followed in decreasing order by NK-cell, monocytes, neutrophils 
and T-cells54. Protein expression in human immune cells has for the fi rst time been 
described by Carayon et al., using a polyclonal antibody (Ab) raised against the C-terminus 
of  the human CB2 receptor. CB2 protein was mainly found in the mantle zones (MZs) of  
secondary follicles of  tonsils, areas where mainly naïve B-cells reside. Also, modulation 
of  this receptor during B-cell differentiation has been demonstrated55. Up till now, this is 
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the only study in which the human CB2 receptor expression in developing B-cells in the 
immune system was described. 
 As already stated above, the peripheral cannabinoid receptor belongs to the family of  
seven transmembrane G-protein-coupled receptors (GPCRs). GPCRs are crucial to many 
cellular functions, such as proliferation, maturation, survival, apoptosis and migration56,57,58. 
The mechanisms through which cannabinoids mediate immunosuppression is still under 
investigation and can generally be categorized into four pathways: apoptosis, inhibition 
of  proliferation, suppression of  cytokine and chemokine production and induction 
of  T regulatory cells (T regs)59. In general, cannabinoids exert their effects through 
inhibition of  adenylate cyclase activity. This blocks forskolin-stimulated cAMP activation, 
leading to decreased activity of  protein kinase A and subsequently to lesser binding of  
transcription factors to CRE (cyclic-AMP responsive element) resulting in dysfunction in 
IL-2 production. This may result in immune modulatory effects60. Cannabinoid ligands 
such as THC, trigger apoptosis of  cultured immune cells (macrophages and lymphocytes) 
through the regulation of  Bcl-2 and caspase activity61. Also, THC interferes with MAP 
kinase signaling pathway, which plays an important role in apoptosis of  Jurkat leukemia 
T-cell line. Specifi cally, THC inhibited the MAPK/MEK/ERK signaling pathway, which 
resulted in translocation of  Bad into mitochondria, and eventually apoptosis. This 
apoptosis could be signifi cantly decreased by CB2 antagonist SR14452862.
 Some cannabinoid ligands may interfere with the immune response resulting 
in impairment of  macrophage functions, alteration of  CD4/CD8 T-cell ratio and 
immune globulin productions, down regulation of  NK-cell activity or perturbation of  
macrophage/T-cell cooperation63,64,65,66. Various effects of  marijuana components on the 
proliferation of  spleen, lymph node and thymus immune cells in vitro and in vivo have been 
described. For example, these components suppress the induction and cytolytic function 
of  murine immune cells. Inhibiting capabilities of  THC on macrophage co-stimulatory 
activity have also been described67,68,69. Immunomodulation by cannabinoids is absent in 
mice defi cient for the cannabinoid receptor Cb270 and formation of  B-and T-cell subsets 
in mice require the presence of  the Cb2 receptor71. 
 An immunomodulatory function of  this receptor in human immune cells has been 
described earlier 51. It has been described that cannabinoids enhance human B-cell growth 
at nanomolar concentrations72. Also, the endogenous cannabinoid ligand 2-AG can act 
as a chemo attractant in vivo for dendritic cells73. Also, moderate proliferation of  virgin 
and germinal center B-cells of  the tonsil occurred upon stimulation with the synthetic 
cannabinoid agonist CP55,940. This proliferation only occurred when the cells were co-
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stimulated with CD40 monoclonal antibody51. Exposure to CD40 activating agents has 
already been described as crucial for the functions of  other GPCRs such as CXCR4. Only 
pretreatment of  germinal center B-cells (GC) with CD40 resulted in migration of  these 
cells upon stimulation with the CXCR ligand stromal-derived factor74. In mouse, Cb2 
mRNA expression in splenic B-cells was augmented following immune cell activation 
with CD4075, indicating a crucial cross-talk of  the CB2 and CD40 receptors. One recent 
study reports that Cb2 mediates immunoglobulin class switching from IgM to IgE in 
cultures of  murine-purifi ed B lymphocytes76.
EXPRESSION AND FUNCTION OF THE PERIPHERAL 
CANNABINOID RECEPTOR IN MYELOID CELLS
To investigate the potential functions of  the Cb2 receptor, migration assays were 
carried out in Cb2-overexpressing cells (32D/GCF-R/Cb2-EGFP) using the potent 
endocannabinoid ligand 2-arachidonoyl glycerol (2-AG) as a Cb2 agonist. Furthermore, 
these cells are also a powerful in vitro model for studying granulocytic differentiation. Two 
distinct biological effects of  the Cb2 receptor have been observed in hematopoietic cells 
expressing the peripheral cannabinoid receptor. The ligand used determined the effect 
observed: stimulation with endocannabinoid 2-AG results in migration and exposure to 
a synthetic ligand CP55,940 induces a block of  neutrophilic differentiation77,78. Thus, 
binding of  distinct ligands to Cb2 receptors results in activation of  distinct effector 
functions. This ligand dependent downstream effect may be explained by the presence of  
distinct complexes in which Cb2 is present39. 
 Low CB2 mRNA expression has been demonstrated on normal human 
neutrophils50. Also, low protein expression using fl owcytometry was detected on human 
neutrophils79 and CB2 mRNA was detected on the human promyelocytic cell line HL-6080. 
Several distinct effects were observed using different agonists of  the Cb2 receptor, such 
as signifi cant induction of  migration upon stimulation with the endocannabinoid 2-AG71. 
It has also been demonstrated that 2-AG induces a rapid transient increase in intracellular 
free calcium (2+) concentrations in HL-60 cells81. Also, in murine leukemia cell lines which 
(over)express the Cb2 receptor, the major effect is stimulation of  migration67. Moreover, 
the Cb2 receptor induces a reversible block in neutrophilic differentiation in this murine 
cell line upon stimulation with a synthetic cannabinoid ligand68. In a human eosinophilic 
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leukemia cell line, the endocannabinoid 2-AG induces migration82. Furthermore, the same 
ligand enhances adhesion of  HL-60 cells differentiated into macrophage like cells83.
CB2 EXPRESSION IN HUMAN MALIGNANT LYMPHOMA AND 
ACUTE MYELOID LEUKEMIA
In human hematopoietic tissues, the decreasing rank order of  CB2 mRNA expression is: 
B-cells, natural killer cells, monocytes, neutrophils, CD8+ T-cells, and CD4+ T-cells50. 
CB2 protein expression was detected in B-cell areas, i.e. the marginal zone and mantle 
zone of  secondary follicles of  tonsils51. To our knowledge no detailed studies have been 
carried out which describe the protein expression of  the CB2 receptor in NHLs. 
 Using RIM, Cb2 was identifi ed as the target gene in the cVIS EVI11 in Cas-
Br-M MuLV-induced myeloid leukemias, indicating that Cb2 may act as a proto-oncogene 
in leukemogenesis. Aberrations in (the expression of) the gene that encodes the Cb2 
receptor leading to aberrant expression of  this receptor may be a critical event in the 
transformation of  normal myeloid cells into leukemic cells21,25. The group of  Delwel 
has previously shown that Cb2 is highly expressed in myeloid cell lines containing a 
retroviral insertion in the Cb2 gene67. Overexpression of  the Cb2 receptor in myeloid 
precursor cells is related with impairment of  neutrophilic development, one of  the major 
characteristic of  myeloid leukemia68. So far, no further detailed studies have been carried 
out which describe the expression of  CB2 in normal human myeloid precursor and AML 
cells.
AIM OF THE THESIS
The aim of  this thesis is to investigate the expression of  the Cb2 receptor and its 
potential as a novel diagnostic and/or prognostic marker in hematological malignancies. 
More specifi cally, we have investigated the expression of  the CB2 receptor in normal and 
malignant hematopoietic and immune tissues with a focus on DLBCL.
 In order to address the question whether CB2 can serve as a prognostic marker, 
we studied CB2 expression using histological material of  well-defi ned patient groups 
drawn from randomized phase III clinical trials and correlated the results with the clinical 
outcome of  these patients. We have also studied expression of  Cb2 (CB2) in vitro under 
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various physiological conditions and investigated the effects of  CB2-receptor ligands, 
using cell culture systems of  malignant lymphoma and myeloid cell lines. 
 In chapter 2 we studied the CB2 expression in normal bone marrow and primary 
AMLs. Subsequently we also determined the function of  the receptor in differentiation or 
stimulation of  migration using a Cb2 transfected 32-D cell line with different Cb2 specifi c 
agonists.
 In chapter 3, we have investigated which cells in primary and secondary follicles 
in normal human lymphoid tissue expressed CB2 and whether CB2 receptors in the 
distinct cell populations were active or inactive. Immunohistochemical studies were done 
using two antibodies: an N-terminal specifi c anti-CB2 antibody and a C-terminal specifi c 
anti-CB2 antibody which only detected phosphorylated inactive receptors. The function 
of  CB2 expression has been investigated in migration assays using an endocannabinoid 
2-AG in a B-lymphoma cell line. 
 In chapter 4, we subsequently have studied the CB2 protein expression in various 
B- and T-cell NHL subtypes and compared the results with the CB2 protein expression in 
their normal physiological counterparts. 
 In chapter 5, we have attempted to clarify the controversies about the prognostic 
value of  various immunohistochemical classifi cation systems in order to test this model 
for its usefulness as a prognostic marker in DLBCL. To this end, we have investigated 
a known immunohistochemical model using CD10, BCL-6 and MUM1 in a specifi c 
algorithm to sub-classify DLBCL in two randomized phase III clinical trials.
 In chapter 6 we have investigated the prognostic value of  the CB2 expression in 
DLBCL using a single center study population.
 In chapter 7 (general discussion), we evaluated the prognostic value of  the CB2 
expression as determined by immunohistochemistry We hypothesize that although the 
protein expression itself  does not have prognostic value in DLBCL, targeting the receptor 
with antagonists or agonists may be of  interest in the treatment of  NHL as well as in 
AML and therefore constitute a subject for further research.
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ABSTRACT 
Cb2, the gene encoding the peripheral cannabinoid receptor, is located in a common virus 
integration site and is overexpressed in retrovirally-induced murine myeloid leukemias. 
Here we show that this G protein-coupled receptor (GPCR) is also aberrantly expressed 
in a high percentage of  human acute myeloid leukemias. We investigated the mechanism 
of  transformation by Cb2 and demonstrate that aberrant expression of  this receptor on 
hematopoietic precursor cells results in distinct effects depending on the ligand used. 
Cb2-expressing myeloid precursors migrate upon stimulation by the endocannabinoid 
2-arachidonoylglycerol and are blocked in neutrophilic differentiation upon exposure to 
another ligand, CP55,940. Both effects depend on the activation of  Gαi proteins and 
require the MEK/ERK pathway. Downregulation of  cAMP levels upon Gαi activation is 
important for migration induction, but is irrelevant for the maturation arrest. Moreover, 
the highly conserved G protein interacting DRY-motif, present in the second intracellular 
loop of  GPCRs, is critical for migration, but unimportant for the differentiation block. 
This suggests that the Cb2-mediated differentiation block requires interaction of  Gαi 
proteins with other currently unknown motifs. This indicates a unique mechanism by 
which a transforming GPCR, in a ligand-dependent manner, causes two distinct oncogenic 
effects, i.e. altered migration and block of  neutrophilic development.
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INTRODUCTION
Using retroviral insertional mutagenesis we recently demonstrated that Cb2, the gene 
encoding the peripheral cannabinoid receptor, is located in a common virus integration 
site (Evi11) in Cas-Br-M MuLV-induced myeloid leukemias, suggesting that Cb2 is a 
proto-oncogene involved in transformation1,2. Cb2 encodes a seven transmembrane 
(7TM) protein, belonging to the family of  Gαi protein-coupled receptors (GαiPCRs)
3. This 
receptor is normally expressed in areas enriched for B lymphocytes, i.e. marginal zone of  
the spleen, in the cortex of  lymph nodes, in the nodular corona of  Peyer’s patches and 
in the mantle zones of  secondary follicles in tonsils3-6. Cb2 receptor is involved in B cell 
differentiation and migration of  splenic B lymphocytes, suggesting a role for this receptor 
in the immune response5,7. The natural activator of  Cb2 has been demonstrated to be 
2-arachydonoylglycerol (2-AG)7-11, although a number of  alternative Cb2 ligands have 
been reported (for review see Howlett et al12).
 Acute myeloid leukemia (AML) is characterized by an accumulation of  immature 
non-functional cells in the bone marrow and blood13. Myeloid leukemia is considered to 
be a multigenetic disease involving cooperation between several disease genes14-16. The 
genetic abnormalities in AML may result in aberrant expression of  proto-oncogenes or 
inactivation of  tumor suppressor genes, and consequently leukemia cells escape from 
regulatory signals, resulting in altered proliferation, aberrant survival and a maturation 
arrest. Our previous observation that Cb2 is overexpressed in myeloid cell lines 
containing a retroviral insertion nearby Cb2 suggest that it maybe involved in leukemic 
transformation in certain mouse leukemias. In the present study we demonstrate that CB2 
receptor is aberrantly expressed in several human myeloid cell lines and primary AML 
samples, whereas normal bone marrow precursor cells do not express this GPCR.
 We generated a Cb2-EGFP fusion construct17, which was introduced into murine 
normal bone marrow cells and into 32D/G-CSF-R cells. 32D/G-CSF-R cells proliferate 
in vitro in the presence of  IL-3 and are capable to terminally differentiate towards mature 
neutrophils upon G-CSF stimulation. Furthermore, this cell line is a useful in vitro 
model to study molecular mechanisms involved in granulocytic differentiation18-20 and 
to perform functional analysis of  transforming genes causing a block of  neutrophilic 
differentiation17,21. The Cb2-EGFP fusion protein appears fully functional, since the 
Cb2-expressing marrow cells and 32D/G-CSF-R/Cb2 cells migrate in response to the 
endocannabinoid 2-AG. In the present study we assessed whether 2-AG was capable of  
inducing a neutrophilic differentiation block of  32D/G-CSF-R/Cb2 cells. We demonstrate 
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that the endocannabinoid 2-AG, although being a potent stimulator of  migration of  Cb2-
expressing cells, could not block G-CSF-induced neutrophilic differentiation. Next, we 
tested whether an other potent cannabinoid ligand CP55,94022,23, could affect neutrophilic 
differentiation of  Cb2-expressing cells. Interestingly, CP55,940 failed to induce migration 
but evoked a complete arrest of  neutrophilic differentiation.
 Classical signaling by GPCRs is based on transduction of  extracellular signals 
to downstream effectors via intracellular, heterotrimeric G protein complexes, which 
comprise α, β and γ subunits24,25. The recruitment of  G proteins to GPCRs may require 
several motifs present in 7TM receptors. A well-characterized domain involving G protein 
recruitment and activation is the so-called DRY motif26-29. The DRY (asp-arg-tyr) box is a 
highly conserved region in 7TM receptors, located N-terminally in the second intracellular 
loop of  most GPCRs. To analyse whether the DRY motif  present in Cb2 receptor is 
crucial for migration and/or block of  differentiation, we generated two different DRY 
mutants, i.e. DRA-Cb2 and DAY-Cb2. Finally we demonstrated that MEK/ERK signaling 
is involved in both Cb2 functions whereas downregulation of  the intracellular cAMP 
levels is only required for migration.
METHODS
Cannabinoid ligands, cytokines and inhibitors of  intracellular signaling
The Cb2 ligands 2-arachidonoylglycerol (2-AG), anandamide (AEA), WIN 55,212-2, 
cannabinol, cannabidiol, D8-tetrahydrocannabinol (D8-THC) and D9-tetrahydro-
cannabinol (D9-THC) were obtained from Sigma (Zwijndrecht, The Netherlands). 
N-palmitoylethanolamine (PEA) and N-acylethanolamine (POEA) were from ICN 
Biomedicals (Zoetermeer, The Netherlands) and CP55,940 from Pfi zer (Groton, CT). 
Cb1 inverse agonist SR141716 and Cb2 inverse agonist SR144528 were kindly donated by 
Dr. Casellas (Sanofi  Recherche, Montpellier, France). Recombinant human stromal cell-
derived factor (SDF-1α) was obtained from R&D systems (Uithoorn, The Netherdands). 
Murine IL-3 was obtained from an IL-3 producing CHO cell line and G-CSF was from 
Amgen (Thousand Oaks, CA). Dibutyryl cyclic AMP (dbcAMP) and U0126 (MEK 
inhibitor) were from Kordia Life Science (Leiden, The Netherlands), whereas PD98059 
(MEK inhibitor) was obtained from Omnilabo International (Breda, The Netherlands). 
The inhibitors were dissolved in DMSO and added to the cultures at the indicated 
concentrations, and were refreshed daily.
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Cb2-EGFP expression construct, site directed mutagenesis and infection of  
32D/G-CSF-R cells
A Cb2-EGFP fusion construct was generated and cloned into pLNCX (Clontech, 
Palo Alto, CA) as described previously17. A QuikChangeTM Site-Directed Mutagenesis 
Kit was used to mutate the DRY motif  present in Cb2-EGFP receptor as indicated 
by the supplier (Stratagene Europe, Amsterdam, The Netherlands). The primers 
5’-GCTGTTGACCGCGCCCTATGTCTGTG-3’ and 5’-CACAGACATAGGGCGC-
GGTCAACAGC-3’ were used to mutate the wt DRY motif  into a DRA motif, and the 
primers 5’-CCGCTGTTGACGCCTACCTATGTCTG-3’ and 5’-CAGACATAGGTAG-
GCGTCAACAGCGG-3’ to mutate the wt DRY motif  into a DAY motif  (Figure 5). 
The Cb2-EGFP and the DRY mutated constructs were verifi ed by nucleotide sequence. 
These expression constructs were transfected into Phoenix cells type E (gift from G. 
Nolan, Stanford, CA) and the viral supernatants were used for infection of  32D/G-
CSF receptor (32D/G-CSF-R) cells. Single clones were obtained using limiting dilution 
in 96 well microtiter trays (Becton Dickinson, Mountain View, CA) and infected clones 
were selected on 0.8 mg/ml G418 (Gibco, Breda, The Netherlands). Cb2-EGFP fusion 
protein and DRY-mutants expression was analyzed by Leica DMRXA microscopy 
(Leica Microsystems, Rijswijk, The Netherlands) and fl ow cytometric analysis of  EGFP 
fl uorescence.
Flow cytometric analysis
32D/G-CSF-R cells transduced with Cb2-EGFP17, as well as with Cb2-EGFP DRA 
mutant, Cb2-EGFP DAY mutant and EGFP control were analyzed by fl ow cytometric 
analysis by means of  EGFP fl uorescence (FACScan fl ow cytometer, Becton Dickinson, 
Mountain View, CA) as described previously17. 
 The myeloid cell lines HL60 (ATCC CCL 240), MV 4-11 (ATCC CRL 9591), U937 
(ATCC CRL 1593), KG1 (ATCC CCL 246), KG1a (ATCC CCL 246.1), K562 (ATCC CCL 
243) and NB-430 and ME-131, as well as primary AML samples and CD34+ cells were used 
for immunofl uorescence analyses. Bone marrow AML samples at diagnosis and healthy 
volunteers were obtained after informed consent. Blast from AML patients and healthy 
bone marrow specimens were isolated from the samples by Ficoll-Hypaque (Nygaard, 
Oslo, Norway) centrifugation32. The cells were then cryopreserved as described33. 
 Normal umbilical cord blood CD34 cells were purifi ed using magnetic cell sorting 
system (MACS cell isolation Kits, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
In brief, cells were thawed, washed twice in RPMI1640 medium (Life Technologies, Breda, 
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The Netherlands) and cultured in this medium suplemented with penicillin (100 U/ml), 
streptomycin (100 ng/ml) and 10% fetal calf  serum (Life Technologies, The Netherlands) 
for one hour at 37ºC and 10%CO2. After washing cells were incubated on ice with the 
polyclonal N-terminal anti-CB2 antibody (1:50) (Affi nity Bioreagents Inc, CO, USA) 
for 1 hour, followed by 30 minutes incubation with the FITC-conjugated secondary 
rabbit antibody (1:200) GAR-FITC/IgG (Nordic Immunological Labs, Tilburg, The 
Netherlands). In case of  dual staining, cells were incubated next for 30 minutes with 
phycoerythrin (PE)-conjugated primary or secondary control antibodies (IgG/GAR-
FITC and IgG1-PE). CD34 PE and CD14 PE were obtained from Becton Dickinson (NJ, 
USA), CD33 PE and IgG1 PE were from Beckman Coulter (CA, USA), and CD66 PE 
was obtained from CLB Laboratories (Amsterdam, The Netherlands). Cells were washed 
twice with Phosphate Buffer Saline (PBS), resuspended in 500 ml PBS containing 0.5% 
BSA (Bovine serum albumine) and analyzed using a FACScan fl ow cytometer (Becton 
Dickinson Mountain View, CA, USA).
Ligand binding analysis
[3H]2-AG was synthesized from 1,3-dibenzyloxy-2-propanol and [3H]arachidonic 
acid (200 Ci/mmol, ARC Inc., St. Louis, MO), as reported34, and [3H]CP55,940 
(5-(1,1’-dimethyheptyl)-2-[1R,5R-hydroxy-2R-(3-hydroxypropyl) cyclohexyl]-phenol; 
126 Ci/mmol) was from NEN DuPont de Nemours (Köln, Germany). Membrane 
fractions were prepared from the different clones (100x106/test) as reported35, and were 
used in rapid fi ltration assays with the synthetic cannabinoid [3H]CP55,940. Apparent 
dissociation constant (Kd) and maximum binding (Bmax) values of  [
3H]CP55,940 were 
calculated from saturation curves through nonlinear regression analysis with the Prism 
3 program (GraphPAD Sofware for Science, San Diego, CA). Binding of  [3H]2-AG was 
evaluated with the same fi ltration assays used for [3H]CP55,940, and apparent Kd and Bmax 
values were calculated through nonlinear regression analysis of  saturation curves35. In all 
experiments, unspecifi c binding was determined in the presence of  10 μM nonlabeled 
agonist. Data reported are the mean (± S.D.) of  at least three independent determinations, 
each in duplicate. Statistical analysis was performed by the nonparametric Mann-Whitney 
test the InStat 3 program (GraphPAD Software for Science).
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In vitro proliferation and neutrophilic differentiation of  32D/G-CSF-R cells
The 32D/G-CSF receptor (32D/G-CSF-R) cell line19 was cultured in RPMI1640 medium 
(Life Technologies, Breda, The Netherlands) supplemented with penicillin (100 IU/ml), 
streptomycin (100ng/ml), 10% Fetal Calf  Serum (FCS) and human G-CSF (100 ng/ml) for 
nine days. Cell counting was performed using a CASY1/TTC cell counter (Schärfe System, 
Germany) and the cell density was readjusted to 2 x 105 cells/ml daily. Morphological 
analysis was done by microscopy on May-Grünwald-Giemsa stained cytospins (Shandon 
Holland, Amsterdam, The Netherlands).
Migration assay 
Migration assays were performed using 5 mm pore size and 6.5 mm diameter transwells 
(Corning Costar, Amsterdam, The Netherlands) as previously described7. In brief, cells 
were washed twice with Hank’s Balanced Salt Solution (HBSS) medium, resuspended in 
100 ml of  migration medium (Iscove's Modifi ed Dulbecco's Medium (IMDM) +0.5% 
BSA) and placed in the upper chamber of  the transwells. In the lower chamber 600 ml 
of  migration medium with or without ligand were placed. After 4 hours of  incubation at 
37ºC and 5% CO2 the upper chamber was removed and the numbers of  migrated cells 
were determined using a CASY1/TTC cell counter (Schärfe System, Germany). Cb1- 
and Cb2-specifi c antagonists (100 nM) were added to the upper chamber when tested. 
PD98059, U0126 and dbcAMP were added to the cells, incubated 30 minutes at 37ºC, and 
then transferred to the upper well. 
Cb2-EGFP retroviral vectors, virus production and infection of  mice bone 
marrow progenitor cells
Cb2-EGFP was obtained by Eco47III/NotI digestion from pEGFP-N1 vector and 
subcloned as a blunt fragment into HpaI site of  pBabe retroviral vector. Correct insertion 
of  Cb2-EGFP was verifi ed by nucleotide sequencing. The expression constructs were 
transfected into Phoenix cells type E (gift from G. Nolan, Stanford, CA) and the virus-
containing supernatants were used for infection of  bone marrow progenitor cells as 
described previously21. Transduction effi ciency was determined by FACS analysis of  EGFP 
fl uorescence. To study migration, cells were cultured in Cell Gro medium supplemented 
as before plus 2.5 μg/ml puromycin (Sigma, Zwijndrecht, The Netherlands) for 4 – 5 days 
and then used in a migration assay. Bone marrow suspension cultures were performed 
in RPMI1640 medium supplemented with 10% FCS, 2.5 μg/ml puromycin (Sigma, 
Zwijndrecht, The Netherlands) and human G-CSF (100 ng/ml). Cultures were carried 
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out in the presence or absence of  CP55,940, the Cb1 inverse agonist, the Cb2 inverse 
agonist or combinations of  these agents. Cell countings were performed every 3 – 4 days 
and cytospins were prepared for morphological analysis.
RESULTS 
CB2 is frequently expressed on human acute myeloid leukemia cells but absent 
on normal myeloid precursors
Cb2 is frequently targeted in retrovirally-induced leukemia, resulting in overexpression of  
this receptor1,7. To investigate whether CB2 may be involved in human malignancies as 
well, we studied expression of  this receptor on malignant and normal myeloid precursor 
cells using specifi c antibodies and fl ow cytometric analysis. High receptor levels were 
observed in HL60, NB4 (Figure 1A), U937 and MV 4-11 (data not shown). The cell lines 
KG1, KG1a, K562 and ME-1 did not show any CB2 protein expression (data not shown). 
High CB2 expression was observed on AML blasts in 14/30 patient samples. Two typical 
examples are demonstrated in Figure 1B. Flow cytometric analysis of  CD34 purifi ed 
fractions from normal bone marrow revealed no expression of  CB2 on these cells (Figure 
1B). Moreover, double labeling of  normal marrow cells using CB2 specifi c antibodies 
in combination with CD34, CD33, CD66 or CD14, revealed no detectable CB2 levels 
on myeloid cells at any differentiation stage (Figure 1C). These data suggest that CB2 
expression on myeloid leukemia cells in humans, as well as in mice, is an abnormal feature.
CP55,940 mediates a decrease of  neutrophilic differentiation and 2-AG-
induces migration of  Cb2-expressing bone marrow precursors
To study the mechanism of  transformation by this GPCR we introduced the Cb2 gene 
fused in frame to EGFP as previously described 7 into percoll separated normal murine 
bone marrow cells. Cb2-expressing bone marrow cells migrated signifi cantly in response 
to the endocannabinoid 2-AG (Figure 2). These 2-AG migrated CB2-EGFP expressing 
bone marrow cells when placed in an in vitro colony assay were capable of  generating 
high numbers of  G-CSF, GM-CSF and IL3 stimulated colonies (data not shown). 2-AG-
induced migration could be fully abolished by addition of  Cb2 inverse agonists, whereas 
Cb1 inverse agonist did not affect migration. EGFP control infected bone marrow cells 
weakly migrated upon 2-AG stimulation. The low numbers of  2-AG migrated EGFP-
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Figure 1 | CB2 expression in human acute myeloid leukemia cells and normal myeloid 
precursors. (A) Flow cytometric analysis of  a representative CB2 positive and a CB2 negative 
myeloid cell line. Staining was performed using a CB2 N-terminal antibody followed by FITC-
conjugated secondary rabbit antibody. (B) CB2 cell surface expression analysis on primary AML 
patient samples and normal CD34+ bone marrow cells using the CB2 N-terminal antibody. (C) 
Immunophenotyping of  normal total bone marrow using fl ow cytometric analysis. 
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Figure 2 | 2-AG-induced migration of  Cb2- or EGFP-transduced murine bone marrow 
cells. Cb2- or EGFP-transduced bone marrow precursors were exposed to medium with or without 
300 nM 2-AG. Cells were placed in the upper well in the presence or absence of  100 nM of  
either Cb2 (C2) or Cb1 (C1) inverse agonist. Data represent the mean values of  three independent 
experiments. Error bars indicate SD.
expressing control cells were not capable of  forming any colonies in vitro. Although 
we did not investigate which cell types were 2-AG responsive, our previous data7 would 
suggest that these cells may be B-lymphocytes. 
 In vitro culture using IL-3 or G-CSF revealed no effect of  2-AG on proliferation or 
differentiation of  Cb2-expressing marrow cells (data not shown). We next studied whether 
another well known Cb2 agonist, i.e. CP55,940, had an effect on marrow precursors 
expressing Cb2. A decrease in neutrophilic differentiation, although statistically not 
signifi cant (ANOVA test, p=0.11), of  Cb2-expressing cells was observed when cultured 
in suspension with G-CSF plus CP55,940 as compared to cultures with G-CSF only 
(Table 1). Moreover, addition of  Cb2 inverse agonist recovered the appearance of  mature 
neutrophils (Table 1), whereas the Cb1 inverse agonist had no effects (data not shown). 
EGFP-transduced bone marrow cells do not show any response to CP55,940 or inverse 
agonists in an in vitro differentiation assay (Table 1).
The endocannabinoid 2-AG stimulates migration and CP55,940 induces a full 
block of  neutrophilic differentiation of  Cb2-expressing 32D/G-CSF-R cells 
To further analyze the effects of  Cb2 and the distinct ligands in detail Cb2-EGFP or 
EGFP constructs were introduced into 32D/G-CSF-R cells. 8 Cb2-expressing clones 
and 8 EGFP control clones were fi rst cultured in the presence of  G-CSF and different 
concentrations of  2-AG (100 nM-1 μM). 2-AG did not affect neutrophilic differentiation 
at any of  the concentrations tested (Figure 3A and B). On the other hand, 2-AG showed 
to be an effi cient stimulator of  migration of  the 32D/G-CSF-R/Cb2 cells as determined 
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in a transwell assay (Figure 3A). This effect was receptor specifi c, since 2-AG-induced 
migration was fully counteracted by the Cb2 inverse agonist SR144528 but not by the Cb1 
inverse agonist SR141716 (Figure 3A). In contrast, the other Cb2 ligand CP55,940 fully 
blocked G-CSF-induced neutrophilic differentiation of  Cb2-expressing 32D/G-CSF-R 
clones (Figures 3A and B). CP55,940 did not affect maturation of  EGFP control 
32D/G-CSF-R cells (Figure 3B). Addition of  Cb2 inverse agonist to the G-CSF/CP55,940 
containing cultures completely restored neutrophilic differentiation of  Cb2-expressing 
32D/G-CSF-R cells, whereas the Cb1 inverse agonist had no effect (Figure 3A). Titration 
experiments revealed that pM concentrations of  CP55,940 were suffi cient to signifi cantly 
stimulate a differentiation block (Figure 3C). Using 100 nM of  CP55,940 and different 
concentrations of  Cb2 inverse agonist we observed that neutrophilic differentiation of  
Cb2-expressing cells could be recovered in a dose dependent manner (Figure 3D). In 
contrast to 2-AG, CP55,940 could not induce migration of  Cb2-expressing cells (Figure 
3A).
Table 1 | Morphologic analysis of  Cb2- and EGFP-transduced murine bone marrow cells cultured 
for 6 days.
CP55,940-mediated block of  differentiation and 2-AG-induced migration are 
pertussis toxin (PTX) sensitive
Cb2 receptor belongs to the GαiPCR sub-family. To study whether Cb2 requires Gαi proteins 
to stimulate migration or block neutrophilic differentiation we used PTX, a molecule that 
prevents heteromere formation between the G protein and the receptor. We observed 
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Figure 3 | Effects of  distinct cannabinoids on the G-CSF-induced neutrophilic differentiation 
and migration of  32D/G-CSF-R cells. (A) Morphologic analysis of  May-Grünwald-Giemsa 
stained cytospins of  one representative Cb2-expressing clone cultured in G-CSF and 100 nM of  
2-AG or CP55,940 (CP), in the presence or absence of  1μM Cb2 (C2) or Cb1 (C1) inverse agonist. 
In vitro migration of  32D/G-CSF-R/Cb2 cells upon 2-AG or CP stimulation. 100nM C2 or C1 
were added to the upper well when tested. (B) Two representative Cb2- and two representative 
EGFP-expressing clones were cultured in G-CSF and 100 nM 2-AG or CP. (C) Differential counts 
of  a representative CP titration experiment in the presence of  G-CSF (day 8 of  culture). White 
bars represent blast cells, black bars intermediate forms and gray bars terminally differentiated 
neutrophils. (D) Differential counts of  a 32D/G-CSF-R/Cb2 clone cultured with G-CSF, 100 nM 
of  CP and different concentrations of  C2.
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full differentiation of  Cb2-expressing 32D/G-CSF-R cells when PTX (100 ng/ml) was 
added to the G-CSF/CP55,940 cultures (Figure 4A and B). Addition of  PTX to  the 
EGFP control clones had no effect on the neutrophilic differentiation of  these cells 
(Figure 4A and B). Moreover, 2-AG-induced migration of  32D/G-CSF-R/Cb2 cells was 
completely abolished by 300ng/ml PTX (Figure 4C).
Mutation of  the DRY-motif  in Cb2 causes a reduced migration response to 
2-AG but does not affect CP55,940-mediated block of  differentiation
To assess whether the Cb2 DRY motif  is important to recruit and activate G proteins 
in the CP55,940-mediated block of  differentiation and/or the 2-AG-induced migration, 
32D/G-CSF-R cells were infected with retrovirus carrying different Cb2-EGFP DRY-
mutants. Distinct constructs, i.e. Cb2-DRY (w.t), Cb2-DRA mutant and Cb2-DAY mutant 
were generated (Figure 5A), introduced into 32D/G-CSF-R cells and studied in transwell 
and differentiation assays. Following G418 selection six 32D/G-CSF-R clones for each 
construct were obtained. Expression of the distinct Cb2-EGFP variants introduced 
into 32D/G-CSF-R cells was analyzed by means of  fl uorescence microscopy and fl ow 
cytometric analysis. A representative clone for each transfected construct is shown in 
Figure 5B. Equal levels of  fl uorescense were detected in the three Cb2 clone types and 
receptor membrane distribution was similar in all cell types (Figure 5B). Binding of  2-AG 
and CP55,940 to the different clones was assessed by ligand binding assays. In Figure 5A 
it is indicated that receptor levels (Bmax), as well as affi nities (Kd) for 2-AG and CP55,940 
on 32D/G-CSF-R cells were comparable between clones transduced with the distinct 
constructs. Cb2 mutants cultured in the presence of  G-CSF plus CP55,940 showed a block 
in neutrophilic differentiation (Figure 5C and D), comparable to the differentiation block 
observed with the non-mutated Cb2 wt transduced cells. This block of  differentiation 
was reversible by the Cb2 inverse agonist, but not by addition of  Cb1 inverse agonist 
(Figure 5D). In contrast, the 2-AG-induced migration of  32D/G-CSF-R/Cb2-mutants 
was signifi cantly reduced in comparison to the non-mutated Cb2 control clones (Figure 
5E). The reduced levels of  2-AG-induced migration could still be abolished by addition 
of  Cb2, but not Cb1, inverse agonist (Figure 5E). 
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Figure 4 | Effect of  pertussis toxin (PTX) on the CP55,940-evoked block of  differentiation 
and the 2-AG-induced migration of  32D/G-CSF-R cells. (A) Two representative Cb2- and 
EGFP-expressing 32D/G-CSF-R clones were cultured for 8 days in the presence of  G-CSF plus 
CP55,9940 (CP) with or without PTX (100 ng/mL). (B) Differential counts of  a representative 
Cb2- and EGFP-expressing 32D/G-CSF-R clone at day 7 of  culture in the presence of  G-CSF 
with or without CP and PTX. White bars represent blast cells, black bars intermediate forms and 
gray bars terminally differentiated neutrophils. (C) Effect of  300 ng/mL PTX on 2-AG-induced 
migration of  32D/G-CSF-R/Cb2 cells. PTX was added to the cells and pre-incubated for 1 hour at 
37°C before placing the cells in the upper chamber of  a transwell assay. Values indicate the average 
of  three representative clones. Error bars indicate SD.
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Figure 5 | Mutation of  the DRY motif  in Cb2 and analysis of  32D/G-CSF-R/Cb2-mutant 
clones. (A) Location of  the DRY motif  in Cb2. Introduced mutations are indicated in bold. Right 
box shows the results of  ligand binding assays. The dissociation constant (Kd) for CP55,940 is 
expressed in pM and for 2-AG in nM. Maximum binding (Bmax) is expressed as fmol/mg protein. 
Data were pooled from independent experiments performed on two clones of  the same cell type. (B) 
Flow cytometric analysis of  representative 32D/G-CSF-R clones expressing the distinct constructs. 
Upper right inserts show cell fl uorescence distribution in the infected cells by microscopy. Original 
magnifi cation of  inserts x 63. (C) 4 representative 32D/G-CSF-R clones expressing Cb2 mutants 
cultured in G-CSF with or without CP, Cb2 (C2) and Cb1 (C1) inverse agonist (100 nM). Counts 
were carried out on day 8 of  culture. White bars represent blast cells, black intermediate forms and 
gray terminally differentiated neutrophils. (D) In vitro migration of  cells containing a DRY, DRA or 
DAY motif. Cells were exposed to medium with 300 nM 2-AG or control medium. 100 nM C1 or 
C2 were added to the upper chamber. The percentage of  migration is the average of  three clones. 
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dbcAMP interferes with migration but not with the neutrophilic differentiation 
block of  Cb2-expressing 32D/G-CSF-R cells 
Since activation of  GαiPCRs inhibits adenyl cyclase activity, we investigated whether 
downregulation of  the intracellular cAMP levels was necessary to drive the distinct Cb2 
effects. Addition of  dbcAMP, a cAMP analog, to the G-CSF plus CP55,940 containing 
cultures did not recover neutrophilic differentiation of  32D/G-CSF-R/Cb2 cells (Figure 
6A and B). dbcAMP did not alter neutrophilic maturation of  EGFP control clones 
(Figure 6A and B). Increasing concentrations of  dbcAMP partially blocked 2-AG-induced 
migration of  Cb2-expressing 32D/G-CSF-R cells (Figure 6C). Thus, downregulation of  
intracellular cAMP levels seems to be partially responsible for Cb2-mediated migration 
but appears unimportant for the block of  neutrophilic differentiation following Cb2 
receptor stimulation.
Interference of  CP55,940-mediated block of  differentiation as well as 2-AG-
induced migration by MEK/ERK pathway inhibitors
We next studied whether signaling via MEK/ERK pathway is critical for the distinct 
Cb2-mediated effects. MEK inhibitors, PD98059 (Figure 6A and B) or U0126 (data not 
shown), fully recovered neutrophilic differentiation of  32D/G-CSF-R/Cb2 cells cultured 
with G-CSF plus CP55,940. MEK inhibitors did not alter differentiation of  EGFP 
control clones (Figure 6A and B). Addition of  U01 26 to transwell assays revealed a dose 
dependent inhibition of  2-AG-induced migration of  Cb2-expressing 32D/G-CSF-R cells 
(Figure 6C). The same results were observed when the cells were exposed to PD98059 in 
a transwell assay (data not shown). This effect appeared highly specifi c since stimulation 
of  migration of  32D/G-CSF-R cells by SDF1, the ligand for CXCR4, could not be 
inhibited by U0126 (data not shown). These data indicate that MEK/ERK signaling is 
critical in 2-AG-induced migration as well as for CP55,940-induced block of  neutrophilic 
differentiation.
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Figure 6 | Effects of  dbcAMP and MEK/ERK inhibitors on 2-AG induced migration 
and the CP55,940-stimulated block of  differentiation. (A) A representative Cb2 and EGFP 
control 32D/G-CSF-R clone cultured with G-CSF, with or without 100 nM CP55,940 (CP), 100 μM 
dbcAMP, or 25 μM PD98059 (PD). (B) Pictures of  May-Grünwald-Giemsa-stained cytospins (day 
8) of  a representative Cb2-expressing 32D/G-CSF-R clone cultured under the different conditions. 
Original magnifi cations x 63. (C) Effects of  different concentrations of  dbcAMP and U0126 on the 
2-AG-induced (300 nM) migration of  a representative Cb2-expressing 32D/G-CSF-R clone. The 
y-axis indicates the percentage of  migrated cells in relation to the non-treated cells. 
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DISCUSSION
The peripheral cannabinoid receptor gene, Cb2, encodes a seven transmembrane (7TM) G 
protein-coupled receptor (GPCR)3. Using retroviral insertional mutagenesis we identifi ed 
Cb2 as the target gene in the Evi11 locus, indicating that Cb2 may be a proto-oncogene 
involved in leukemogenesis1,2. We previously observed that Cb2 is highly expressed in 
myeloid cell lines containing a retroviral insertion in Cb21,7, and here we showed that 
CB2 is overexpressed in several human myeloid leukemia cell lines. Interestingly, here we 
report that CB2 is frequently overexpressed in AML blast, whereas normal bone marrow 
fractions are CB2 negative. It is unclear why CB2 is so highly expressed in particular AML 
samples and cell lines. We did not fi nd any correlation between the different morphologic 
AML subtypes and CB2 expression levels. Likewise, no correlation was found between 
the origin of  the distinct cell lines and Cb2 protein levels. Real-time PCR studies revealed 
high levels of  CB2 mRNA in the CB2 positive cell lines and not in the negative lines, 
suggesting altered transcription (unpublished observation). The cause of  these differences 
in transcription remains to be elucidated. When overexpressed in the myeloid precursors 
Cb2 induces a block in neutrophilic development17 and stimulates migration of  Cb2-
expressing cells in vitro7. The endocannabinoid 2-AG is the most potent agonist capable 
of  inducing migration of  cannabinoid receptor expressing cells7,9-11. Here we report that, 
2-AG has no effect on the G-CSF-induced differentiation of  32D/G-CSF-R/Cb2 cells 
in vitro, whereas another well described ligand CP55,94022,23, stimulates a neutrophilic 
differentiation block. The fact that the Cb2 inverse agonist SR144528 could fully 
counteract the two functions demonstrates receptor specifi city. To our knowledge this is 
the fi rst example of  a GPCR that, when overexpressed in myeloid precursors cells, causes 
two different effects depending on the ligand. 
 Normal murine bone marrow precursors aberrantly expressing Cb2 show a 
moderate but steady impairment of  maturation when cultured with G-CSF plus CP55,940. 
Leukemia is a multigenic disease, meaning that a combination of  genetic defects is required 
to obtain a full leukemia15,16. For instance, we previously demonstrated that aberrant 
Cb2 expression frequently coincides with aberrant expression of  Evi136,37, another 
transforming gene shown to be involved in impairment of  neutrophilic development38-40. 
The observation that in 32D/G-CSF-R cells Cb2 overexpression causes a complete block 
of  neutrophilic differentiation most likely refl ects cooperation between Cb2 and other 
genetic defects present in this myeloid precursor cell line. Interestingly, Evi1 retroviral 
insertions as well as overexpression have been reported for 32D cells41. It would be of  
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interest to study whether overexpression of  Cb2 in combination with Evi1 in normal 
marrow precursors would lead to a more severe block of  neutrophilic differentiation.
 The experiments presented in this manuscript demonstrate that Cb2 receptor may 
evoke two distinct biological effects depending on the ligand used for stimulation, i.e. 
migration upon 2-AG presentation and block in neutrophilic differentiation following 
exposure to CP55,940. How the interaction of  distinct Cb2 ligands to Cb2 receptor may 
result in activation of  different processes in the same cell is an interesting question to 
be addressed. Several examples exist of  one receptor interacting with distinct ligands. 
The cytokines IL-3, IL-5 as well as GM-CSF interact with different receptor complexes 
which all share a common beta-receptor chain. The specifi city of  these distinct ligands 
for the different complexes is determined by the ligand specifi c receptor alpha chains42,43. 
Similarly, IL-2, IL4, IL-7, IL-9 and IL-15 each interact with unique receptor complexes 
which all share a common gamma chain44,45. The distinct effects that we observed 
upon 2-AG or CP55,940 stimulation may be explained by stimulation of  two distinct 
receptor complexes which both contain the Cb2 receptor. For a long time it was generally 
believed that GPCRs function as monomers. However, GPCRs may be involved in high 
molecular weight complexes formed by homo- as well as hetero-dimers. Interestingly 
dimer formation may affect receptor-ligand binding, signaling and function46-48. Another 
intriguing observation is that agonist presentation can promote or decrease receptor 
dimerization in several GPCRs49-51. In addition, receptor heterodimerization between 
GPCRs may result in generation of  novel ligand binding sites 52, or novel ligand binding 
properties53. GPCRs may even interact with non-G protein-coupled receptors, such 
as tyrosine kinase receptors54. In this respect it is interesting to note that a functional 
interaction between CB1 receptor and fi broblast growth factor receptor as well as with 
the insulin-like growth factor 1-receptor has been demonstrated55,56. Our observation that 
binding of  distinct ligands to Cb2 receptors evoked different effects, may be explained by 
the Cb2 receptor being present in distinct complexes depending on the ligand, or acting 
as a monomer with one agonist and as a di- or multimere with the other. 
 Cb2 belongs to the family of  GPCRs3,57,58, suggesting that signaling upon receptor 
stimulation may require G proteins. The inhibition of  migration by PTX administration, 
as well as the ineffi cient chemotaxis of  cells expressing DRY-Cb2 mutants, indicate that 
Cb2 receptor requires G protein activity to induce migration upon 2-AG stimulation. In 
additon, most chemokine receptors belong to the subgroup of  GαiPCRs
59-61, suggesting 
that adenyl cyclase inactivation and cAMP downmodulation via Gαi proteins may be critical 
for induction of  migration. The decrease of  2-AG-induced migration of  32D/G-CSF-R/
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Cb2 cells following dbcAMP administration demonstrates that this pathway is critical for 
Cb2-mediated cell motility. On the other hand, our data show that downregulation of  the 
intracellular cAMP levels is not the only pathway involved in migration of  Cb2-expressing 
cells. Transwell studies using MEK inhibitors demonstrate that this route plays a critical role 
in 2-AG-stimulated chemotaxis as well. Previous studies demonstrated that stimulation of  
cannabinoid receptors Cb1 and Cb2 causes phosphorylation of  ERK and consequently 
activation of  this pathway62-64. Although critical for Cb2-induced chemotaxis, MEK/
ERK signaling is not a prerequisite for GPCR-induced migration in general. For instance, 
SDF-1-induced migration of  32D/G-CSF-R/Cb2 cells, that endogenously express 
CXCR4 receptor, is insensitive to the addition of  MEK inhibitors (data not shown). 
We clearly demonstrate that the 2-AG-induced migration involves MEK/ERK pathway, 
but the mechanism of  activation remains unclear. Multiple examples show that MEK/
ERK signaling route may be activated through the βγ complex65, although G protein-
independent manners of  ERK activation have been proposed as well for GPCRs65,66. 
Summarizing, Cb2-mediated migration depends on at least two distinct signaling pathways 
which both appear to be indispensable (Figure 7). 
Figure 7 | Schematic representation of  Cb2 signaling. Signal transduction pathways linked 
to Cb2 leading to the 2-AG-induced migration and the CP55,940-evoked block of  neutrophilic 
differentiation.
As with migration induction, our data suggest that multiple pathways are involved in the 
Cb2-induced block of  differentiation (Figure 7). MEK/ERK signaling has been shown 
to be critical, since MEK inhibitors fully recovered G-CSF-induced differentiation in 
the presence of  CP55,940. Previously, we demonstrated as well involvement of  PI3-K 
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in the Cb2-mediated block of  differentiation17. On the other hand, intracellular cAMP 
downregulation is unimportant for this effect. Moreover, the DRY motif, which is critical 
for the 2-AG-induced migration was completely unnecessary for the induction of  a 
maturation arrest. These experiments would suggest that G protein signaling is dispensable 
for the Cb2-induced differentiation block. However, we demonstrated that the CP55,940-
evoked block in differentiation of  32D/G-CSF-R/Cb2 cells could be fully reversed by 
the addition of  PTX. Therefore, these data suggest that activated Cb2 receptors may 
induce the proper signals via G proteins, but since we observed that the DRY motif  is 
unnecessary for the CP55,940-induced block of  differentiation, we suggest involvement 
of  another currently unknown G protein interaction domain in Cb2. 
 Multiple GPCRs have previously been reported to have transforming abilities, 
e.g. the α1B-adenergic67, thrombin68, and serotonin 1 C receptors69 and the receptor 
encoded by the Mas oncogene70,71. In contrast to Cb2, which interacts with Gαi subunits, 
a large number of  these previously identifi ed transforming GPCRs can associate with 
Gαs subunits
72. An interesting question to be addressed is whether transformation of  
myeloid precursor cells by Cb2 is a feature unique for this particular GPCR or whether the 
peripheral cannabinoid receptor is a paradigm for a novel class of  transforming GPCRs. 
The fact that we have shown that stimulation of  migration as well as the interference with 
differentiation by Cb2 are PTX sensitive, meaning involvement of  Gαi, may indicate that 
other Gαi interacting GPCRs with transforming abilities may exist. Interestingly, using 
retroviral insertional mutagenesis we and others recently identifi ed among a large panel of  
novel leukemia disease genes, four GPCR encoding genes73,74, unpublished observation. 
Three of  those genes encode GPCR that may interact with Gαi subunits, i.e. endothelial 
differentiation gene 3-R (Edg3-R), chemokine-R7 (CCR7) and vomeronasal1-R (V1-R). 
Introduction of  these transforming receptors or other potentially interesting GPCRs into 
32D/G-CSF-R cells will be a valid approach to answer the question whether Cb2 is a 
paradigm for a novel class of  transforming GPCRs.
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ABSTRACT
Using two distinct anti-CB2 receptor antibodies, we investigated the expression patterns 
of  the peripheral cannabinoid receptor CB2 in human secondary lymphoid organs. 
Immunohistochemical analysis using an N-terminal specifi c anti-CB2 antibody revealed 
high protein expression in the germinal centres (GCs) of  secondary follicles. A C-terminal 
specifi c anti-CB2 antibody, which only recognises a non-phosphorylated inactive receptor, 
showed positivity in the mantle zones (MZs) and marginal zones (MGZs) of  the secondary 
follicles where resting cells reside, and in the primary follicles. In contrast, no positivity 
was observed in GCs using the C-terminal antibody, suggesting that active CB2 receptors 
are mainly present on cells in the GCs. Dual immunohistochemical analysis revealed that 
B-lymphocytes express the CB2 protein abundantly. In contrast to B-cells in the MZ or 
MGZ, CB2 expressing cells in the GCs co-express the co-stimulatory membrane protein 
CD40 and the proliferation marker Ki-67. Using the human Raji B-cell line as a model, 
we demonstrate in a transwell assay that moderate migration occurs upon stimulation of  
the CB2 receptor with the endocannabinoid 2-arachidonoylglycerol, which is enhanced 
by CD40 co-stimulation. Our fi ndings, that GC-related cells express active CB2 and that 
CB2-dependent migration requires CD40 co-stimulation, suggests that CB2 is involved 
in B-cell activation. 
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INTRODUCTION
Two cannabinoid receptors, which are expressed in distinct organ systems, have previously 
been identifi ed. The central cannabinoid receptor CB11 is primarily expressed in brain, 
whereas the peripheral cannabinoid receptor CB22 is mainly present in immune tissues. 
CB2 mRNA has been detected in human haematopoietic cells, with B-cells expressing 
the highest transcript levels3,4. In fact, using a polyclonal antibody (PoAb) raised against 
the C-terminus of  the human CB2 receptor, Carayon et al demonstrated expression of  
the CB2 protein in the mantle zones (MZs) of  secondary follicles of  tonsils5. These 
investigators reported that there was no CB2 staining on B-lymphocytes in the germinal 
centres of  the secondary follicles. Importantly, the antibody used recognised CB2 
receptors in a non-phosphorylated inactive state5,6. The observation that no expression 
was evident on B-cells in the germinal centres (GCs), could mean that the cells in the GCs 
did not express CB2 receptors at all or that CB2 receptors were present on these cells, but 
in an active form undetectable with this antibody. Insight into the distribution of  active 
versus inactive CB2 receptors on cells of  the immune system may provide understanding 
of  the functional aspects of  this receptor in its physiological environment. Using another 
anti-CB2 antibody raised against the N-terminus of  the CB2 receptor in combination 
with the previously reported C-terminal specifi c anti-CB2 antibody, we therefore have 
investigated the distribution of  CB2 receptors within normal lymphoid organs. We have 
demonstrated different staining patterns depending on the CB2 antibody used, implying 
distinct distribution of  active versus non-active receptors. The inactive receptors were 
found in the MZs of  secondary follicles, whereas active peripheral cannabinoid receptors 
were present in the GCs. Next, dual immunohistochemistry was applied to investigate 
the immunophenotype of  the CB2-expressing cells. The data show that whether present 
in an active or inactive form CB2 was mainly expressed on B-lymphocytes. Moreover, in 
the GCs of  secondary follicles the active form of  CB2 was observed in cells expressing 
both the co stimulatory molecule CD40 and the proliferation marker Ki-67, suggesting an 
immunomodulatory function of  the CB2 receptor in the GCs. We therefore assessed the 
functional relation between CB2 and CD40. We have demonstrated that the major function 
of  the CB2 receptor on splenic B-cells is stimulation of  migration, upon exposure to the 
endocannabinoid 2-arachidonoylglycerol (2-AG)7. Using the Raji B-lymphoma cell line as 
a model, we investigated the involvement of  CD40 on CB2 mediated effects on B-cells. 
We have found that migration is a major function of  the CB2 receptor upon stimulation 
with 2-AG, which is signifi cantly augmented following CD40 stimulation, suggesting 
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cross talk between the two receptors. Our investigations suggest a critical role for CB2 in 
migration of  B-cells and the GC-response. 
MATERIALS AND METHODS
Antibodies, ligands and cell lines
The polyclonal human anti-C-terminal-CB2 receptor antibody and the synthetic peptide 
derived from the predicted amino acid-sequence of  the carboxyterminus of  the receptor 
(Y-P-D-S-R-D-L-D-L-S-D-C) were kindly provided by P. Case llas (Sanofi -Synthelabo 
Recherche, Montpellier, France). The anti-CB2 receptor PoAb raised against the fi rst 33 
amino acid residues of  the N-terminus of  the receptor was purchased from Affi nity 
Bioreagents Inc (ABR, CO, USA). The non-stimulatory/non inhibitory CD40 control 
antibody (nCD40), the anti-CD40 stimulatory antibody (sCD40/clone 7) and the anti-CD40 
inhibitory antibody (iCD40/5D12) were kindly donated by Dr. L. Boon (PanGenetics BV, 
Amsterdam, The Netherlands). Other antibodies used for immunohistochemical analysis 
are listed in Table 1. The Raji cell line, donated by I.Touw (Department of  Haematology 
Erasmus MC, Rotterdam, The Netherlands) was cultured in RPMI 1640 medium 
(Life Technologies, Breda, The Netherlands) and supplements: penicillin (100 U/ml), 
streptomycin (100 ng/ml) and 10% fetal calf  serum (Life Technologies). The Chinese 
Hamster Ovary (CHO) cell line and CHO cell line transfected with CB2 (CHO-CB2), 
kindly donated by P.Casellas, were cultured in MEM-alpha Medium (Life Technologies) 
and supplements. The CB2 cannabinoid ligand 2-arachidonoylglycerol (2-AG) was 
obtained from Sigma (Zwijndrecht, The Netherlands). The CB1-specifi c inverse agonist 
SR141716 and CB2- specifi c inverse agonist SR 144528 were kindly donated by P. Casellas.
Immunohistochemistry
Single staining
Formalin-fi xed, paraffi n embedded normal lymph node, spleen and thymus were retrieved 
from the fi les of  the department of  Pathology at the Erasmus MC. Five μm thick sections 
were deparaffi nized, rehydrated and endogenous peroxidase was blocked with 3% H2O2 
in methanol for 20 minutes at room temperature (RT). Heat induced antigen retrieval 
(required for staining with the C-terminal anti-CB2 antibody) was achieved by boiling 
the sections for 20 minutes at 100°C in citrate buffer (10 mM, pH 6.0) in a Micromed 
T/T Mega microwave oven (Salm and Kipp, Breukelen, The Netherlands). Sections were 
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cooled down, washed and incubated with the fi rst panel of  primary antibodies for 1 
hour at RT (C-terminal anti-CB2 1:400, or N-terminal anti-CB2 1:600), and subsequently 
incubated for 10 minutes with biotinylated secondary antibodies (anti- mouse and rabbit 
immunoglobins; Labvision) followed by a 10-minute incubation with streptavidin-
conjugated (S-ABC) horseradish peroxidase (Labvision). Visualisation was achieved 
using 3-amino-9-ethylcarbazole (AEC; Sigma USA) in NaAc buffer (0.2M, pH 4.6) for 
30 minutes in dark, which yielded in a red signal. Finally, sections were counterstained 
with haematoxylin according to Harris (Klinipath, Duiven, The Netherlands), dehydrated 
and covered by imsol (Klinipath) and by pertex (Histolab, Göteborg, Sweden). Standard 
haematoxylin-eosin (HE) staining and negative controls (omission of  primary antibody) 
of  all examined tissues were included. Specifi city controls were performed by pre 
incubating the C-terminal anti-CB2 receptor antibody for one hour with the synthetic 
peptide at 10 mg/ml.
Table 1 | Antibodies and conjugates used for dual immunohistochemical analysis.
Primary antibodies Specifi city Dilution/
Epitope retrieval1
Source
CD3 (polyclonal)
CD20 (monoclonal)
CD79a (monoclonal)
IgD (polyclonal)
CD40 (monoclonal)
Ki-67 (monoclonal)
Pan-T cell
Pan B cell
Pan B cell; plasma cells
Naive B cells
B-cell subset (GC-related)
Proliferating cells
1:600/yes
1:400/no
1:100/yes
1:200/yes
1:100/yes
1:100/yes
DAKO
DAKO
DAKO
DAKO
Donated
Immunotech2
Secondary antibodies and conjugates
Swarbio
RaMbio
S-ABCAP-kit
S-ABC HRP-kit
Swine-anti -rabbit
Rabbit anti-mouse
Streptavidin-biotin alkaline phospatase
Streptavidin biotin horse radish peroxidase
1:200
1:200
1:100
1:100
DAKO
DAKO
DAKO
DAKO
1Antigen retrieval was performed by pretreating sections in a microwave oven (see Materials and Methods). 
2Immunotech, Prague, Czech Republic.
Dual staining
A panel of  B and T-cell markers, a proliferation marker (Ki-67) and biotin conjugated 
secondary antibodies were used for dual immunohistochemistry. The list of  the antibodies, 
their antigen retrieval and their sources and dilutions are listed in Table 1. Sections were 
fi rst incubated with the CB2 antibodies, and stained with AEC as described for the single 
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staining procedure. Sections were individually incubated with the primary antibodies 
listed in Table 1 for 30 minutes, washed and incubated with the biotin conjugated 
secondary antibodies for 30 minutes at RT. An S-ABC conjugated alkaline phosphatase 
kit (DAKO, Glostrup, Denmark) was used to enhance the signal. Visualisation of  the 
signal was achieved using a solution containing Fast Blue BB salt (4-benzoylamino-2, 
5-diethoxylbenzene diazoniumchloride; Sigma), naphtol-AS-MX phosphate (Sigma) and 
levamisole hydroxychloride (Acros Organics, Geel, Belgium) in Tris/HCl buffer (0.2M, 
pH 8.0). Sections were incubated for 30 minutes in dark with this solution, which fi nally 
resulted in blue staining of  cells. In case of  co-expression/ co-staining, the mixture of  red 
and blue signals resulted in a dark purple staining of  cells. Cells were counter-stained with 
haematoxylin according to Harris (Klinipath) and covered by pertex. 
Flowcytometric analysis 
Flow cytometric analysis was carried out using a FACScan fl ow cytometer (Becton 
Dickinson Mountain View, CA). In brief, cells were washed with Hanks balanced salt 
solution (HBSS) (HANKS, Invitrogen Corporation, Paisley, U.K.) and PBS, incubated on 
ice with the polyclonal N-terminal anti-CB2 antibody (1:50) or the nCD40 monoclonal 
antibody (1:100) for an hour, washed twice with PBS and incubated with the FITC-
conjugated secondary rabbit (1:200 GAR-FITC/IgG; Nordic Immunological Labs, 
Tilburg, The Netherlands) or mouse antibody (1:200 GAM-FITC; ITK Diagnostics, 
Uithoorn, The Netherlands) for 30 minutes. Finally, cells were washed twice with PBS 
and resuspended in 500 ml PBS and analysed.
Immunofl uorescence microscopy and cytospins
After fl owcytometric analysis cytospins of  cells stained with the N-terminal CB2 were 
made and analysed for membrane expression. To investigate cytoplasmatic CB2 expression, 
cells were fi xed in 4% paraformaldehyde at 4ºC for 20 minutes, washed twice in PBS and 
incubated for 1 hour at RT with the N-terminal CB2 antibody in a permeabilising PBG-T 
solution (0.1M phosphate buffer; 0.5%BSA; 0.2% gelatine; 0.05% Triton X100). Then cells 
were washed twice in PBG-T and incubated with the FITC-conjugated secondary rabbit 
antibody (1:200) for 1 hour at RT. Cells were washed again and embedded in vectashield. 
(twice in PBG-T and twice in milliQ, embedded in vectashield) (Brunschwig Chemie, 
Amsterdam, The Netherlands) and visualised with an immunofl uorescence microscope 
(Leica Mikroskopie & 
Systeme GmbH, Solms, Germany).
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Migration assay
Migration assays were performed using 6.5mm-diameter transwells with a 5 mm pore size 
(Corning Costar, Amsterdam, The Netherlands). In brief, cells were washed twice with 
HBSS medium, resuspended in 100 ml of  migration medium (Iscoves modifi ed Dulbecco 
medium (IMDM) plus 0.5% BSA) and placed in the upper chamber of  a transwell with 
or without CB1- or CB2-specifi c inverse-agonists (100nM). In the lower chamber, 600 
ml migration medium with or without ligand (2-AG 300nM) was placed. After 4 hours 
of  incubation at 37ºC and 5% CO2, the upper chamber was removed and the numbers 
of  migrated cells were determined using a CASY1/TTC cell counter (Schärfe System, 
Reutlingen, Germany).
RESULTS
Flowcytometric analysis of  CB2 transduced CHO cells
Two polyclonal antibodies directed to the peripheral cannabinoid receptor (CB2) were 
used in this study to investigate expression of  this receptor in human immune tissues. 
Specifi city of  the antibodies was confi rmed using CHO cells transfected with human 
CB25. CB2 membrane staining was demonstrated with the antibody directed to the 
N-terminal extra cellular domain using non-permeabilised CHO-CB2 cells (Figure 1A). 
Membrane bound and cytoplasmic CB2 expression was demonstrated in permeabilised 
CB2 expressing CHO cells (Figure 1B). An antiserum recognising the intracellular 
C-terminal part of  CB2 was also highly positive in permeabilised CHO-CB2 cells (Figure 
1C). As expected, no positivity was observed when the latter antibody was used on non-
permeabilised CHO-CB2 cells (data not shown). Remarkably, a lower signal was evident 
when the N-terminal specifi c antibody (Figure 1A and B) was used as compared to the 
analysis with the C-terminal specifi c anti-CB2 (Figure 1C), which may suggest that the 
latter antibody binds CB2 with a higher affi nity or that the differences in staining by the 
CB2 antibodies may be the result of  differences in epitope accessibility. No positivity at 
all was observed using the CB2 antibodies in non-transduced CHO-cells (Figure 1D and 
E). Importantly, the C-terminal anti-CB2 antibody only recognises the receptor in an 
inactivated non-phosphorylated state5,6. The N-terminal CB2 antibody on the other hand, 
recognises the receptor in both an active and inactive state. 
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Figure 1 | CB2 protein expression in CHO and CHO-CB2 cells. CB2 membrane expression (A) 
and intra cellular CB2 protein expression (B) was shown in CHO-CB2-cells transfected with human 
CB2 (CHO-CB2) using the N-terminal anti-CB2 antibody. Intra cellular CB2 protein in CHO-CB2 
cells using the C-terminal anti-CB2 antibody (C) was also investigated. CB2 protein expression was 
analysed in non-CB2-transduced CHO cells using the N-terminal (D) and C-terminal (E) anti-CB2 
antibodies respectively. Intra cellular CB2 was analysed in permeabilised cells (see Materials and 
Methods). The fi lled areas show CB2 protein expression, the grey lines represent background staining 
(only secondary Ab).
CB2 receptor expression in primary and secondary follicles in spleen and 
lymph node
Primary follicles
Immunohistochemical staining of  spleen sections using a C-terminal (inactive CB2 
receptor) or N-terminal anti-CB2 receptor antibody (non-discriminating) showed CB2 
expression in the follicular B-cell areas. In primary follicles, the cells were highly positive 
using the C-terminal specifi c CB2 antibody (Figure 2A and B). Weaker expression was 
observed using the N-terminal CB2 antibody (Figure 2C and D). These data suggest 
that mainly inactive CB2 receptors are present on cells in the primary follicles. Specifi city 
was evident, since binding of  the C-terminal antibody was completely blocked when the 
antibody was pre-incubated with its specifi c peptide (Figure 2E). No staining was observed 
when only the secondary antibody was used (Figure 2F). Exactly the same results were 
obtained when normal lymph nodes were studied (data not shown). 
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Figure 2 | CB2 expression in primary follicles of  the human spleen. CB2 expression is 
demonstrated using the C-terminal (A,*5; B *20) and the N-terminal (C, *5; D, *20) anti-CB2 
antibodies respectively. Specifi city of  the C-terminal anti-CB2 antibody was confi rmed by pre-
incubation with a specifi c C-terminal peptide (E; 5*). Staining with only the secondary antibody 
(F; 5*) served as a negative control. P=primary follicle; red staining=C-or N-terminal CB2 antibody 
staining; blue staining=counterstaining with haematoxylin. See page 162 for color fi gure.
Secondary follicles
CB2 expression patterns in the secondary follicles of  lymph nodes were also determined 
using the same antibodies. The C-terminal CB2 specifi c antibody mainly recognised cells 
present in the MZ and the MGZ of  the secondary follicles (Figure 3A-C). The N-terminal 
specifi c CB2 receptor antibody only weakly recognised cells in these zones (Figure 3E). 
On the other hand, using this antibody, strong staining was observed in the GCs of  the 
secondary follicles (Figure 3D-F), whereas only weak staining was found in those regions 
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using the C-terminal antibody (Figure 3A-C). Strong binding of  the CB2 N-terminal 
specifi c antibody suggests high receptor numbers present on the cells in the GCs. These 
results also suggest that cells in the GC mainly express active CB2, whereas inactive CB2 
is present on cells in the MZ and MGZ of  the secondary follicles. Remarkably, most 
prominent staining with the two antibodies occurred in the cytoplasm of  the cells (Figure 
3C and F).
Figure 3 | Single immunohistochemical analysis in primary and secondary follicles of  
the human lymph node. C-terminal anti-CB2 antibody staining pattern is depicted in fi gures 
(A; 1.25*), (B; 10*) and (C; 20*). N-terminal anti-CB2 antibody staining pattern is shown in fi gures 
(D; 1.25*), (E; 10*) and ((F;20*, insert *40). P= primary follicle; s= secondary follicle; MZ=mantle 
zone; MGZ=marginal zone; GC=germinal centre. Black rectangles represent magnifi cations of  
Peripheral cannabinoid receptors on B-lymphocytes | 61
areas of  interest. Red staining=C-or N-terminal CB2 staining; blue staining=counterstaining with 
haematoxylin. See page 163 for color fi gure.
Differential CB2 receptor expression on B-cell subsets
Inactive CB2 receptors on resting B-cells 
Dual-immunohistochemistry using B-cell specifi c antibodies (Table 1) has been carried 
out in combination with the anti-CB2 receptor antibodies. First, we studied the cells 
carrying inactive CB2 receptors. Almost all cells in the primary follicles and in the MZ 
and MGZ of  secondary follicles, co-expressed (dark purple) CD79a (pan B-cell marker; 
blue) and the inactive CB2 (red) on their surfaces (Figure 4A). The same results were 
obtained with another pan B-cell marker, CD20 (data not shown). Similarly, signifi cant 
expression of  inactive CB2 (red membrane/cytoplasmic staining) was evident in IgD 
expressing resting follicular B-cells (dark purple membrane staining) in primary follicles 
and MZ/MGZ of  secondary follicles (Figure 4B). No staining was observed when the 
primary antibodies were omitted in the immunohistochemical analysis (data not shown).
CB2 receptors on activated B-cells in the germinal centres (GC)
Next, we investigated the immunophenotype of  the CB2 receptor expressing cells in the 
GC of  the secondary follicles in lymph nodes. CB2 receptor expressing cells in the GC 
(as demonstrated with low staining with C terminal CB2 antibody and strong staining with 
N-terminal antibody) showed strong positivity with the pan B-cell marker CD79a (Figure 
4C). These cells also expressed CD20 (data not shown), but were mostly IgD negative 
(Figure 4D). As expected the CD79a positive cells in the GC showed no co-staining with 
the C-terminal CB2 antibody (Figure 4E). Altogether, these data suggest the abundant 
expression of  active CB2 receptors on B-cells in the GCs.
 To investigate whether the cells in the GC, expressing an active CB2 receptor, 
indeed represent activated B-lymphocytes engaged in the GC response, we analysed co-
expression of  CD40 or Ki-67 with CB2. The cells in the GC showing intense staining 
with anti-N-terminal CB2 were highly CD40 and Ki67 positive as well (Figure 5A and B). 
No co-staining was observed using anti-Ki-67 and the C-terminal specifi c CB2 antibody 
(Figure 5 C). 
CB2 receptor specifi c migration is enhanced by CD40 specifi c stimulation 
Co-expression of  CD40 and active CB2 receptors on B-cells in the GC, prompted us to 
investigate a functional interaction between those two molecules. CB2 has been described 
as a G-protein-coupled-receptor (GPCR) involved in migration following exposure to 
62 | Chapter 3
the endocannabinoid, 2-arachidonoylglycerol (2-AG)7. We studied CB2/CD40 interaction 
using the Raji B-cell line as a model. First CD40 membrane expression on Raji was 
demonstrated by fl owcytometry (Figure 6A). Using the N-terminal specifi c CB2 antibody, 
protein expression was observed in the cytoplasm of  these cells (Figure 6C), as was 
observed by the immunohistochemical analysis (Figure 3). CB2 membrane expression 
was undetectable (Figure 6B). 
Figure 4 |CB2 coexpression analysis in normal human lymph nodes. Co expression was 
analysed in primary and secondary follicles using the C-terminal anti-CB2 antibody with the pan 
B-cell marker CD79a (A; 10*) or with IgD (B; 20*). Using the N-terminal anti-CB2 antibody, 
co expression of  CD79a expressing cells (C; 10* and 40*), or IgD (D; 10*) expressing cells was 
also analysed. Detailed co expression analysis of  CD79a positive GC cells using the C-terminal 
anti-CB2 antibody is shown in fi gure (E; 10*). Open and fi lled arrows indicate coexpression; red 
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arrows inidcate lack of  coexpression. Red staining= C-or N-terminal CB2; blue staining= CD79a 
(A,C, and E) or IgD (B and D); purple staining=coexpression. The fi lled rectangle represents the 
magnifi cation of  the area of  interest. P=primary follicle. See page 166 for color fi gure.
Figure 5 | Coexpression of  CD40 and Ki67 positive GC cells. Coexpression of  CD40 and 
Ki67 positive cells in the GCs of  secondary follicles of  lymph nodes using the N-terminal anti-CB2 
antibody (A; 10 and 20* respectively; and B; 20 and 40* respectively). The C-terminal anti-CB2 
antibody was used to determine co expression of  Ki-67 positive GC cells (C; 20 and 40*respectively). 
Open rectangles represent magnifi cations of  areas of  interest. Costaining is indicated by purple 
membrane staining of  CB2 and CD40 (A) or red membrane staining (N-terminal CB2) with blue 
nuclear staining (Ki-67; B). Cells are either highly red (membrane/cytoplasmatic) or blue (nuclear) 
stained when costaining is absent (C). See page 167 for color fi gure.
Next, transwell assays were carried out to investigate migration in response to distinct 
stimuli (Figure 7). Raji cells moderately migrated upon stimulation with 2-AG (Figure 
7A). However, following stimulation with an anti-CD40 stimulatory antibody (sCD 40), 
enhanced migration was observed upon exposure to 2-AG. This migration was specifi c 
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since the CB2 receptor inverse agonist (SR144528) completely abolished this effect. The
Figure 6 | CD40 and CB2 expression in Raji cell line. Flowcytometry of  Raji cells determining 
CD40 expression (A). CB2 membrane expression on non-permeabilised cells (B) and intra cellular 
CB2 protein in permeabilised cells (C) was analysed using the N-terminal specifi c anti-CB2 receptor 
antibody. The fi lled areas represent CD40 (A) or CB2 (B) positive cells; the grey lines (A and B) 
represent background staining (only secondary antibody). The green dots represent CB2 protein in 
the cytoplasm; blue counter stain with diamino-2-phenylindole refl ects the nuclei of  Raji cells. See 
page 162 for color fi gure.
CB1 receptor specifi c antagonist (SR 141716) did not infl uence the sCD40-enhanced 
migration (Figure 7A). An inhibitory CD40 specifi c antibody (iCD40), when added in 
10-fold excess, completely abolished the sCD40 (stimulatory antibody) enhanced 2-AG 
induced migration of  Raji-cells (Figure 7B). Non-stimulatory CD40 antibodies (nCD40) 
serving as a control did not enhance 2-AG induced migration (Figure 7B). CB2 membrane 
expression did not detectably increase following exposure to the CD40 stimulatory 
antibody, as determined by fl owcytometry (data not shown). 
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Figure 7 | Migration of  Raji cells in response to distinct stimuli. Cells were 
stimulated for 24 hours in the presence or absence of  sCD40 monoclonal antibody 
(MoAb) (K7; 100nM), sCD40 MoAb (100nM) plus iCD40 (5D12; 1000 nM) or nCD40 
(100nM). Migration was investigated in the presence or absence of  the CB2 ligand 2-AG 
(300nM). The upper wells contained either non-stimulated or stimulated cells in the 
presence or absence of  CB1 (SR141716; 100nM) or CB2 specifi c inverse agonists (SR 
144528; 100nM). Y-axis shows percentage of  migration from an input of  1 х 105 cells. A, 
represents the mean migration with the Ses of  the means of  three individual experiments.
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DISCUSSION
In this study we investigated the distribution CB2 receptors as well as their activation 
status in human immune tissues using two distinct anti-CB2 antibodies. Specifi city of  
a C-terminal and a N-terminal specifi c CB2 antibody was demonstrated in CHO cells 
transfected with human CB2. We demonstrated that CB2 protein was present on the 
membrane as well as in the cytoplasm of  these cells (Figures 1A-E). Applying these 
antibodies in single immunohistochemical staining, we observed distinct expression 
patterns in B-cell areas in human lymphoid organs. In conjunction with previous studies5 
we found CB2 receptors in the MZs using the anti-C-terminal CB2 antibody. We also 
observed CB2 positivity in primary follicles and in the MGZs of  secondary follicles, using 
this antiserum. As the C-terminal specifi c antibody only recognizes non-phosphorylated 
CB2, apparently inactive CB2 receptors are present on B-lymphocytes in these particular 
areas. It will be of  interest to investigate CB2 phosphorylation in B-lymphocytes, especially 
in relation to the antigen specifi c activation and proliferation of  these cells.
 Only low CB2 positivity was observed in the MGZ when the N-terminal specifi c 
antibody was used. A possible explanation for the differences observed between the two 
antibodies may be that the C-terminal specifi c antibody binds CB2 with a higher affi nity 
than the N-terminal specifi c CB2 antiserum (Figure 1). Alternatively it is also possible 
that the differences in staining by the CB2 antibodies may be the result of  differences in 
epitope accessibility.
 In this paper, using the N-terminal specifi c antibody, we have demonstrated, that 
various CB2 expressing B-cell subsets exist. Some of  these B-cell populations are only 
weakly stained with the C-terminal anti-CB2 antibody. Therefore, the CB2 receptors on 
these cells are most probably phosphorylated and therefore in an active state6. Because 
of  the low affi nity of  the N-terminal specifi c antibody, a strong positivity most likely 
indicates high numbers of  CB2 receptors on these cells. These cells reside in an anatomical 
location where B-memory cells are formed and affi nity maturation occurs, i.e. the GC 
of  secondary follicles, and they express CD79a but are mainly IgD negative (Figures 
4C and D). B-cells in primary follicles or in the MZ/MGZ of  secondary follicles may 
express low levels of  CD40. On the other hand, B-cells in the GCs of  secondary follicles 
highly express CD40 as well as Ki-67, a proliferation marker (Figures 5 A and B), markers 
characteristic for actively cycling B-cells in the GC. All in all, it appears that functional 
CB2 receptors are present on immunologically active B-lymphocytes.
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Dual immunohistochemistry using pan-B-cell markers confi rmed previous observations 
that in general B-lymphocytes are the leukocyte subsets expressing CB2 mRNA and 
protein3-5 (Figure 4). Furthermore, modulation of  this receptor during B-cell differentiation 
has been demonstrated5 using the C-terminal anti-CB2 antibody. In accordance with this 
fact, we found CD79a, IgD positive resting B-cells in the MZs highly expressing inactive 
CB2 (Figure 4A and B). The co expression of  CB2 and CD40 on activated B-lymphocytes 
prompted us to investigate the functional relation between those two membrane proteins. 
CD40 belongs to the TNF-receptor family and is involved in B-cell activation, survival, 
proliferation, differentiation and Ig-isotype switch8. Previous studies in mice have shown 
that upon CD40 stimulation mCB2 mRNA may be up regulated9. An increase in CB2 
mRNA following CD40 stimulation has been demonstrated in human tonsillar B-cells as 
well5. We demonstrate, using a B-lymphoid cell line as a model, that migration of  B-cells 
in response to the CB2 specifi c ligand 2-AG was signifi cantly enhanced following CD40 
stimulation. The mechanism of  activation appears to be a different one, since we neither 
found any increase of  the CB2 protein levels, nor did the CB2 receptor activation status 
change following CD40 stimulation (data not shown). The peripheral cannabinoid receptor 
belongs to the family of  G-protein coupled 7-transmembrane receptors (GPCRs)3,4. 
GPCRs are crucial to many cellular functions such as proliferation, maturation, survival, 
apoptosis or migration10-12; Carayon et al showed moderate proliferation of  virgin and 
GC tonsillar B-cells upon stimulation with the synthetic cannabinoid agonist CP55,940 
only when the cells were stimulated with CD40 MoAbs5. In our functional study with Raji 
B-lymphoma cells, we observed moderate migration upon stimulation with the CB2 ligand 
2-AG. Interestingly, this migration was greatly enhanced when cells were stimulated for 24 
hrs with a stimulating CD40 MoAb (Figure 7). Furthermore, this enhanced migration was 
CB2 and CD40 receptor specifi c, since the effects could be specifi cally blocked by the CB2 
inverse agonist (SR144528) and the CD40 antagonist (5D12). A similar observation has 
been reported for CXCR4 and CD40 on GC cells. CD40 pre treatment of  these cells led 
to an increased migration upon stimulation of  by the CXCR4 ligand SDF-113. Apparently, 
exposure to CD40 activating agents is crucial for the induction of  a functional response 
of  certain GPCRs such as CB2 or CXCR4. 
 Studies of  the potential involvement of  cannabinoid receptors and stimulation 
by cannabinoids in the immune system have been reported previously14-19. In fact, 
immuno-modulation by cannabinoids is absent in mice defi cient for the cannabinoid CB2 
receptor20. Recently it was also demonstrated that human antigen presenting dendritic 
cells produce high levels of  endocannabinoid ligand 2-AG21 and that 2-AG is probably 
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the physiological ligand for the cannabinoid CB2 receptor22. These fi ndings together with 
our observations that 1) active CB2 receptors are present on immunologically active cells 
and 2) CB2 response may be increased by the co stimulatory molecule CD40 provide 
evidence that CB2 receptors may be involved in B-cell activation.
 The observation that CB2 receptors are present on B-lymphocytes and show 
migratory function in a malignant B-cell line raises the question whether this receptor is 
also involved in the malignant transformation of  B-cells resulting in lymphomas or whether 
this receptor contributes to a specifi c function of  malignant B-cells. CB2 dependent 
migration in vitro in a B-lymphoma cell line could give a direction towards homing of  
malignant B-cells in vivo. In the staging of  B-lymphomas, bone marrow infi ltration is one 
of  the important parameters. Therefore analysis of  the CB2 receptor status could play an 
important role as a prognostic and /or diagnostic marker, possibly predicting spreading 
from the initial localisation of  the tumour. In high-throughput non-Hodgkin lymphoma 
(NHL) patient screens using tissue micro arrays, currently in progress to identify potential 
novel diagnostic and or prognostic markers in NHL, CB2 is the most interesting one. 
Furthermore, a correlation between the active CB2 receptor state in normal immune 
tissues and NHLs can also be made to see whether in a malignant setting the functional 
relation between CB2 and CD40 receptors is still evident.
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ABSTRACT
The peripheral cannabinoid receptor CB2 is expressed highly on normal human 
B-lymphocytes. C-terminal specifi c anti-CB2 antibody recognises a non-phosphorylated 
inactive receptor on naïve and resting B-lymphocytes. Another, N-terminal specifi c CB2 
antibody, primarily recognises B-cells present in the germinal centres of  secondary follicles 
in lymph nodes. We hypothesise that N-terminal specifi c CB2 antibody recognises activated 
CB2 receptors. In this study we showed using these antibodies, that expression of  CB2 
is generally absent on T-lymphocytes in reactive, non-malignant human lymphoid tissues. 
Applying single and dual immunohistochemistry, CD23+ follicular dendritic cells and a 
small but signifi cant subpopulation of  CD68+ macrophages showed positive staining with 
the N-terminal specifi c CB2 antibody but not with the C-terminal specifi c CB2-antibody. 
This may indicate the presence of  an active CB2 receptor on these cells with possible 
involvement in immunomodulation. In contrast to the low expression on normal T-cells, 
abundant levels of  CB2 protein were present on T-Non-Hodgkin Lymphomas (NHL). 
Moreover, in many B-NHL, high CB2 protein expression was found as well. In contrast 
to the distinct expression patterns in normal immune tissues using the two different CB2 
antibodies, NHL specimens in general stained positively with both. We conclude that CB2 
receptor expression pattern may be abnormal in NHL.
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INTRODUCTION
Two distinct cannabinoid receptors have previously been identifi ed, i.e. the “central” 
cannabinoid receptor CB1, mainly expressed in brain1-6 and the “peripheral” cannabinoid 
receptor CB2 expressed in particular haematopoietic cells, with highest transcript levels 
in B-cells7-9. It has been reported that activation or inactivation of  CB2 receptor using 
specifi c agonists or inverse-agonists results in phosphorylation at serine 352, located 
intracellularly at the C-terminus of  CB210,11. Although the exact function of  CB2 in B-cell 
development is still elusive, we recently reported some striking features of  CB2 receptor 
expression and receptor status in human immune tissues12. High CB2 protein expression 
was observed in the mantle zones (MZs) and marginal zones (MGZ) in secondary follicles 
of  human lymph nodes, using a C-terminal specifi c antibody, which only identifi es inactive 
serine 352 non-phosphorylated receptors12. Although, weak staining was observed on 
B-cells in the germinal centres (GCs) of  secondary follicles using this latter antibody, 
high numbers of  CB2 receptors could be detected on B-cells in GCs using another CB2 
specifi c antibody directed to the N-terminal extra cellular part of  the receptor. The fi nding 
that the staining pattern with this antibody was completely opposite to that obtained with 
the C-terminal specifi c antiserum12, led to the conclusion that this antiserum probably 
recognizes activated CB2 present on B-cells in the GCs. Furthermore, we found that these 
cells are located in these immunologically active areas and express CD40 and Ki-67 as well 
suggesting an immunomodulatory function for this receptor12. 
 A role for cannabinoid receptors on normal haematopoietic cells other than 
B-lymphocytes has been suggested. For instance, several investigators have reported that 
CB2 transcripts may be present in macrophages, dendritic cells or T-lymphocytes9,13. On 
the contrary, little is known about CB2 protein expression or receptor activation status in 
these cells. In the fi rst part of  the study presented here, we investigated which areas other 
than the B-cell regions in various haematopoietic and immunologic organs express CB2 
receptors. Using dual-immunohistochemical methods, we studied which cells expressed 
CB2 and applying the different CB2 receptor specifi c antibodies, we studied a possible 
correlation with CB2 receptor activation status on these cells. 
 Cannabinoid receptors may play a role in leukaemia and lymphoma development14-16. 
CB2 receptors have been identifi ed on acute myeloid leukaemia (AML) cells, whereas 
they were not found on their normal bone marrow counterparts16. Intriguingly, using in 
vitro models, it was observed that activation of  CB2 on myeloid leukaemia cells causes 
neutrophilic differentiation block, which could be reversed using a CB2 specifi c inverse 
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agonist. These studies suggest that CB2 receptors may play a role in AML development 
in mouse and in human. It has also been demonstrated that cannabinoid ligands may 
interfere with proliferation of  lymphoid tumor cells15. These latter experiments have 
been performed with cell lines only, and the expression and activation status of  the CB2 
receptors has not been studied. Flygare et al. recently reported response to canabinoids 
of  mantle cell lymphoma’s, although they concluded that particularly CB1 receptors were 
responsible for these effects14. In the second part of  the study, we applied histochemistry 
using the distinct CB2 specifi c antibodies and investigated whether CB2 receptors may 
be expressed on distinct lymphoma subtypes and whether CB2 receptors present on 
these cells may be active or inactive. We hypothesise that CB2 expression and probably 
activation status in the various lymphoma subtypes is signifi cantly distinct from that in 
normal reactive lymphoid tissue and may consequently be abnormal. 
MATERIALS AND METHODS
Patient samples
Whole sections of  FL (n=13), MCL (n=18), DLBCL (n=150) and T-NHL (n=7), patients 
were analysed immunohistochemically (Tables 3 and 6). These patients were originally 
included in the HOVON 25 trial (Dutch-Belgian Hemato-Oncology Cooperative Group)17 
in which 389 patients of  65 years and older with an intermediate or high grade lymphoma 
according to the Working Formulation and an advanced stage disease (Ann Arbor stages 
II-IV) were included between August 1994 and September 2000. Informed consent was 
obtained from all patients according to regulations of  the Dutch health authorities. Cases 
were considered as positive if  cells of  interest stained >75%, and partially positive if  they 
were >50% positive. We selected from the archives of  the Department of  Pathology of  
the Erasmus Medical Centre (MC), all cases aged above 18 years with a biopsy proven 
NHL. In total, we included 360 patients with different sub types of  NHL, of  which 
suffi cient and representative material was available for tissue micro array (TMA) analysis. 
All AIDS-related NHL cases were excluded. All cases with reliable immunohistochemical 
staining were included in the fi nal analysis containing MCL (n=16), MZL (n=19), LBL 
(n=3), DLBCL (n=84), FL (n=42) and T-NHL (n=25) (Tables 4, 5 and 7). For the TMA, 
hematoxylin and eosin-stained sections of  paraffi n-embedded, formalin fi xed tissue were 
used to defi ne diagnostic areas. From each case, three representative 0.6-mm cores were 
obtained and inserted adjacently into a recipient paraffi n block using a tissue arrayer 
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(Beecher Instruments, Silver Spring, MD). In total, we generated two TMA blocks with 
control specimens of  lymphoid tissues, i.e., the spleen, thymus and lymph node which 
were inserted in two separate rows containing at least three cores per tissue. Stains were 
scored on a 4-point scale regarding the TMA analysis. 0=negative, 1=<25% cells positive, 
2=25 – 50% cells positive, 3=51 – 75% cells positive, 4=>75% cells positive. Cases with 
scores 0, 1 or 2 were designated as negative in the fi nal analysis, whereas scores 3 or 4 were 
designated as positive. In case of  staining of  the three cores with variable outcome, the 
mean expression of  three cores was taken.
 For the expression analysis on human lymphoid tissues, we retrieved formalin-
fi xed, paraffi n embedded normal lymph node (n=3), spleen (n=2) and thymus (n=1) 
from the fi les of  the Department of  Pathology at the Erasmus MC. Single and dual 
immunohistochemical procedures were carried and partially and complete co-staining was 
defi ned if  cells were 25 – 50% and >50% positive respectively. Analysis and scoring of  the 
whole, TMA and lymphoid organ sections was independently performed by two medical 
doctors with suffi cient experience. Disagreements were resolved by joint review on a 
multiheaded microscope. 
Reagents and immunohistochemical procedures
The polyclonal human C-terminal anti-CB2 receptor antibody and its synthetic peptide 
were kindly provided by P. Casellas (Sanofi -Synthelabo Recherche, Montpellier, France). 
The anti-CB2 receptor polyclonal antibody raised against the fi rst 33 amino acid residues 
of  the N-terminus of  the receptor was purchased from Affi nity Bioreagents Inc (ABR, 
CO, USA). For the dual immunohistochemical analyses we used the antibodies as listed 
in Table 1. 
Single staining procedure on normal and malignant specimens
Five-micrometer sections were used for staining of  whole sections of  patients from the 
HOVON 25, the TMA and lymphoid organs for the staining experiments. In brief, sections 
were deparaffi nized, rehydrated and endogenous peroxidase was blocked with 3% H2O2 
in methanol for 20 minutes at room temperature (RT). Heat induced antigen retrieval 
(required for staining with the C-terminal anti-CB2 antibody) was achieved by boiling 
the sections for 20 minutes at 100ºC in citrate buffer (10 mM, pH 6.0) in a Micromed 
T/T Mega microwave oven (Salm and Kipp, Breukelen, The Netherlands). Sections were 
cooled down, washed and incubated with the fi rst panel of  primary antibodies for 1 
hour at RT (C-terminal anti-CB2 1:400, or N-terminal anti-CB2 1:600), and subsequently 
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Table 1 | Antibodies and conjugates used for immunohistochemical analysis.
Primary antibodies Specifi city Dilution/Epitope 
retrieval*
Source
CD1a (monoclonal)
CD2 (monoclonal)
CD3 (polyclonal)
CD5 (monoclonal)
CD8 (monoclonal)
CD15 (monoclonal)
CD23 (monoclonal)
CD68 (monoclonal)
CD79a (monoclonal)
 IgD (polyclonal)
CD40 (monoclonal)
Cortical thymocytes; Langerhans cells
Early T-cells
Pan-T cell
Mature T-cells
Cytotoxic, suppressor T-cells
Granulocytes, monocytes, Reed-Sternberg cells
B-cell subset/ Follicular dendritic cells
Macrophages
B cell; plasma cells
Naive B cells
GC-B-cells
1:10/yes
1:50/yes
1:600/yes
1:200/yes
1:100/yes
1:25/yes
1:20/yes
1:1000/yes
1:100/yes
1:200/yes
1:100/yes
Immunotech
Novocastra
DAKO
Novocastra
DAKO
B&D
Novocastra
DAKO
DAKO
DAKO
Donated
Secondary antibodies and conjugates
Swarbio
RaMbio
S-ABCAP-kit
S-ABC HRP-kit
Swine-anti -rabbit
Rabbit anti-mouse
Streptavidin-biotin alkaline phospatase
Streptavidin biotin horse radish peroxidase
1:200
1:200
1:100
1:100
DAKO
DAKO
DAKO
DAKO
Antigen retrieval was performed by pre treating sections in a microwave oven (see Materials and Methods). 
Immunotech, Prague, Czech Republic; Novocastra, Newcaste upon Tyne, UK; B&D, San Jose, CA, USA.
incubated for 10 minutes with biotinylated secondary antibodies (anti-mouse and rabbit 
immunoglobins; Labvision,Fremont, CA, USA) followed by a 10 minute incubation 
with streptavidin-conjugated (S-ABC) horseradish peroxidase (Labvision). Visualisation 
was achieved using Diaminobenzidine (DAB) (Fluka, Buchs, Switzerland) for 7 minutes 
in dark. Finally, sections were counterstained with haematoxylin according to Harris 
(Klinipath, Duiven, The Netherlands), dehydrated and covered by imsol (Klinipath) and 
by pertex (Histolab, Göteborg, Sweden). Standard haematoxylin-eosin (HE) staining and 
negative controls (omission of  primary antibody) of  all examined tissues were included. 
Specifi city controls were performed by pre incubating the C-terminal anti-CB2 receptor 
antibody for one hour with the synthetic peptide at 10 mg/ml. No peptide has been 
developed yet for the N-terminal specifi c antibody used in our experiments, which was 
purchased commercially. Other commercially available antibodies against N-CB2 of  
which a peptide control was available were tested. Upon elaborate testing, none of  these 
antibodies were suited for histological staining experiments. Different conditions of  
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both CB2 antibodies for antigen retrieval were tested. Intracellularly located epitope of  
C-CB2 was only detectable with microwave pretreatment, whereas no pre-treatment was 
necessary to detect the extracellulary located epitope of  the N-CB2 receptor. Accurate 
titrations, including negative controls omitting the primary antibody were performed 
in order to achieve reliable staining patterns on paraffi n sections. In these experiments 
the optimal staining pattern was chosen taking unspecifi c background staining into 
account. We have only accepted positive staining when a clear distinctive cytoplasmatic or 
membrane staining was detected.
Dual staining procedure on normal lymphoid tissues
A panel of  cell specifi c markers, and biotin conjugated secondary antibodies were used 
for dual immunohistochemistry of  the lymphoid tissues. The list of  the antibodies, 
their antigen retrieval their sources and dilutions are listed in Table 1. Sections were 
fi rst incubated with the CB2 antibodies as described above, and stained with 3-amino-
9-ethylcarbazole (AEC; Sigma USA) in NaAc buffer (0.2M, pH 4.6) for 30 minutes 
in dark, which yielded in a red signal. Then sections were individually incubated with 
the primary antibodies listed in Table 1 for 30 minutes, washed and incubated with the 
biotin conjugated secondary antibodies for 30 minutes at RT. An S-ABC conjugated 
alkaline phosphatase kit (DAKO, Glostrup, Denmark) was used to enhance the signal. 
Visualisation was achieved using a solution containing Fast Blue BB salt (4-benzoylamino-2, 
5-diethoxylbenzene diazoniumchloride; Sigma), naphtol-AS-MX phosphate (Sigma) and 
levamisole hydroxychloride (Acros Organics, Geel, Belgium) in Tris/HCl buffer (0.2M, 
pH 8.0) for 30 minutes in dark resulting in blue staining of  cells. In case of  co-expression/ 
co-staining, the mixture of  red and blue signals resulted in a dark purple staining of  cells. 
Cells were counter-stained with haematoxylin according to Harris (Klinipath) and covered 
by pertex. 
RESULTS 
CB2 receptor expression in normal lymphoid tissue 
As reported in our previous study12 C-terminal specifi c anti-CB2 antibody recognized 
B-cells in the primary follicles and in the MZs and MGZs of  secondary follicles (Figure 
1A and C). N-terminal CB2 specifi c staining was observed in the GCs of  secondary 
follicles (Figure 1B and D). A small subset of  the cells (≤5%) in the T-cell areas of  normal 
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lymph nodes expressed CB2, as detected by the N-terminal specifi c antibody (Figure 1D, 
arrow). No positive staining was found using the C-terminal specifi c antibody in this area 
(Figure 1A and C)12. Hardly any CB2 expression on T-cells was detected, using T-cell 
specifi c markers (CD3, CD5 and CD8) in combination with both CB2 specifi c antibodies 
(Table 2 and Figure 1). This result was confi rmed by multiparameter fl owcytometry using 
CB2 and CD3 specifi c antibodies (data not shown). CB2 expression was undetectable in 
the peri-arteriolar-lymphocytic sheet (PALS) of  the spleen and in the thymus, applying 
single immunohistochemistry (data not shown). The results of  distinct dual staining 
experiments are summarised in Table 2. 
Figure 1 | CB2/CD3 dual staining of  normal reactive lymph nodes. Dual staining procedures 
using the C-terminal (panel A, C and E) or N-terminal (panel B, D and F) anti-CB2 antibodies (red 
staining) combined with the pan-T-cell marker CD3 (all panels) (blue staining) on normal lymph 
node sections. Note the almost complete separation of  red and blue staining areas. See text for 
further discussion. The following areas in the lymph node are indicated: GC; germinal centre, MZ: 
mantle zone. MGZ: marginal zone, P: para-cortical (T-cell) area. Original object lens magnifi cations: 
A: 1,25x, B: 2.5x, C and D: 10x, E and F: 40x. See page 170 for color fi gure.
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Table 2 | CB2 expression on lymphoid and accessory cells as determined by dual immuno-
histochemistry.
Antibody Examined lymphoid tissue:
Spleen/LN/Thymus
N-CB2 C-CB2
CD1a
CD2
CD3 
CD5
CD8 
CD15
CD23
CD79a 
IgD
CD40
CD68  
Thymus
Thymus
All
All
All
Spleen and LN
Spleen and LN
Spleen and LN
Spleen and LN
Spleen and LN
Spleen and LN
–
–
+/– –
–
–
–
+/–
(+ in GC)
+/–
–
+/–
(+ in GC)
+/–
–
–
–
–
–
–
+/–
(+ in MZ/MGZ)
+/–
+
+/–
(+ in MZ/MGZ)
–
Dual immunohistochemistry was performed on spleen, lymph node (LN) and/or thymus sections. The 
panel of  antibodies was combined with each of  the CB2 antibodies (N-CB2 and C-CB2). +/– indicates 
that different subsets of  cells are recognized by each CB2 antibody. + or – indicates that the majority of  the 
cells (≥ 75%) either co-stained or did not co-stain with the CB2 antibody. +/– – indicates that a very small 
number of  cells (< 5%) show co-expression. 
Follicular dendritic cells and a subset of  macrophages express CB2 
We also analysed by means of  dual-immunohistochemistry the expression of  CB2 
receptors on granulocytes/monocytes (CD15+), macrophages (CD 68+) and follicular 
dendritic cells (CD23+) in reactive lymph node and spleen. A small but signifi cant number 
of  CD68+ macrophages showed co-staining with the N-terminal specifi c CB2 antibody 
but not with the C-terminal specifi c antiserum (Table 2). Remarkably, CD23+ follicular 
dendritic cells present in the GCs showed intense co-staining with the N-terminal specifi c 
CB2 antibody (Table 2, Figure 2 C and D), but not with the C-terminal specifi c one (Table 
2, Figure 2A and B). No co-expression on CD15+ cells was observed with any of  the CB2 
specifi c antibodies (Table 2). 
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Figure 2 | CB2/CD23dual staining of  normal reactive lymph nodes. Dual staining of  
secondary follicles of  human normal reactive lymph nodes using the C-terminal (A and B) or 
N-terminal (C and D) specifi c anti-CB2 antibodies (red staining) with CD23 (blue staining). Note 
the reticular blue-purple staining pattern in the germinal centre (C and D). Co-staining was absent 
in the GC B-cells (A and B). The following areas in the lymph node are indicated: GC; germinal 
centre, MZ: mantle zone. MGZ: marginal zone, P: para-cortical (T-cell) area. Original object lens 
magnifi cations: A and C: 10x, B and D: 20x. Panels A and B were taken form different germinal 
centres for technical reasons. See page 171 for color fi gure.
Frequent expression of  CB2 receptors in B-NHL and T-NHL
We investigated CB2 expression on distinct B-cell lymphoma subtypes. CB2 distribution 
on DLBCL samples was investigated on whole sections from the HOVON 25 study 
(n=150) and in the TMA series (n=84). We considered the staining to be positive when 
either on whole sections or on TMA cores 50% or more cells were positive. On whole 
sections we observed a high percentage of  positive staining using both CB2 antibodies, 
that is 80% positive staining using N-terminal specifi c anti-CB2 and 74% positive staining 
using C-terminal specifi c antibodies (Table 3). DLBCL samples on the TMA appeared 
highly positive for both antibodies as well, i.e. 73% using N-terminal CB2 and 96% using 
the C-terminal specifi c CB2 antibody (Table 4). From the 13 FL cases included in the 
HOVON 25 study, 6 (46%) were N-terminal CB2 positive, whereas 13 (100%) were 
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C-terminal CB2 positive (Table 3). Sixty percent of  all FL cases from the TMA study 
showed high CB2 protein expression using the N-terminal specifi c anti- CB2 antibody, 
and 98% FL cases were positive with the C-terminal specifi c antibody (Table 5). Of  these 
cases, 12 were grade I FL, 16 were grade II, 8 were grade III and 6 were of  unknown grade 
FL. Staining with the distinct CB2 antibodies did not discriminate between the different 
grades of  the FLs (Table 5). Of  the 17 MCLs in the HOVON 25 study, 3 (18%) were 
positive using the N-terminal specifi c CB2 antibody, whereas 17 (100%) were positive 
using the C-terminal antibody (Table 3). In the TMA we observed 6/16 (38%) N-terminal 
CB2 positive and 15/16 (94%) C-terminal CB2 positive cases. Fourteen (74%) of  the 19 
MZL cases present in the TMA study expressed the CB2 receptor as detected with the 
N-terminal antibody and 17/19 (89%) were positive using the C-terminal CB2 antibody 
(Table IV). No MZLs were analysed in the HOVON 25 study. Representative examples 
of  CB2 positive DLBCL, FL and MCL are shown in Figures 3D-L.
Table 3 | CB2 expression on mature and immature B-cell lymphoma’s: HOVON 25 study: FL,MCL 
and DLBCL.
FL MCL DLBCL Total
Cases 13 17 150 180
N–CB2 
 + (>75%)
 +/– (>50%)
 – (<50%)
6 (46%)
0 (0%)
7 (54%)
3 (18%)
0 (0%)
14 (82%)
103 (69%)
16 (11%)
31 (20%)
112(62%)
16 (9%)
52(29%)
C–CB2 
 + (>75%)
 +/– (>50%)
 – (<50%)
11(85%)
2 (15%)
0 (0%)
15 (88%)
2 (12%)
0 (0%)
101 (67%)
10 (7%)
39(26%)
127 (71%)
14 (8%)
39 (21%)
Semi quantitative counting on whole sections was performed as cells being ≥75% positive (+), >50% partially 
positive (+/–) and ≤50% as negative (–). In the fi nal analysis, positive and partially positive cases were taken 
together. Only sections which were reliably interpretable using both CB2 antibodies were analysed. Follicular 
lymphoma (FL), Mantle cell lymphoma (MCL) and Diffuse large B-cell lymphoma (DLBCL).
In contrast to the expression on normal T-cells, almost all T-cell lymphomas highly 
expressed CB2 receptors (Tables 6 and 7). Representative examples are shown in Figure 
3A-C. 6/7 (86%) T-NHL cases from the HOVON 25 study stained positive with the 
N-terminal specifi c antibody, whereas 3/7 (43%) stained positive with the C-terminal 
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specifi c antibody (Table 6). Analysis of  25 cases from another cohort analysed by 
TMA revealed that 21 (84%) were N-CB2 positive and 24 (96%) were positive using 
the C-terminal specifi c antibody (Table 7). Sub-typing T-NHL into anaplastic large cell 
lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), T-cell lymphoblastic lymphoma 
(T-LBL), revealed similar staining patterns using both antibodies against CB2 (Tables 3 
and 4). An exception of  this pattern was observed with the PTCL in the HOVON 25 
study where 1 of  4 cases (25%) expressed the CB2 using the C-terminal specifi c antibody. 
However, using the N-terminal specifi c antibody 3 of  the 4 cases (75%) stained positively. 
Figure 3 | CB2 expression in malignant lymphoma’s. Whole sections of  malignant lymphomas 
were stained with C- and N-terminal CB2 antibodies respectively (brown staining). Representative 
cases showing positive staining with both antibodies including negative controls are shown: A-C: 
T-cell NHL; D-F: FL; G-I: DLBCL; J-L: MCL. Original object lens magnifi cation: 40x (inserts,20x). 
See page 174 for color fi gure.
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Table 4 | CB2 expression on mature and immature B-cell lymphoma’s: TMA study: MCL, MZL, 
LBL and DLBCL. 
MCL MZL B-LBL DLBCL Total
Cases 16 19 3 84 122
N-CB2 pos:
Score (3 and 4)
6/16 (38%) 14/19 (74%) 2/3 (67%) 62/84 (73%) 84/122 (69%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
 0 (0%)
 4 (25%)
 6 (38%)
 4 (25%)
 2 (12%)
 0 (0%)
 4 (21%)
 1 (5%)
 4 (21%) 
10 (53%)
0 (0%)
0 (0%)
1 (33%)
1 (33%)
1 (33%)
 0 (0%)
11 (4%)
11 (12%)
13 (15%)
49 (58%)
 0 (0%)
19 (15%)
19 (15%)
22 (19%)
62 (51%)
C-CB2 pos:
Score (3 and 4)
15/16 (94%) 17/19 (89%) 3/3 (100%) 81/84 (96%) 116/122 (95%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
 0 (0%)
 0 (0%)
 1 (6%)
 0 (0%)
15 (94%)
 0 (0%)
 0 (0%)
 2 (11%)
 5 (26%)
12 (63%)
0 (0%)
0 (0%)
0 (0%)
2 (67%)
1 (33%)
 1 (1%)
 1 (1%)
 1 (1%)
12 (15%)
69 (82%)
 1 (1%)
 1 (1%)
 4 (3%)
19 (15%)
97 (80%)
CB2 staining was considered positive if  ≥50% of  the cells (score 3 or 4) of  interest were positive. The rest of  
the scores (0, 1 and 2) were regarded as negative. The percentages behind he scores 0 – 4 correspond to the 
percentage of  positive cells. Only scores which were reliably interpretable using both CB2 antibodies were 
analysed. Mantle cell lymphoma (MCL), Marginal zone lymphoma (MZL), Lymphoblastic lymphoma (LBL) 
and Diffuse large B-cell lymphoma (DLBCL). 
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Table 5 | CB2 expression on mature and immature B-cell lymphoma’s: TMA study: FL.
FLI FLII FLIII  FL uk Total
Cases 12 16 8 6 42
N-CB2 pos:
Score (3 and 4)
9/12(75%) 8/16 (50%) 6/8 (75%) 2/6 (33%) 25/42 (60%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
 0 (0%)
 1 (25%)
 2 (38%)
 1 (25%)
 8 (12%)
 0 (0%)
 3 (19%)
 5 (31%)
 2 (12%) 
 6 (38%)
0 (0%)
1 (12%)
1 (12%)
4 (50%)
2 (25%)
0 (0%)
2 (33%)
2 (33%)
0 (0%)
2 (33%)
 0 (0%)
 7 (17%)
10 (23%)
 7 (17%)
18 (43%)
C-CB2 pos:
Score (3 and 4)
12/12 (100%) 15/16 (94%) 8/8 (100%) 6/6 (100%) 41/42 (98%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
 0 (0%)
 0 (0%)
 0 (0%)
 2 (17%)
10 (83%)
 0 (0%)
 0 (0%)
 1 (6%)
 5 (31%)
10 (63%)
0 (0%)
0 (0%)
0 (0%)
2 (25%)
6 (75%)
0 (0%)
0 (0%)
0 (0%)
4 (67%)
2 (33%)
 0 (0%)
 0 (0%)
 1 (2%)
13 (31%)
28 (67%)
CB2 expression was determined on follicular lymphoma (FL) samples of  patients with distinct FL grades. 
Some FLs were of  unknown grade (UK). CB2 staining was considered positive if  ≥ 50% of  the cells (score 3 
or 4) of  interest were positive. The rest of  the scores (0, 1and 2) were regarded as negative. The percentages 
behind he scores 0 – 4 correspond to the percentage of  positive cells. Only scores which were reliably 
interpretable using both CB2 antibodies were analysed.
Table 6 | CB2 expression on mature and immature T-NHL: HOVON 25 study.
ALCL PTCL Total
Cases 3 4 7
N-CB2 
 + (>75%)
 +/– (>50%)
 – (<50%)
3 (100%)
0 (0%)
0 (0%)
1 (25%)
2 (50%)
1 (25%)
4 (57%)
2 (29%)
1 (14%)
C-CB2 
 + (>75%)
 +/– (>50%)
 – (<50%)
0 (0%)
2 (75%)
1 (25%)
0 (0%)
1 (25%)
3 (75%)
0 (0%)
3 (43%)
4 (56%)
Semi quantitative counting on whole sections was performed as cells being ≥ 75% positive (+), > 50 
% partially positive (+/–) and ≤50% as negative (–). In the fi nal analysis, positive and partially positive 
cases were taken together. Only sections which were reliably interpretable using both CB2 antibodies were 
analysed. ALCL (anaplastic large cell lymphoma), PTCL (peripheral T-cell lymphoma).
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Table 7 | CB2 expression on mature and immature T-NHL B: TMA study.
ALCL PTCL-nos T-LBL Total
Cases 10 8 7 25
N-CB2 pos:
Score (3 and 4)
8/10 (80%) 7/8 (88%) 6/7 (86%) 21/25 (84%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
0 (0%)
0 (0%)
2 (20%)
1 (10%)
7 (70%)
0 (0%)
1 (12%)
0 (0%)
0 (0%) 
7 (88%)
0 (0%)
0 (0%)
1 (14%)
1 (14%)
5 (72%)
 0 (0%)
 1 (4%)
 3 (12%)
 2 (8%)
19 (76%)
C-CB2 pos:
Score (3 and 4)
10/10 (100%) 8/8 (100%) 6/7 (86%) 24/25 (96%)
 0 (0%)
 1 (1-25%)
 2 (25-50%)
 3 (50-75%)
 4 (75-100%)
0 (0%)
0 (0%)
0 (0%)
2 (20%)
8 (80%)
0 (0%)
0 (0%)
0 (0%)
1 (12%)
7 (88%)
0 (0%)
0 (0%)
1 (14%)
1 (14%)
5 (72%)
 0 (0%)
 0 (0%)
 1 (4%)
 4 (16%)
20 (80%)
CB2 staining was considered positive if  ≥ 50% of  the cells (score 3 or 4) of  interest were positive. The rest 
of  the scores (0, 1and 2) were regarded as negative. The percentages behind he scores 0 – 4 correspond to 
the percentage of  positive cells. . Only scores which were reliably interpretable using both CB2 antibodies 
were analysed. ALCL (anaplastic large cell lymphoma), PTCL-nos (peripheral T-cell lymphoma not otherwise 
specifi ed), T-LBL (T-cell lymphoblastic lymphoma).
DISCUSSION
CB2 receptor expression in normal lymphoid tissue 
We investigated the expression of  peripheral cannabinoid receptors in normal human 
lymphoid tissues and their malignant counterparts using CB2 antibodies. Positive staining 
with an antibody directed against the C-terminus is indicative for inactive receptors since 
it only recognizes non-phosphorylated Ser-352 and consequently inactive CB211. We 
demonstrated previously12 that B-cells in the MZ and MGZ of  secondary follicles express 
inactive CB2, since they stain positively with this antibody. In contrast, these cells hardly 
stained for the N-terminal specifi c anti-CB2. Moreover, B-cells present in the GCs of  
secondary follicles, areas considered to contain a high number of  active B-cells, showed 
strong staining with the N-terminal specifi c CB2 antibody. The staining pattern with C- 
and N- terminal specifi c antibodies seems mutually exclusive. Based on the combined 
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staining pattern we have hypothesized that the antibody recognizing the N-terminus of  
the receptor probably represents the recognition of  the active state of  the receptor. 
The non-staining of  the N-terminal antibody in the B-cell areas which stain with the 
C-terminal specifi c antibody and therefore considered to be inactive as demonstrated 
by Bouaboula et al.11, may be caused by the occurrence of  conformational or affi nity 
changes leading to epitope inaccessibility. An alternative explanation may be that indeed 
the N-CB2 does recognize the epitope, but the amount of  receptors in the cells in these 
areas is too low, because the cells in these areas are assumed to be in a more inactive state. 
This is consistent with the positive staining with N-CB2 in the active germinal centre 
area of  the lymph node. This latter staining pattern may correspond with activated/Ser-
352 phosphorylated CB2 receptors on GC B-cells. However, additional functional studies 
investigating the phosphorylation status of  the receptor in lymphocytes in relation to the 
antigen specifi c activation are needed to confi rm this hypothesis. These data may also be 
of  importance, for the interpretation of  CB2 expression on other haematopoietic cells. 
 Using the N-terminal specifi c antibody, only a few CB2 positive cells in the 
paracortex could be found in normal reactive lymphoid tissues. Using the pan T-cell 
marker CD3, double staining was detected using only the N-terminal CB2. Moreover, 
double staining could not be found using anti CD1, CD2, CD5 and CD8 with both CB2 
antibodies. Sub-typing with CD4 was unsuccessful, probably due to technical reasons. 
Based on these fi ndings one can state, that co-staining with the N-terminal antibody 
may suggest that the few CB2 positive T-cells in the paracortex of  the lymph nodes may 
represent T-lymphocytes expressing activated peripheral cannabinoid receptors. 
 On most T-cells, no CB2 was detectable using both antibodies, however, 
this does not necessarily imply that there are no receptors present at all. It has been 
reported that mRNA levels in normal human leukocyte subsets is very low in T-cells8-10. 
Consequently the levels of  receptor expression may be below detection. Another study 
implies cannabinoid receptor involvement in T-lymphocytes using radio-ligand binding 
assays18. In this study, investigating the inhibition of  T-cell-dependent immune responses 
by cannabinoids, only the mRNA expression of  CB2 was investigated and found on 
T-lymphocytes using a T-cell line (HPB-ALL cells). However, no protein analysis was 
carried out and the mechanisms of  the involvement of  cannabinoid receptors have still 
not been fully elucidated. Moreover, recent studies suggest that effects of  cannabinoid 
ligand on T-cells are independent of  the presently known CB1 and CB2 cannabinoid 
receptors19. They and others19-22 have suggested a third receptor and / or non-receptor 
mediated mechanism which could explain these effects. We have studied CB2 expression 
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on the NSB, HUT 102 and HPB-ALL T-cell lines and have found only minimal CB2 
expression on HPB-ALL T-cell line (data not shown). To investigate protein expression 
on normal T-lymphocytes, we have analyzed two tonsils of  healthy children and have 
carried out dual and triple fl owcytometry using T-cell specifi c antibodies and CB2. We 
were unable to detect CB2 protein using the N-terminal specifi c antibody (data not 
shown). This fi nding is confi rmed by dual staining immunohistochemistry experiments 
in which we could only detect sporadic double staining on T-cells. In the tumor cases the 
possibility remains that there is some unspecifi c staining. However, we have therefore only 
accepted positive staining when a clear distinctive cytoplasmatic or membrane staining 
was detected. 
Expression of  CB2 on follicular dendritic cells and a subset of  macrophages
We observed a high number of  cells which stain with the N-terminal specifi c CB2 
antibody on several other smaller subsets of  cells in lymph nodes, i.e. on follicular CD23+ 
dendritic cells and a sub population of  CD68+ macrophages. It is possible that expression 
of  activated CB2 on these cells also points to a particular activation status of  the cells, 
corresponding with proliferation, differentiation or a role in immune modulation. 
Expression of  CB2 receptors in B-NHL and T-NHL 
High levels of  active CB2 on DLBCL was expected in a certain percentage of  cases, since 
several studies showed that a large fraction of  DLBCLs exhibit a GC B-cell phenotype. 
However, our previous fi ndings that normal B-cells in primary follicles or in the mantle 
zone and marginal zone of  secondary follicles mainly stain with anti-C-terminal CB2, 
which would suggest that B-NHL of  the FL-, MZ- or MGZ-type would stain positive 
with the C-terminal specifi c antibody and not with the N-terminal specifi c one. Although 
the C-terminal specifi c anti-CB2 identifi ed more CB2 positive B-cells in most tumours, 
the N-terminal specifi c antibody stained positive in most of  the B-NHL cases as well. A 
similar discrepancy was also demonstrated in human acute myeloid leukaemia’s (AML). 
CD34 positive normal bone-marrow samples lack CB2 protein expression as determined 
with the N-terminal specifi c antibody, whereas AML blasts frequently show high 
expression of  the CB2 receptor16. Moreover, a functional role of  CB2 was demonstrated 
in AML. A block of  neutrophilic differentiation was observed upon stimulation with 
synthetic cannabinoid ligands, using in vitro AML models16. 
 In contrast to normal T-cells, we have found frequent CB2 expression on T-NHL, 
especially when using the N-terminal specifi c antibody. One explanation for this fi nding 
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could be, that T-NHL arises from the small, hard to detect fraction of  normal CB2 
expressing T-cells. However, since we have found CB2 expression on every T-NHL type 
that we studied, i.e. ALCL, PTCL as well as T-LBL, this explanation seems unlikely. Besides 
the fact that we found high CB2 levels on T-cell lymphoma’s, it was also striking that 
both CB2 antibodies frequently stained positive on these tissues. The fact that anti-CB2 
directed to the non-phosphorylated C-terminal part of  this receptor only stained positive 
in normal tissues when the N-terminal specifi c antibody does not, further underlines that 
T-cell lymphoma’s as well as B-cell lymphoma’s probably express an aberrantly functioning 
CB2 receptor. 
 We conclude that peripheral cannabinoid receptor expression and activation status 
on B-NHL, T-NHL and AML differs from that observed on their normal counterparts. 
CB2 may be aberrantly expressed and may be involved in tumour development. 
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ABSTRACT
Purpose: Until now molecular biological techniques are not easily used in daily clinical 
practice to stratify patients for therapeutic purposes. Therefore, we have investigated the 
prognostic relevance of  the immunohistochemical (IHC) Germinal Center B-cell (GCB) 
versus (vs.) non-GCB diffuse large B-cell lymphoma (DLBCL) subtypes. 
Patients and methods: We have analyzed tumor samples from patients treated in two 
prospective, phase III multi-center trials, i.e. HOVON 25 (patients ≥ 65 years, n=153) and 
HOVON 26 (patients < 65 years, n=144) using whole sections (WS) or tissue micro array 
(TMA). CD10, BCL6 and MUM1 were applied in a specifi c IHC algorithm. The impact 
on clinical outcome using WS or TMA and variations in cut-off  levels of  these markers 
was also investigated.
Results: The GCB subtype was not associated with a better OS in either trial. Small 
differences were observed in the HOVON 25 trial between techniques, with TMA 
showing a better outcome for GCB than did WS. Variation of  cut off  levels in the specifi c 
algorithm did not improve the prediction of  clinical outcome. 
Conclusion: We did not observe a consistent predictive power of  the GCB and non-
GCB classifi cation by IHC in this large series of  DLBCL patients treated with CHOP. 
This underscores the need to determine the biological variation and the standardization 
of  the protein expression levels and to further study the relevance of  prognostic IHC 
classifi cations, preferably in phase III clinical trials.
Keywords: DLBCL, phase III trial, germinal center B-cell, immunohistochemistry, 
prognosis
Clinical relevance of  DLBCL classifi cation | 93
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) as described by the World Health Organization 
(WHO) 2008 classifi cation is the most frequent lymphoma subtype of  the aggressive Non-
Hodgkin’s lymphomas (NHL)1. The addition of  rituximab to CHOP (cyclophosphamide, 
doxorubicin, vincristine and prednisone) containing regimens (R-CHOP) highly improves 
outcome. However, survival of  both elderly and young patients with NHL is still 
unsatisfactory, making improvement of  current therapeutic strategies necessary2-12. One 
of  the most promising strategies may be tailoring the therapy to the clinical and biological 
factors of  patients and disease, which infl uence outcome. To this end, the International 
Prognostic Index (IPI) up till now has been the most powerful tool for predicting clinical 
outcome of  patients with DLBCL. However, the IPI refl ects a mixture of  underlying 
biologic differences and thus has its limits with respect to the aim of  personalized therapy. 
Therefore, novel biological prognostic markers refl ecting the heterogeneous biology of  
DLBCL have been investigated with the ultimate goal to fi nd DLBCL subtypes with 
different prognosis13. Gene expression profi ling (GEP) using oligonucleotide arrays 
indeed confi rmed the existence of  subgroups of  patients, treated either with CHOP or 
CHOP-like regimens14-19. Most of  these patients can be divided in having either a favorable 
germinal center B-cell (GCB) or an unfavorable activated B-cell (ABC) phenotype of  
DLBCL. This fi nding is supported by other investigators such as Tagawa et al. showing a 
correlation between cytogenetic alterations and GCB versus ABC expression subgroups, 
reiterating this biological difference20. However, up to now molecular techniques such as 
gene expression profi ling (GEP), cytogenetics, comparative genomic hybridization (CGH) 
and genome wide association studies (GWAS) are diffi cult to apply in clinical practice 
to stratify patients for therapeutic purposes. Because of  its wide availability, histological 
sub classifi cation systems using immunohistochemistry (IHC) have been considered to 
be more feasible. Hans et al. published one approach to determine prognostic entities 
within the group of  DLBCL patients treated with CHOP-like chemotherapy21. A panel 
of  3 antibodies against CD10, BCL6 and MUM1 were applied in a specifi c algorithm 
in a tissue micro array (TMA). Using this approach, these investigators could identify 
patients with a favorable GCB or a non-favorable non-GCB (ABC) phenotype. These 
IHC results correlated with the results obtained with GEP21. Using the same algorithm, 
other studies have reported comparable predictive power of  IHC subgroups in DLBCL 
patients treated with anthracyclin-containing regimens. In these studies, patients with high 
IPI scores treated with high-dose chemotherapy and autologous stem cell transplantation 
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were analyzed as well22-24. However, other studies using similar algorithms have reported 
no predictive value, also in patients treated with R-CHOP25-27. 
 In this paper, we analyzed the prognostic relevance of  the IHC GCB versus non-
GCB DLBCL subtypes in two prospective, randomized phase 3 multi-center studies. 
These studies were performed in 2 large cohorts of  elderly and young patients, uniformly 
treated with CHOP. We also have made an attempt to optimize the algorithm as described 
by Hans et al., by making variations in the cut-off  points of  the algorithm21. The effect 
of  the choice of  IHC assays, i.e., WS or TMA on this algorithm was investigated as well. 
Also BCL2 expression has been analyzed since this marker has been described as being 
useful to sub classify the non-GCB group21,24,28. 
PATIENTS, MATERIALS AND METHODS
Patients 
We studied tissue samples of  DLBCL patients who participated in 2 prospective 
randomized phase 3 clinical trials. All patients received an anthracyclin containing chemo-
therapy regimen (CHOP). All diagnoses of  DLBCL were confi rmed by central pathology 
review using the WHO 2001 criteria.
 In patient cohort 1, samples from patients who participated in the HOVON 25 
(HO25) trial (n=389) were collected from the contributing centers using the HOVON 
(Dutch-Belgian Hemato-Oncology Cooperative Group) database (virtual tissue bank). 
Inclusion criteria were age ≥ 65 years, previously untreated intermediate or high-grade 
DLBCL according to the Working Formulation or the WHO 2001 classifi cation and Ann 
Arbor stage II, III or IV. Patients were included in this trial between August 1994 and 
September 20019. Suffi cient material was available for IHC analysis of  134 (34%) patients 
by TMA (HO25 TMA) and 153 (39%) patients using WS (HO25 WS). There were 73 
patients (19%) of  whom tissue was included in both HO25 WS and HO25 TMA. In 
cohort 2, we included patients who participated in the HO26 trial (n=513). Inclusion 
criteria were previously untreated aggressive NHL according to the intermediate-or high-
grade Working Formulation, age < 65 years, and Ann Arbor stage II, III or IV. Patients 
were included between November 1994 and February 200411. Suffi cient material was 
available of  144 (28%) patients for IHC analysis on TMA. All studies were conducted 
according to regulations of  the Dutch health authorities and in accordance with the 
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Declaration of  Helsinki. The trials have been registered as ISRCTN26340837 (HO25) 
and ISRCTN11397785 (HO26), see e.g. www.controlled-trials.com.
Materials and methods
Patient samples (paraffi n-embedded tissue blocks) were collected from the participating 
centers. The TMA’s were constructed at the Department of  Pathology of  The Netherlands 
Cancer Institute (Amsterdam). H-E sections of  paraffi n-embedded, formalin-fi xed tissue 
were used to defi ne the diagnostic areas. From each case 2 representative 0.6 mm cores 
were obtained and inserted adjacently into a recipient paraffi n block using a tissue arrayer 
(Beecher Instruments, Silver Spring, MD, USA). All IHC procedures and analyses were 
performed at the Department of  Pathology at Erasmus Medical Center Rotterdam, 
according to standard IHC procedures. Antigen retrieval was performed by pre treating 
sections in a microwave oven (Salm and Kipp, Breukelen, The Netherlands). The primary 
antibodies CD10, BCL6, MUM1 and BCL2 were obtained from Novocastra and DAKO 
respectively. The secondary antibodies and conjugates (goat-anti-rabbit horse-radish 
peroxidase (HRP) and streptavidin biotin complex-HRP) were purchased from Labvision. 
Negative controls (omission of  primary antibody) of  all examined tissues were included. 
Stains were scored on a 5-point scale: 0=negative (all cells negative), 1= 1 – 25% cells 
positive, 2= 26 – 50% cells positive, 3= 51 – 75% cells positive and 4= 76 – 100% cells 
positive. Of  the cores or whole sections with variable outcome, the mean expression was 
taken and reduced to the highest score. Cases were assigned to the GCB or non-GCB 
group, according the Hans algorithm21 in which positivity of  the antibodies was defi ned as 
a score of  > 2. Cases that were negative for all markers were assigned to the ABC group. 
Different cut-off  points were taken for the variation in the assessment of  positivity for 
each antibody resulting in different distributions of  the GCB vs. non-GCB sub groups 
(GCB0, GCB1 and GCB2). This was performed in order to defi ne an optimal algorithm 
(i.e. ≥ 2 or 3 for CD10, ≥ 2 for BCL6 and ≥ 2 or ≥ 4 for MUM1). All samples were 
independently evaluated in a semi-quantitative way using the above-mentioned scoring 
system by two investigators (NR and KHL). Discordant scores were resolved by joint 
review on a multi-headed microscope. 
Statistical analysis
All endpoints were defi ned according to the updated Cheson criteria 200729. Progression-
free survival (PFS) was defi ned as the time from registration in the trial until lymphoma 
progression or death as a result of  any cause. Event-free survival (EFS) was measured 
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from registration in the trial to any treatment failure including disease progression, or 
discontinuation of  treatment for any reason. Overall survival (OS) was calculated from 
registration until death. Patients were censored at the date of  last contact if  they were 
still alive. The Kaplan-Meier method was used to estimate the survival endpoints PFS, 
EFS and OS30. Survival analysis was performed using univariate Cox regression to see 
whether there was a difference in survival between subgroups31. Hazard ratios (HRs) and 
95% confi dence intervals (CIs) were determined for all three survival endpoints. Kaplan-
Meier curves were generated to illustrate differences in PFS, EFS and OS between GCB 
and non-GCB patients, and were compared using the log-rank test (data not shown)32. 
Multivariate Cox regression analysis with GCB, BCL2 and a GCB х BCL2-interaction 
term was used to evaluate whether analyses of  BCL2 within the subgroups of  GCB and 
non-GCB patients were appropriate33,34. All reported P values were two-sided and, in 
view of  the exploratory nature of  these analyses, were calculated without adjustment for 
multiple testing. P-values ≤ 0.05 were considered statistically signifi cant.
RESULTS
Clinical characteristics and treatment outcome of  patients 
The treatment outcome for the two trials is summarized in Table 1. The 5-year PFS was 
22% in trial 1 (HO25) using WS, 24% using TMA and 42% in trial 2. The 5-year EFS was 
20%, 23% and 38% respectively. The 5-year-OS was 26%, 29% and 58% respectively. The 
main differences in the clinical characteristics of  the DLBCL patients in the HO25 and 
HO26 trials were observed for median age, stage of  the disease and the IPI (Supplemental 
Table 1). There were no major differences in patient characteristics between the IHC GCB 
and non-GCB sub types in both trials (Supplemental Table 2). We compared the initial 
patient characteristics of  the DLBCL cases in the HO25 study with those included for 
IHC (HO25 WS and HO25 TMA) and found no signifi cant differences. The prognostic 
signifi cance in OS for the IPI in this initial study was high (P < 0.001)9. In the HO26 
study, no major differences in patient characteristics were present either between the cases 
in our sample and the initial study population11. In this original HO26 study the predictive 
value of  the IPI was weak (P=0.02) (data not shown).
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Immunohistochemistry
CD10, BCL6 and MUM1 antibodies were used to assign patients into the GCB or the 
non-GCB DLBCL groups. Insuffi cient data or core loss resulted in the exclusion of  
11 (WS) and 23 (TMA) patients in trial 1 and 2 patients (TMA) in trial 2. CD10, BCL6 
and MUM1 positivity (score ≥ 2) varied signifi cantly (P ≤ 0.01) in the two trials. The 
distribution between the GCB and the non-GCB subtypes as determined by the Hans 
algorithm (cut-off  point ≥ 2 for all markers) was not different between the patient groups 
from the 2 trials (P=0.10) (Supplemental Table 3). 
 There were no discrepancies on the level of  assigning each case to GCB or non-
GCB in the TMA’s, because the discrepancies in scoring resulting in this assignment 
were resolved on the level of  the individual markers. For HO25 WS, the assignment of  
each case was done by NR en KHL individually. This has resulted in the same overall 
percentage for both investigators as shown in Table 1. 
 On case level, 52 out of  153 cases (34,6%) were assigned differently. All 
discrepancies were subsequently resolved at the individual marker level using a double-
headed microscope and reassigned. This has not changed the overall percentage 
signifi cantly as shown in Table 1. 
Prediction of  the Hans algorithm for clinical outcome
The prognostic impact of  GCB, the single markers CD10, BCL6, MUM1 and BCL2, as 
well as the IPI, on PFS, EFS and OS is shown in Table 1 and Figure 1-3. In both trials no 
statistically signifi cant differences were found between GCB versus non-GCB subtype. 
Only when using the TMA technique in the elderly trial (HO25), a small improvement 
of  OS (P=0.03) was observed in the GCB subtype, which remained signifi cant in a 
multivariate analysis when adjusted for IPI (HR=0.52, 95% CI 0.30 – 0.90, P=0.01). 
Higher CD10 positivity was not associated with better or worse clinical outcome in 
either trial. A signifi cant positive impact was observed for BCL6 expression in the elderly 
trial (HO25 TMA; PFS, EFS and OS P < 0.01). BCL6 remained statistically signifi cant 
when adjusted for IPI in multivariate analyses: (for PFS, HR=0.66, 95% CI=0.50 – 0.88, 
P=0.001; for EFS, HR=0.66, 95% CI=0.50-0.87, P < 0.001); and for OS, HR=0.61, 95% 
CI=0.44-0.83, P < 0.001). No signifi cance was observed using WS, neither studying trial 2. 
MUM1 expression did not correlate with clinical outcome in any study. BCL2 expression 
was correlated with a worse PFS and EFS in trial 2 only (Table 1). 
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Table 1 | PFS, EFS and OS of  the different patient groups.
PFS HR 95% CI EFS HR 95% CI OS HR 95% CI
Trial 1 HO25 WS
GCB 1.03 .71-1.49 1.11 .77-1.61 .98 .67-1.43
CD10 1.05 .94-1.18 1.06 .95-1.18 1.02 .91-1.15
BCL6  1.01  .90-1.14 1.02 .91-1.14 .99 .88-1.12
MUM1 .96 .86-1.08 .96 .85-1.07 .95 .84-1.07
BCL2  1.06  .94-1.19 1.04 .92-1.17 1.05 .93-1.19
IPI  1.28  1.06-1.54a 1.27 1.06-1.52a 1.25 1.03-1.51a
Trial 1 HO25 TMA
GCB .64 .39-1.06 .63 .38-1.04 .56 .33-.96a
CD10  .94  .81-1.10 .95 .81-1.11 .93 .79-1.09
BCL6  .70  .54-.91b .71 .55-.92b .65 .49-. 87b
MUM1  .90  .73-1.11 .89 .72-1.10 .87 .70-1.08
BCL2  .91  .80-1.05 .92 .80-1.05 .91 .79-1.05
IPI  1.19  .97-1.46 1.20 .98-1.47 1.14 .93-1.40
Trial 2 HO26 TMA
GCB 1.20 .77-1.85 1.02 .66-1.56 1.21 .73-2.01
CD10  1.13  .97-1.30 1.06 .92-1.23  1.11 .94-1.31
BCL6  1.07  .91-1.27 1.01 .86-1.19  1.06  .87-1.28
MUM1  0.92  .78-1.09 .92 .78-1.09  .99  .82-1.20
BCL2  1.19 1.04-1.36a 1.18 1.03-1.35a  1.13  .96-1.33
IPI  1.32  .98-1.78 1.34 1.00-1.78  1.38  .98-1.94
HR indicates hazard ratio; and CI, confi dence interval; aP < 0.05 bP < 0.01
Clinical outcome using either WS or TMA
We next analyzed whether the use of  either WS or TMA infl uenced the sub division in 
GCB vs. non-GCB groups in trial 1. Tissue of  73 patients of  the HO25 trial was included 
in both TMA and WS analysis. In these patients, discordant scores were identifi ed for the 
markers CD10, BCL6, MUM1 and BCL2. Discordance was defi ned as > 25% difference 
in score system. We observed a large variation in scoring regarding BCL6, MUM1 and 
BCL2, resulting in a larger proportion of  the GCB sub type in WS and non-GCB sub type 
in TMA setting. From the 73 patients, 58 could be assigned for sub classifi cation. Twenty 
discrepant cases were found using the Hans algorithm. Sixteen cases were classifi ed as 
GCB and 4 as non-GCB in the WS setting. The reverse holds true for TMA (Table 2A 
and B).
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Table 2A | Difference in scores using WS compared to TMA in HO25 trial.
Marker Score
% positive
0
0
1
1-25
2
26-50
3
51-75
4
76-100
Number 
discrepant (%)
CD10 (n=60)
WS  2 0 1  2  6
11 (18)
TMA  6 3 0  1  1
BCL6 (n=53)
WS  2 0 7 12 10
31 (53)
TMA 26 0 3  1  1
MUM1 (n=57)
WS  1 0 5 11 17
34 (60)
TMA 22 8 3  0  1
BCL2 (n=50)
WS  3 1 4  5 12
25 (50)
TMA 13 4 2  1  5
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Table 2B | Distribution of  discrepant GCB and ABC sub groups using WS and TMA (HO25 trial).
Discrepant 
case nr.
WS 
CD10 
score
WS
BCL6 
score 
WS
MUM1 
score
WS
Sub type
TMA
CD10 
score
TMA
BCL6 
score
TMA
MUM1 
score
TMA
Sub type
1 4 0 1 GCB 1 0 0 ABC
2 3 3 4 GCB 1 0 0 NGCB
3 4 4 1 GCB 0 0 0 ABC
4 4 1 2 GCB 0 0 0 ABC
5 2 3 3 GCB 0 0 0 ABC
6 0 4 1 GCB 0 0 0 ABC
7 1 3 0 GCB 0 0 0 ABC
8 0 2 0 GCB 0 0 4 ABC
9 0 3 4 ABC 0 2 0 GCB
10 4 3 4 GCB 1 0 0 ABC
11 0 1 4 ABC 0 2 0 GCB
12 0 3 0 GCB 0 0 0 ABC
13 3 3 0 GCB 0 0 0 ABC
14 0 3 0 GCB 0 0 0 ABC
15 4 3 2 GCB 0 0 0 ABC
16 0 0 3 ABC 4 2 1 GCB
17 4 0 0 GCB 0 0 0 ABC
18 0 0 1 ABC 3 0 0 GCB
19 2 3 4 GCB 1 0 0 ABC
20 0 2 1 GCB 1 1 0 ABC
GCB (germinal center B-cell); ABC (activated B-cell); WS (whole sections); TMA (tissue micro array).
Outcome prediction in the variations in cut-off  points for the markers used in 
the Hans algorithm
We next investigated whether variation in cut-off  values of  CD10, BCL6 and MUM1 
expression resulted in better clinical outcome prediction. The defi nitions for the respective 
GCB sub types were as follows: 
GCB0: CD10 ≥ 2, BCL6 ≥ 2 and MUM1 ≥ 2,
GCB1: CD10 ≥ 3, BCL6 ≥ 2 and MUM1 ≥ 2,
GCB2: CD10 ≥ 2, BCL6 ≥ 2 and MUM1 ≥ 4.
 None of  the variants resulted in a change of  outcome prediction (Supplemental 
Table 4). We also applied more variations for BCL6 (scores ≥ 1, 3 and 4) since inter 
observer variations for this protein have been reported, again with no effect35 (data not 
102 | Chapter 5
shown). A lower cut-off  value for CD10 (≥ 1) had no impact either (data not shown). 
Given the above mentioned results, we did not perform statistical analysis for scores of  
individual markers other than 2.
The impact of  BCL2 protein expression within GCB and non-GCB patients
As none of  the Cox regression analyses showed a statistically signifi cant interaction 
between GCB and BCL2, subgroups analyses of  BCL2 within GCB and non-GCB 
patients were not warranted. Therefore the best estimate of  the hazard rate of  BCL2 
within these subgroups remains the overall estimate shown in Table 1, which implies an 
adverse effect of  BCL2 positivity on PFS and EFS in the HO26 trial, but not in de HO25 
trial.
Table 3 | Variation in algorithm to defi ne GCB and  non-GCB DLBCL sub types. 
PFS HR 95% CI EFS HR 95% CI OS HR 95% CI
Trial 1 HO25 WS 
GCB0  1.03  .71-1.49 1.11 .77-1.61 .98 .67-1.43
GCB1  .94  .64-1.39 1.01 .69-1.48  .94 .64-1.40
GCB2  1.08  .75-1.54 1.15 .81-1.64 1.01 .70-1.46
Trial 1 HO25 TMA 
GCB0  .64  .39-1.06 .63 .38-1.04 .56 .33-.96a
GCB1  .69  .41-1.15 .68 .41-1.13 .66 .38-1.12
GCB2  .64  .39-1.06 .63 .38-1.04 .56 .33-.96a
Trial 2 HO26 TMA
GCB0  1.20  .77-1.85 1.02 .66-1.56  1.21  .73-2.01
GCB1  1.17  .75-1.83 1.01 .65-1.56  1.11  .66-1.88
GCB2  1.14  .75-1.72 .92 .61-1.38  1.07  .66-1.74
GCB0=CD10, BCL6 and MUM1 ≥ 2; GCB1=CD10 ≥ 3, BCL6 and MUM1 ≥ 2; GCB2=CD10 and BCL6 
≥ 2, MUM1 ≥ 4, aP < 0.05.
DISCUSSION
We could not confi rm the prognostic relevance of  the IHC GCB or non-GCB sub 
classifi cation in these 2 large cohorts of  uniformly treated patients with DLBCL with a 
follow-up of  8 (HO25) or 7 years (HO26). Age difference is not a likely explanation for 
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this result, since the participants in the studies have different median ages. Moreover, the 
failure to demonstrate prognostic signifi cance of  the GCB and non-GCB sub classifi cation 
did not result from the distribution of  clinical characteristics, because the treatment (arm) 
was not signifi cantly different for the GCB or non-GCB subtype. Although we could not 
fi nd a predictive power of  the Hans model in our study, others have corroborated this 
model as being predictive. Therefore we have used different cut-off  levels in attributing 
classifi ers. More specifi cally, special attention was paid in varying the CD10 cut-off  levels, 
because in most studies the positivity of  CD10 is a prominent denominator of  whether 
the case will be classifi ed as GCB or non-GCB. However, the variations did not result in 
improved or altered outcome prediction. This is in accordance with other investigators 
using a dichotomous system of  scoring CD1022,35. Also, variation in the cut-off  level 
of  MUM1 or BCL6 (data not shown except for score 2) did not improve the predictive 
power22. 
 The results of  our study indicate that our fi ndings regarding the prognostic value 
of  the Hans algorithm are most probably not caused by variations in the cut-off  levels 
of  the individual markers CD10, BCL6 and MUM1.Moreover, our cut-off  value of  1 or 
partly 2 more or less corresponds with the cut-off  value of  30% of  the study of  Hans and 
other studies reporting a predictive or a non-predictive effect22,25. 
 The discrepancies in predictive value of  the Hans model in the various studies 
are probably better explained by the variation of  tissue processing procedures (paraffi n 
blocks originated from different pathology laboratories) prior to the construction of  
the TMAs and IHC procedures may have caused the above-mentioned variations. As 
reported earlier, IHC analysis in TMA is comparable with WS in NHL36,37. Indeed, we 
found no consistent differences in clinical outcome of  the IHC GCB vs. non-GCB sub 
classifi cation between both techniques. However, for the individual markers CD10, BCL6 
and MUM1, a trend towards lower positive scores was found in the HO25 TMA setting. 
We have therefore searched for discrepancies of  more than 2 points in scoring between 
the 2 cores in the HO25 TMA. The number of  discrepant cases (2 cores) for BCL2, 
MUM1 and CD10 were 3 out of  144 cases and for BCL6, 4 out of  144 cases (data not 
shown). The fact that the TMAs appear not to be representative of  whole sections may be 
better explained by variance in the immunogenecity of  the different areas of  the tumour 
which were sampled.
 This may partly explain the relative high percentage of  ABC sub type in the 
HO25 TMA as compared to the HO25 WS. In our clinical trials, the percentage of  
GCB classifi ed cases is slightly less than what has been reported in literature as lower 
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levels, ranging from 42 to 58% compared to 26 – 39% in our trials21-23,25. To analyze the 
difference in the distribution of  GCB and non-GCB we have varied the cut-off  levels in 
the scoring system. Indeed with the cut-off  level 1 in the scoring of  CD10 we have found 
a distribution that is comparable with other publications namely 50% (±10). However, 
even in these cases we could not detect a predictive effect (data not shown). Therefore, 
(semi-) quantitative expression analysis of  each marker that contributes to the GCB and 
non-GCB DLBCL sub groups as well as BCL2 was investigated. Moreover, variable 
results have been reported concerning the relative value of  these markers38-49. We also did 
not obtain consistent results with respect to the prognostic relevance of  CD10, BCL6 and 
BCL2 in our data set. A possible explanation of  the difference in outcome for BCL6 and 
BCL2 between the HO25 and HO26 studies may be that the patient characteristics of  the 
individual studies are different, especially when considering age. 
 The IPI (in which age is an important denominator) was only predictive for outcome 
in the HO25 WS study. This can be explained by the fact that no major differences were 
found in our sample and the initial study population of  the HO25 study. Moreover, the 
IPI was weakly predictive in this initial study population. We do not have a plausible 
explanation for the discrepancy in predictive value of  the IPI in the HO25 TMA sample. 
However, the GCB vs. non-GCB classifi cation has been described as a prognostic factor 
which is independent of  the IPI score.
 Recently it was suggested that the huge variability in laboratory processing and 
staining techniques might ultimately explain the wide variation reported in the literature 
concerning the prognostic impact of  these markers. These investigators reported highly 
variable results and very poor reproducibility in scoring for BCL6, MUM1, and BCL2, 
and to a lesser extent for CD1035. In this paper, IHC and scoring procedures of  patient 
samples of  the two clinical trials were performed in a central lab. However, sampling 
fi xation and paraffi n embedding of  the specimens were performed in laboratories of  
local hospitals at which the patient presented at primary diagnosis. This may also have 
infl uenced the IHC results and is concordant with the reported concerns regarding the 
standardization of  the IHC procedures and prognostic relevance of  the investigated 
markers.
 It has recently been demonstrated that the addition of  rituximab to the anthracyclin-
based regimen does not eliminate the difference between clinical outcome between GCB 
and non-GCB sub types as determined by GEP. In keeping with the results based on 
CHOP regimens, controversial results are also reported in R-CHOP treated patients 
regarding the prognostic relevance of  IHC based cell of  origin algorithms. Possibly, with 
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ongoing research, techniques such as GEP, CGH and GWAS may become an alternative 
to determine the distinct biological DLBCL entities in clinical practice50. 
 However, for the moment further development of  immunohistochemical methods 
seems to be the most practical in terms of  feasible usage in daily clinical practice when 
stratifying patients for therapeutic purposes. Ongoing immunohistochemical research 
using novel markers is warranted to dissect favorable and non-favorable subgroups 
of  patients. However, when using these markers, changes to the Hans algorithm most 
probably have to be made because markers associated with a GCB profi le such as the 
HGAL protein did not fi nd a complete correlation with the GCB and non-GCB division 
as defi ned by Hans et al.51.
 In conclusion, we could not demonstrate a consistent predictive power of  
clinical outcome of  the IHC GCB and non-GCB classifi cation in these large cohorts 
of  prospectively treated and well documented DLBCL patients. This underscores the 
need to further determine the biological variation of  the protein expression levels, to 
improve and standardize the detection of  protein expression levels and to further study 
the relevance of  prognostic classifi cations based on IHC algorithms using other markers 
in large cohorts of  patients, preferably treated in prospective clinical trials. 
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Supplemental Table 1 | Patients characteristics in the trials.
Total Trial 1 H.25 WS 153 Trial 1 H.25 TMA 134 Trial 2 H.26 TMA 144
Age (P<0.001)
Median  73  72  50
Range  65-85  65-90  
Sex (%) (P=0.45)
Male  82 (54)  75 (56)  70 (49)
Female  71 (46)  59 (44)  74 (51)
Stage (Ann Arbor) (%) (P<0.001)
II  45 (29)  44 (33)  30 (21)
III  34 (22)  25 (19)  62 (43)
IV  74 (48)  65 (49)  52 (36)
WHO performance status (%) (P=0.06)
0  64 (42)  61 (46)  74 (53)
1  60 (39)  51 (39)  53 (38)
2  22 (14)  15 (11)   9 (6)
3   6 (4)   5 (4)   3 (2)
Missing *   1   2   5
LDH (%) (P=0.06)
Normal  51 (34)  53 (40)  68 (47)
Elevated 100 (66)  80 (60)  76 (53)
Missing *   2   1   –
# Extra nodal sites involved (P=0.4)
0-1 130 (85) 115 (86) 129 (90)
≥ 2  23 (15)  19 (14)  15 (10)
IPI (%) (P<0.001) 
Low  19 (13)  21 (16)  62 (45)
Low-intermediate  48 (32)  45 (34)  62 (45)
High-intermediate  51 (34)  41 (31)  14 (10)
High  32 (21)  24 (18)   1 (1)
Missing *   3   3   5
Bone marrow involvement (%) (P=0.33)
No 121(79) 102(76) 115(83)
Yes  32(21)  32(24)  23(17)
Missing *  – -   6
Bulky disease (%) (P=0.96)
No 121 (79) 104 (78) 112 (78)
Yes  32 (21)  30 (22)  31 (22)
Treatment arm (%)
8cycles CHOP  74 (48)  68 (51)  65 (45)
8cycles CHOP + G-CSF  79 (52)  66 (49)  –
6 cycles dose intensive CHOP  –  –  79 (55)
*Patients with missing data have been excluded when calculating percentages.
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Supplemental Table 2 | Patient characteristics according to GCB and ABC sub classifi cation. 
Total H.25 WS 
ABC 87
H.25 WS 
GCB 55
H.25 TMA 
ABC 82
H.25 TMA 
GCB 29
H. 26 TMA 
ABC 97
H.26 TMA 
GCB 45
Age
Median 72 73 73 69 51 50
Range 65-83 65-85 65-90 65-83 16-65 17-65
Sex (%)
Male 48 (55) 30 (55) 44 (54) 17 (59) 44 (45) 25 (56)
Female 39 (45) 25 (45) 38 (46) 12 (41) 53 (55) 20 (44)
Stage (Ann Arbor) (%)
II 28 (32) 15 (27) 27 (33) 27 (33) 21 (22)  9 (20)
III 18 (21) 15 (27) 16 (20) 16 (20) 47 (48) 14 (31)
IV 41 (47) 25 (45) 39 (48) 39 (48) 29 (30) 22 (49)
WHO performance status (%)
0 38 (44) 24 (44) 34 (41) 13 (45) 52 (54) 21 (47)
1 32 (37) 23 (42) 32 (39) 12 (41) 35 (36) 17 (38)
2 14 (16)  6 (11) 11 (13)  2 (7)  5 (5)  4 (9)
3  3 (3)  1 (2)  3 (4)  2 (7)  1 (1)  2 (4)
Missing *  –  1 (2)  2 (2)  –  4 (4)  1 (2)
LDH (%) 
Normal 26 (30) 22 (40) 32 (39) 13 (45) 43 (44) 24 (53)
Elevated 61 (79) 31 (56) 50 (61) 15 (52) 54 (56) 21 (47)
Missing *  –  2 (4)  –  1 (3)  –  –
# Extra nodal sites involved
0-1 74 (85) 48 (87) 72 (88) 24 (83) 91 (94) 37 (82)
≥ 2 13 (15)  7 (13) 10 (12)  5 (17)  6 (6)  8 (18)
International Prognostic Index (%)
Low 11 (13)  8 (15) 14 (17)  5 (17) 40 (41) 21 (47)
Low-intermediate 28 (32) 18 (33) 26 (32)  8 (28) 43 (44) 19 (42)
High-intermediate 27 (31) 17 (31) 23 (28) 12 (41) 10 (10)  3 (7)
High 21 (24)  9 (16) 17 (21)  3 (10)  –  1 (2)
Missing *  –  3 (5)  2 (2)  1 (3)  4 (4)  1 (2)
Bone marrow involvement (%)
No 70 (80) 46 (84) 64 (78) 20 (69) 78 (80) 35 (78)
Yes 17 (20)  9 (16) 18 (22)  9 (31) 14 (14)  9 (20)
Missing *  –  –  –  –  5 (5)  1 (2)
Bulky disease (%)
No 72 (83) 41 (75) 65 (79) 22 (76) 80 (82) 30 (67)
Yes 15 (17) 14 (25) 17 (21)  7 (24) 17 (18) 14 (31)
Missing *  1 (2)
Allocated treatment arm (%)
Control 42 (48) 27 (49) 40 (49) 17 (59) 44 (45) 19 (42)
Experimental 45 (52) 28 (51) 42 (51) 12 (41) 53 (55) 26 (58)
*Patients with missing data have been excluded when calculating percentages.
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Supplemental Table 3 | IHC data of  the DLBCL sub classifi cation, IPI score and used markers. 
Total HO25 WS  153 HO25 TMA 34 HO26 TMA 144
Sub type (%) P=0.10
 GCB (0)
 ABC
 Missing*
55 (39)
87 (61)
11
29 (26)
82 (74)
23
45 (32)
97 (68)
 2
CD10 P=0.01
 0%
 1-25%
 26-50%
 51-75%
 76-100%
 Missing*
97 (67)
 7 (5)
 7 (5)
 6 (4)
27 (19)
 9
54 (48)
37 (33)
 3 (3)
 6 (5)
13 (12)
21
57 (40)
49 (35)
 6 (4)
12 (8)
18 (13)
 2
BCL6 P < 0.001
 0%
 1-25% B
 26-50%
 51-75%
 76-100%
 Missing*
46 (33)
18 (13)
17 (12)
31 (22)
27 (19)
14
79 (69)
21 (18)
11 (10)
 1 (1)
 3 (3)
19
24 (17)
48 (34)
30 (21)
20 (14)
18 (13)
 4
MUM1 P < 0.001
 0%
 1-25% 
 26-50%
 51-75%
 76-100%
 Missing*
33 (24)
16 (12)
18 (13)
23 (17)
46 (34)
17
68 (58)
36 (31)
 6 (5)
 2 (2)
 6 (5)
16
21 (15)
45 (31)
31 (22)
24 (17)
22 (15)
 1
BCL2 P < 0.001
 0%
 1-25% 
 26-50%
 51-75%
 76-100%
 Missing*
22 (17)
20 (15)
18 (14)
14 (11)
56 (43)
23
34 (31)
31 (28)
14 (13)
 7 (6)
24 (22)
24
48 (34)
34 (24)
16 (11)
21 (15)
21 (15)
 4
IPI P < 0.001
 Low
 Low-interm
 High-interm
 High
 Missing*
19 (13)
48 (32)
51 (34)
32 (21)
 3
21 (16)
45 (34)
41 (31)
24 (18)
 3
62 (45)
62 (45)
14 (10)
1 (1)
 5
* Patients with missing data have been excluded when calculating percentages; GCB (0)=CD10, BCL6 and 
MUM1 ≥ 2.
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ABSTRACT
Background: The peripheral cannabinoid receptor (CB2) is mainly detected on B-cells 
in the Germinal centers (GCs) of  the immune system, using an antibody directed against 
the extra cellular N-terminal domain of  the receptor. We retrospectively investigated the 
CB2 receptor expression in Diffuse Large B-cell Lymphomas (DLBCL) and its clinical 
relevance for treatment outcome. 
Patients and Methods: We have constructed a tissue micro-array (TMA) using lymphoma 
tissue of  a large cohort of  DLBCL patients (N=104) who were treated with CHOP. 
Results: Forty-fi ve out of  79 evaluable cases (57%) were CB2 positive. The expression 
of  CB2 receptors was variably present in both the Germinal Center B-cell (GCB) (n=31) 
and the non-GCB/activated B-cell (ABC) (n=43) DLBCL sub types. CB2 positivity was 
not associated with a different outcome in this patient cohort (CR; P=0.87, EFS; P=0.32, 
DFS; P=0.06 and OS; P=0.18). Implementation of  CB2 expression in the Hans algorithm 
using the markers CD10, BCL6 and MUM1 did not result in added prognostic value (all 
P values > 0.1).
Conclusions: We hypothesize that although CB2 is normally expressed in GCs, the 
expression in one of  the malignant counterparts such as DLBCL is aberrant. This may be 
an explanation for the absence of  prognostic relevance for the expression of  this protein.
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INTRODUCTION
The peripheral cannabinoid receptor, encoded by the CB2 gene, is a seven transmembrane 
receptor, which shows high homology with the central cannabinoid receptor CB1. In 
healthy individuals CB2 is mainly expressed on a subset of  B-lymphocytes1-6. Using the 
N-terminal specifi c CB2 antibody, it has been shown that B-lymphocytes in the germinal 
centers (GCs) highly express the protein, whereas weak or no staining was apparent on 
B-cells in the marginal- and mantle zones of  secondary follicles. This suggests a germinal 
center like expression pattern6. The role of  CB2 in the development or function of  these 
B-cell subsets is at present unclear. Several pieces of  evidence suggest that CB2 may 
act as an onco protein. Cb2 was fi rst identifi ed as a proto-oncogene in mouse myeloid 
leukemias by retroviral insertional mutagenesis7-9. Flow cytometric analysis using an 
N-terminal specifi c CB2 antibody revealed that in humans, the receptor was absent on 
normal bone marrow myeloblasts but was highly expressed on a signifi cant number of  
acute myeloid leukemia (AML) samples. Introduction of  Cb2 into murine myeloid model 
32D completely abolished neutrophil development, a hallmark of  AML 0.
 Further evidence of  altered expression in hematopoietic malignancies came from 
a recent study focusing on B- and T-cell lymphomas11. T-cell lymphomas frequently 
showed high CB2 expression, whereas no CB2 expression was evident on normal 
T-cells. The presence of  CB2 on B-cell lymphomas was expected, but it is not clear yet 
whether distribution of  CB2 protein on distinct B-cell lymphomas mirrors the expression 
pattern that we previously reported or whether CB2 expression may be altered in 
these malignancies as well. One study reports that signifi cant reduction of  tumor size 
and mitotic index of  human mantle cell lymphoma (MCL) occurred following in vivo 
treatment with cannabinoid receptor ligands in xenografted mice12. This suggests that 
the presence of  CB2 receptors on those tumor cells is related to biological behavior 
which may have therapeutic implications in the human clinical setting. However MCL 
is a relative rare disease, which makes it diffi cult to use it as a model for studying the 
role of  CB2 expression in B-cell non-Hodgkin’s lymphoma in a consistent manner. In 
contrast, diffuse large B-cell lymphomas (DLBCL) occur more commonly, making it a 
more suitable lymphoma subtype to be studied in this respect. DLBCL is a heterogeneous 
group of  diseases responding variably to therapy. This possibly refl ects the differences in 
biology among patients13-23. Various attempts have been made to understand and unravel 
this heterogeneity by applying gene expression profi ling (GEP) or immunohistochemistry, 
also in search for novel biological prognostic markers. Two major forms of  DLBCL 
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which appear to have a different physiological counterpart as distinct B-cell lymphoma 
types found in secondary follicles are currently distinguished using GEP24. The clinically 
favorable subtype is nowadays classifi ed as the GCB-type (germinal center) DLBCL 
and the clinically non-favorable sub type as non-GCB/ABC type DLBCL. The GEP 
technology is, however not or not readily available in clinical practice. Therefore, attempts 
have been made to replace GEP with immunohistochemistry on paraffi n embedded 
tissues, using combinations of  immunological markers. Until now, these attempts have 
not been uniformly successful25-43.
 In this study, we retrospectively analyzed the expression pattern of  the peripheral 
cannabinoid receptor expression in a cohort of  104 DLBCL samples using a tissue micro-
array (TMA). We compared the results with those obtained using the immunohistochemical 
GCB- versus non-GCB DLBCL subtype classifi er as defi ned by Hans et al, applied on the 
same 104 cases33. We demonstrate that although CB2 expression is normally expressed on 
GCB-type B-cells in healthy individuals, DLBCL from both subtypes can be CB2 receptor 
positive or negative. Consequently, we could not demonstrate a predictive value of  CB2 
expression as determined with immunohistochemical staining on the survival of  DLBCL. 
We hypothesize that the absence of  clinical relevance of  the CB2 protein is related to the 
aberrant expression on hematological malignancies including DLBCL. 
PATIENTS AND METHODS
Patients
We retrieved all cases with a newly diagnosed, biopsy proven DLBCL from the archives 
of  the Department of  Pathology of  the Erasmus Medical Center. In total, 104 cases 
were included for the retrospective analysis. The majority of  the patients (78%) received 
an anthracycline-containing chemotherapy regimen (CHOP-like cyclophosphamide, 
doxorubicin, vincristine and prednisone). The remaining 34 patients were treated 
alternatively (17 radiotherapy, 3 rituximab, 2 leukeran, 1 methotrexate and cytarabine, 
2 resection, 1 prednisone and 8 no treatment). The study was approved by the medical 
ethics committee of  the Erasmus MC, and was conducted in accordance with the 
Declaration of  Helsinki. Since this study is based on retrospective data it was not always 
possible to obtain informed consent. In these cases we proceeded according to the Dutch 
code of  conduct for use of  remaining tissues after diagnostic procedures (EUDRACT 
registration data).
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Construction of  the TMA and scoring system 
Hematoxylin-eosin (H-E) stained sections of  paraffi n-embedded, formalin-fi xed tissue 
were used to defi ne the diagnostic areas. From each case, 3 representative 0.6 mm cores 
were obtained and inserted adjacently into a recipient paraffi n block using a tissue arrayer 
(Beecher Instruments, Silver Spring, MD). Only cases with suffi cient and representative 
material were included. Availability of  at least one reliable core with a diameter of  0.6 mm 
was required for inclusion in this study. 
 Cores were also stained with H-E and negative controls (omission of  primary 
antibody) of  all examined tissues were included. Stains were scored on a 5-point scale: 
0=negative, 1=<26% cells positive, 2=26 – 50% cells positive, 3=51 – 75% cells positive, 
4=>75% cells positive. Cases with scores 0, 1, 2 or 3 were designated as negative, whereas 
score 4 was designated as positive in case of  CB2. Of  the cores with variable outcome, the 
mean expression of  the cores was taken and upgraded to the highest score. CD10, BCL6, 
MUM 1 antibodies (Abs) were used to assign patients into the GCB or the non-GCB 
DLBCL groups according to the Hans algorithm33. The GCB sub group was defi ned as 
CD10+ and/or BCL-6+ profi le, whereas CD10-/BCL-6-/+, MUM1+ cases were assigned 
to the non-GCB group. Cases that were negative for all markers were assigned into the 
non-GCB group. Positivity of  the single markers including BCL2 was defi ned as a score 
2 (>25% of  the cells with positive staining (Table 1). 
Table 1 | Defi nition of  GCB and non-GCB DLBCL subtype.
Subtype DLBCL CD10 BCL-6 MUM1
GCB + - -
GCB – + –
GCB + + –
GCB + + +
GCB + – +
Non-GCB – – +
Non-GCB – + +
Non-GCB – – –
DLBCL, diffuse large B-cell lymphomas, GCB, germinal center B cell. – indicates a score of  0-1, + indicates 
a score of  2 – 4 . Scoring system (in % of  positive cells):0=0, 1=1 – 25, 2=26 – 50, 3=51-75 and 4=76 – 100.
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Immunohistochemistry
Table 2 summarizes the Abs and IHC procedures used in this study. The anti-CB2 receptor 
polyclonal antibody (Ab), raised against the fi rst 33 amino acid residues of  the N terminus 
(N-CB2) of  the receptor, was purchased from Affi nity BioReagents (ABR, Golden, CO). 
Five-micrometer paraffi n sections from formalin-fi xed material were dehydrated and 
deparaffi nized according to standard pathology laboratory procedures. Visualization was 
achieved using Diaminobenzidine (DAB; Fluka, Buchs, Switzerland) in dark for 7 minutes. 
Finally, sections were counterstained with hematoxylin, according to Harris (Klinipath, 
Duiven, Netherlands), dehydrated, and covered by pertex (Histolab, Göteborg, Sweden). 
Normal expression of  the CB2 Ab was analyzed in sections of  non-malignant human 
lymph nodes and spleens. All samples were independently evaluated in a semi-quantitative 
way by two medical doctors with suffi cient experience (NR and KHL). Discordant scores 
were resolved by joint review on a multi-headed microscope.
Table 2 | Antibodies and conjugates used for IHC analysis.
Primary antibodies Specifi city/incubation time Dilution/Epitope 
retrieval*
Source
CB2 Polyclonal 1:600/no ABR
CD10 
BCL6 (PG-B6P),
MUM1 (MUM 1P)
BCL2 
Monoclonal / 30 minutes
Monoclonal / overnight
Monoclonal /40 minutes
Monoclonal/ 30 minutes
1:10/yes
1:10/yes
1:200/yes
1:200/yes
Novocastra 
DAKO
DAKO
DAKO
Secondary Abs and conjugates
GaM-HRP
S-ABC HRP-kit
Goat-anti-rabbit. horse radish peroxidase 
(HRP)/1hour
Streptavidin biotin complex-HRP/15 minutes
1:200
1:100
DAKO
Labvision
Antigen retrieval was performed by pretreating sections in a microwave oven (Salm and Kipp, Breukelen, 
Netherlands). Antibodies were obtained from: Affi nity BioReagents (ABR, Golden, CO), Novocastra 
(Newcastle upon Tyne,UK), DAKO (Glostrup, Denmark) and Labvision (Fremont, California).
Statistical analysis 
The clinical parameters of  interest in this study were complete response (CR) rate, event-
free survival (EFS), disease-free survival from CR (DFS) and overall survival (OS), CR was 
defi ned as disappearance of  all symptoms and signs and all measurable lesions, normal 
lactate dehydrogenase (LDH) for at least 6 weeks, and no bone marrow infi ltration. EFS 
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was measured from diagnosis until no CR, relapse, or death from any cause, whichever 
came fi rst. DFS was calculated from date of  CR until relapse or death. OS was calculated 
from the date of  diagnosis until death from any cause. Patients were censored if  they were 
still alive at the date of  last contact. 
 Patient characteristics between subgroups of  patients (CB2+ vs. CB2-, GCB vs. 
Non-GCB, and CHOP vs. no CHOP received) were compared using the Pearson χ2 
test or the Fisher exact test in case of  discrete variables, whichever appropriate, or the 
Wilcoxon rank sum test in case of  continuous variables. The CR rate was compared 
between subgroups using univariate logistic regression analysis. EFS, DFS, and OS 
were estimated by the Kaplan-Meier method, and 95% confi dence intervals (CIs) were 
constructed. Survival analysis was performed using Cox regression to see whether there 
was a difference in survival between subgroups. Kaplan-Meier curves were generated 
to illustrate differences between the 2 treatment arms and compared using the log-rank 
test44-46. 
 All reported P values are two-sided and in view of  the exploratory nature of  these 
analyses, were calculated without adjustment for multiple testing. P-values ≤ 0.05 were 
considered statistically signifi cant.
RESULTS
The expression of  CB2 protein was initially studied in 104 DLBCL patients (66 males 
and 38 females). In total, 79 patients could be reliably evaluated using TMA. Of  these 79 
patients, 45 cases (57%) were CB2 positive (score 4). CB2 has been demonstrated to be 
expressed in GCB-cells of  normal human lymph nodes, whereas weak or no staining with 
Abs directed to the N-terminus of  CB2 has been reported in B cells outside the GCB 
areas of  the secondary lymph nodes. Therefore, the next step was to evaluate whether 
CB2 positivity in DLBCLs correlated with a GCB-phenotype. To this end, we used the 
sub classifi cation as reported previously by Hans et al.33. Thirty-fi ve (42%) and 49 (58%) 
patients were classifi ed as GCB or non-GCB subtype respectively (Table 3 and 4). We 
demonstrated that of  the 35 cases assigned to the GCB phenotype, only 19 cases showed 
CB2 positivity. Unexpectedly, 12 DLBCLs did not show CB2 expression. In the 49 cases 
assigned to the non-GCB phenotype, 19 cases were CB2 negative and 24 cases were CB2 
positive. Of  20 cases, no correlation between the subtypes and CB2 could be made, due 
to unreliability of  staining or core loss (Table 5). Thus, the absence of  concordance in
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Table 4 | Patient characteristics according to GCB and non-GCB subtypes.
Characteristics GCB 
(%)
nGCB 
(%)
Total classifi -
able (%)
Missing 
(%)
Total 
(%)
Total 35 49 84 20 104
Age at diagnosis
 Median 
 Range
59
28-90
65
18-90
63
18-90
50
24-86
60
18-90
Sex
 Male 
 Female 
23 (66)
12 (34)
29 (59)
20 (41)
52 (62)
32 (38)
14 (70)
 6 (30)
66 (63)
38 (37)
Stage (Ann Arbor)
 I
 II
 III
 IV
 Unknown*
10 (30)
 8 (24)
 4 (12)
11 (33)
 2
14 (33)
 5 (12)
 8 (19)
15 (36)
 7
24 (32)
13 (17)
12 (16)
26 (35)
 9
 3 (18)
 5 (29)
 2 (12)
 7 (41)
 3
27 (29)
18 (20)
14 (15)
33 (36)
12
WHO performance status
 0
 1 
 2
 3 
 4
 Unknown*
24 (73)
 5 (15)
 2 (6)
 1 (3)
 1 (3)
 2
26 (59)
11 (25)
 2 (5)
 3 (7)
 2 (5)
 5
50 (65)
16 (21)
 4 (5)
 4 (5)
 3 (4)
 7
13 (68)
 3 (16)
 1 (5)
 2 (11)
 –
 1
63 (66)
19 (20)
 5 (5)
 6 (6)
 3 (3)
 8 
LDH
 Normal
 Elevated
 Unknown*
26 (76)
 8 (24)
 1
33 (70)
14 (30)
 2
59 (73)
22 (27)
 3
 8 (42)
11 (58)
 1
67 (67)
33 (33)
 4
# Extra nodal sites involved
 0-1
 ≥ 2
26 (74)
 9 (26)
43 (88)
 6 (12)
69 (82)
15 (18)
15 (75)
 5 (25)
84 (81)
20 (19)
International Prognostic Index (IPI)
 Low
 Low-intermediate
 High-intermediate
 High
 Unknown*
19 (63)
 6 (20)
 2 (7)
 3 (10)
 5
18 (51)
 9 (26)
 4 (11)
 4 (11)
14
37 (57)
15 (23)
 6 (9)
 7 (11)
19
 7 (47)
 4 (27)
 3 (20)
 1 (7)
 5
44 (55)
19 (24)
 9 (11)
 8 (10)
24
Age-adjusted IPI
 Low
 Low-intermediate
 High-intermediate
 High
 Unknown*
16 (55)
 6 (21)
 5 (17)
 2 (7)
 6
14 (40)
11 (31)
 7 (20)
 3 (9)
14
30 (47)
17 (27)
12 (19)
 5 (8)
20
 5 (38)
 4 (31)
 4 (31)
 –
 7
35 (45)
21 (27)
16 (21)
 5 (6)
27
Bone marrow involvement  6 (18)  7 (16) 13 (16)  3 (17) 16 (16)
Bulky disease  1 (3)  1 (2)  2 (3)  1 (6)  3 (3)
GCB, germinal center B cell.
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Table 5 | CB2 expression in GCB and non-GCB subtypes.
CB2 - CB2 + — Total
GCB
Non-GCB
—
12
19
 3
19
24
 2
 4
 6
15
 35
 49
 20
Total 34 24 25 104
GCB, germinal center B cell; CB2 ± indicates the negative and positive cases respectively; — indicates 
missing or non-interpretable cases.
CB2 expression between the DLBCL subgroups and their physiological counterparts in 
the human normal B-cell population, may suggest sub lineage infi delity in these malignant 
B-lymphocytes. 
 We next studied the prognostic value of  CB2 detection in DLBCL. No major 
differences were observed in the clinical presentation between the CB2+ and CB2- cases 
(Table 6). Seventy patients received CHOP or CHOP-like therapy, whereas 34 patients 
received a non-CHOP based therapy. The median age of  the patients was 60 years (range 
18-90). The median follow-up of  41 surviving patients was 44 months (range 2 – 143). The 
fi ve-year EFS, DFS and OS of  these 104 patients were 25%, 55% and 41% respectively. 
As expected, the IPI was a strong predictor of  CR, EFS, DFS and OS (P < 0.001 for all 
four endpoints) (Table 3). The clinical outcome of  the patients in the subgroups with 
a distinct CB2 expression is summarized in Table 4. CB2 positivity was not associated 
with a different clinical outcome in these 104 cases (CR; P=0.87, EFS; P=0.32, DFS; 
P=0.06 and OS; P=0.18). However, the amount of  expression of  this protein seems to be 
correlated with an improved survival (P=0.05) (Table 3, Figure 1). 
 In contrast to the CB2 studies, we found a signifi cantly different clinical outcome 
between GCB and non-GCB sub types (Table 3; Figure 2). No difference in clinical 
parameters was observed between the two DLBCL sub groups (Table 4). No association 
with clinical outcome was found for the expression of  the separate markers BCL6 and 
MUM1 (Table 3). We found no indication for a different effect of  BCL2 within the 
subgroups of  GCB and non-GCB patients. 
 We next studied the additive value of  CB2 expression in the distinct DLBCL 
subtypes. Nine-teen CB2 positive cases were present in the GCB group (n=31) and 19 in 
the non-GCB group (n=43) (Table 5). CB2 positivity was not associated with improved 
outcome in the GCB or the non-GCB sub types (Fi gures 3 and 4).
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Table 6 | Baseline Patients Characteristics.
Characteristics CB2+
(%)
CB2-
(%)
Total
classifi able (%)
Missing
(%)
Total
(%)
Total 45 34 79 25 104
Age at diagnosis
 Median 
 Range
64
18-90
59
28-89
63
18-90
56
28-84
60
18-90
Sex
 Male 
 Female 
29 (64)
16 (36)
21 (62)
13 (38)
50 (63)
29 (37)
16 (64)
 9 (36)
66 (63)
38 (37)
Stage (Ann Arbor)
 I
 II
 III
 IV
 Unknown*
15 (38)
 8 (20)
 5 (13)
12 (30)
 5
 6 (21)
 6 (21)
 6 (21)
11 (38)
 5
21 (30)
14 (20)
11 (16)
23 (33)
10 
 6 (26)
 4 (17)
 3 (13)
10 (43)
 2
27 (29)
18 (20)
14 (15)
33 (36)
12
WHO performance status
 0
 1 
 2
 3 
 4
 Unknown*
25 (66)
 6 (16)
 3 (8)
 2 (5)
 2 (5)
 7 
22 (67)
 8 (24)
 0
 3 (9)
 0 
 1
47 (66)
14 (20)
 3 (4)
 5 (7)
 2 (3)
 8
16 (64)
 5 (20)
 2 (8)
 1 (4)
 1 (4)
 0
63 (66)
19 (20)
 5 (5)
 6 (6)
 3 (3)
 8 
LDH
 Normal
 Elevated
 Unknown*
33 (75)
11 (25)
 1
23 (72)
 9 (28)
 2
56 (74)
20 (26)
 3
11 (46)
13 (54)
 1
67 (67)
33 (33)
 4
# Extra nodal sites involved
 0-1
 ≥ 2
37 (82)
 8 (18)
28 (82)
 6 (18)
65 (82)
14 (18)
19 (76)
 6 (24)
84 (81)
20 (19)
International Prognostic Index (IPI)
 Low
 Low-intermediate
 High-intermediate
 High
 Unknown*
21 (64)
 6 (18)
 3 (9)
 3 (9)
12
14 (54)
 7 (27)
 2 (8)
 3 (12)
 8
35 (59)
13 (22)
 5 (8)
 6 (10)
20
 9 (43)
 6 (29)
 4 (19)
 2 (10)
 4
44 (55)
19 (24)
 9 (11)
 8 (10)
24
Age-adjusted IPI
 Low
 Low-intermediate
 High-intermediate
 High
 Unknown*
17 (50)
10 (29)
 4 (12)
 3 (9)
11
11 (48)
 6 (26)
 6 (26)
 0
11
28 (49)
16 (28)
10 (18)
 3 (5)
22
 7 (35)
 5 (25)
 6 (30)
 2 (10)
 5
35 (45)
21 (27)
16 (21)
 5 (6)
27
Bone marrow involvement  6 (14)  3 (10)  9 (12)  7 (29) 16 (16)
Bulky disease  1 (2)  1 (3)  2 (3)  1 (5)  3 (3)
* Not included when calculating percentages; Because of  rounding, percentages may not add up to 100%; 
Patient characteristics were not signifi cantly different between the CB2+ and CB2-subtypes.
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Figure 4 | CB2 expression in the germinal center B cell (GCB) subtype. A and B : CB2 negative 
case. C and D: CB2 positive case. Original object lens magnifi cations are 10× and 40× respectively. 
See page 175 for colour picture.
DISCUSSION
In this study, we found that using immunohistochemical methods the expression of  the 
peripheral cannabinoid receptor CB2 did not defi ne cases with favorable or unfavorable 
clinical outcome. Although CB2 has a GCB-like expression pattern in normal lymph 
nodes, no association with clinical outcome was demonstrated in DLBCLs with either a 
GCB or non-GCB phenotype as defi ned by Hans et al.33. We suggest that these fi ndings 
are related with the aberrant CB2 protein expression in DLBCL. Other hematological 
malignancies including AML also demonstrate this phenomenon with differentiation 
block or confers abnormal migration in a ligand-dependent manner47. Likewise, almost 
no CB2 protein expression was observed on normal T-cells, whereas various T-cell 
lymphomas showed abundant CB2 protein expression suggesting an aberrant expression 
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of  this receptor11. The absence of  correlation of  the expression pattern of  CB2 in B-cell 
lymphoma cells with their normal physiological counterparts, including the absence of  
correlation between the GCB and non-GCB DLBCL subtypes may represent yet another 
example of  abnormal expression of  the CB2 receptor. In contrast, in this study we 
were able to demonstrate two clinically discriminative DLBCL subtypes using the Hans 
algorithm whereas this is not always the case in other studies. This may be due to variation 
in the IHC techniques48,49. 
 Careful interpretation is required regarding CB2 receptor expression. Lack of  
receptor expression using the N-terminal specifi c CB2 Ab, does not necessarily imply that 
the receptor is indeed absent on B-lymphocytes, since protein expression can be found 
using another C-terminal specifi c antibody which only recognizes a non-phosphorylated 
inactive receptor6. In fact, we observed that when cells were positive using this latter Ab, 
they nearly always stained negatively for the N-terminal specifi c anti-CB2 Ab. On the 
other hand, cells positive for the N-terminal specifi c CB2 Ab, stained negatively with the 
Ab directed against the C-terminus of  the receptor. Thus, the distinct CB2 expression 
profi les on normal lymphoid tissues seem to be dependent on the activation status of  
the receptor6. This may also be the case in the malignant counterpart of  these B-cells, 
meaning that the CB2 positive cells that we have identifi ed here most probably express 
an active CB2 receptor. We have found that migration is a major function of  the CB2 
receptor upon stimulation with its ligand 2-arachnoidoyl glycerol (2-AG)6. Thus, a higher 
expression of  the active CB2 receptor may also play a role in enhancing the migratory 
capabilities of  the malignant hematological cell. In fact, other investigators also found 
that on mRNA level, the majority of  the lymphomas expressed higher CB2 mRNA levels 
as compared to reactive lymphoid tissue. Moreover, the levels of  cannabinoid expression 
within lymphoma entities were highly variable12. 
 Although we were not able to demonstrate a prognostic signifi cance of  CB2 
expression, there are indications that targeting this receptor may be useful as part of  
therapeutic strategies. In functional studies using lymphoma cell lines, a CB2 ligand 
anandamide analog R(+)-methanandamide (R(+)-MA) induced cell death in mantle cell 
lymphoma (MCL) cells, which over expressed CB2 receptors in vivo. Also, treatment 
with R(+)-MA caused a signifi cant reduction of  tumor size and mitotic index in mice 
xenografted with human MCL12. These results suggest that therapies of  malignant 
lymphomas (over)expressing CB2 using cannabinoid receptor ligands may favorably 
impact the clinical outcome.
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 In this study we could not demonstrate a clinical predictive signifi cance of  CB2 
expression in DLBCL. Furthermore, we found no correlation of  CB2 expression with 
clinical outcome within the GCB or non-GCB DLBCL sub groups. We conclude that the 
expression of  CB2 in DLBCL does not have a clinical signifi cance with respect to the 
survival parameters, but the therapeutic possibilities of  targeting this receptor remains to 
be investigated.
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Discussion
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In this thesis we have investigated the function and expression of  the CB2 receptor in 
normal and malignant hematological cells and analyzed its potential as a novel prognostic 
factor in especially DLBCLs. We have used clinical data and histological material from 
well-defi ned patient groups and correlated the immunohistochemical data with existing 
immunohistochemical classifi cation systems. 
Expression and function of  CB2 receptors in AML cells
In chapter 2 we have shown that the CB2 expression pattern on AML blasts is different 
from normal immature myeloid cells in the bone marrow. Very low to absent protein 
expression was detected on normal immature myeloid cells, whereas approximately 50% 
of  the primary AML cells showed high CB2 receptor expression. Moreover, using a 32-D 
cell line model, in which Cb2 was introduced, we have shown that the function of  the 
receptor was dependent on the type of  agonist. A block of  neutrophilic differentiation 
was induced using a synthetic cannabinoid agonist CP 55940 and migration of  these 
cells occurred upon stimulation with the endogenous cannabinoid 2-AG. This effect is 
Cb2 specifi c since a specifi c antagonist SR 144528 abolished both effects. It would be 
interesting to further investigate whether these effects also occur in primary AML cells 
upon stimulation with cannabinoid ligands. 
 Targeting the Cb2 receptor by their ligands may become part of  novel treatment 
modalities. It would be therefore very interesting to investigate whether these or other 
(endo) cannabinoid ligands could induce differentiation in primary AMLs. Also, hampering 
the migratory or homing capacity of  malignant cells in vivo may lead to less spreading 
of  the initial tumor to other organs or lymph nodes. However, little is known about 
this function of  this G-protein coupled receptor. The functional mechanisms of  other 
GPCRs such as CXCR, which has been shown to be very important in the migration and 
homing of  malignant hematopoietic cells, could give clues how to target CB2 receptors in 
future research1. 
Expression and function of  CB2 receptors in normal immune tissues
In chapter 3, we have investigated the distribution of  CB2 receptors as well as their 
activation status in human immune tissues using two distinct anti-CB2 antibodies. 
We found that the N-terminal specifi c antibody was mainly present in areas of  active 
immunomodulation, e.g. on B-cells in the GCCs of  secondary follicles. The C-terminal 
specifi c anti-CB2 antibody, which only recognized the inactive non-phosphorylated 
receptors, was mainly present in the mantle (MZ) and marginal zones (MGZ) of  the 
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secondary follicles areas where mainly resting B-cells reside2. The results in Chapter 3 
suggests that activated phosphorylated CB2 receptors were present on immunologically 
active areas such as the GCs. Investigation of  the CB2 phosphorylation in B-lymphocytes 
in relation to the antigen specifi c activation by cannabinoid ligands is needed to validate 
this observation. Also, careful comparison of  the differences in distribution patterns 
of  the CB2 receptor in lymphoid tissues under various physiological activation states is 
required, since these differences may be explained by affi nity or epitope accessibility of  
the receptors. 
 It would be interesting to further investigate whether the activation status of  the 
receptor is indeed related to an immunomodulatory function of  the receptor in primary 
lymphoma cells. An immunomodulatory function of  these ligands via the CB2 receptor 
have been shown in mice defi cient for the receptor in which formation of  B-and T-cell 
subsets were absent3. Furthermore, functional cross-talk between CB2 receptors and 
other receptors such as CD40, which has been involved in GPCRs, is demonstrated in 
virgin tonsillar B-cells, which showed augmented proliferation upon stimulation with 
CD40 ligands4. We also showed that signifi cant migration occurred in the Raji-B-cell 
line upon stimulation with the endocannabinoid 2-AG. This migration was signifi cantly 
augmented by CD40 stimulation. This observation was made in a malignant B-cell line 
and therefore raised the question whether this receptor was also involved in the malignant 
transformation of  B-cells resulting in lymphomas or whether this receptor contributed to 
a specifi c function of  malignant B-cells, such as homing of  malignant B-cells in vivo or that 
CB2 receptors may be involved in B-cell activation. Analysis of  the CB2 receptor and its 
downstream effects upon stimulation on molecular level is therefore necessary to assess 
its possible role in tumorigenesis and spreading of  tumor cells from its initial localization. 
Data of  these investigations may be useful as part of  a therapeutic strategy. 
Expression of  CB2 receptors in B-NHL and T-NHL 
High levels of  active CB2 on DLBCL was expected in a certain percentage of  cases, since 
several studies showed that a large fraction of  DLBCLs exhibit a GCB-cell phenotype and 
the N-terminal specifi c antibody staining was mainly present in the GCs. Also, a high CB2 
expression using the N-terminal antibody was expected in follicular lymphoma (FL). In 
contrast, high C-terminal CB2 expression was expected in the lymphoma subtypes such 
as mantel cell lymphoma (MCL) or marginal zone lymphoma (MGZL), which have their 
normal counterparts in the primary follicles (mantle zone) or marginal zone of  secondary 
follicles with low levels of  active CB receptors. However, we have found the N-terminal 
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specifi c antibody staining positive in most of  the B-NHL, including MCL and MZL, 
although the C-terminal specifi c anti-CB2 antibody also stained more B-cells in most 
tumors.
 These data indicate that the presence or absence of  active CB2 receptors as detected 
by the N-terminal specifi c CB2 antibody, on normal B-cells does not (always) correspond 
with the expression in their malignant counterparts. This suggests that CB2 receptor 
expression may be aberrant in B-cell malignancies. This observation is further supported 
by the fact that in contrast to normal T-cells, frequent CB2 expression was present on 
T-NHL. This fi nding is probably not explained by the fact that certain T-NHL arise from 
a small, hard to detect fraction of  normal CB2 expressing T-cells since CB2 expression 
was detected using both CB2 antibodies on almost all T-NHL subtypes. The fact that, in 
contrast to the many malignant B-cell lymphoma subtypes, anti-CB2 directed to the non-
phosphorylated C-terminal part of  this receptor only stained positive in normal tissues 
when the N-terminal specifi c antibody did not, further supports the conclusion that T-cell 
lymphomas as well as B-cell lymphomas probably express an aberrantly functioning CB2 
receptor. The question thus arises whether this difference may indicate a possible use of  
CB2 expression as a prognostic factor. Therefore, we proceeded to immunohistochemical 
analysis of  the CB2 receptor expression using lymphoma tissue of  large groups of  
patients treated in randomized clinical trials.
The GCB vs. non-GCB classifi cation in DLBCL according to the Hans model
In order to investigate the possible effect of  the presence or absence of  the CB2 receptor 
on the prognosis in DLBCLs, we fi rst have investigated the clinical signifi cance of  
the classifi cation system as described by Hans et al5. This was the fi rst system based 
on immunohistochemistry and the results correlated quite well with those of  the gene 
expression array. Likewise, we have used a panel consisting of  CD10, BCL-6 and MUM1 
antibodies in a specifi c algorithm to assign cases in the GCB -or non-GCB DLBCL sub 
groups. The clinical data and histological material were from patients who were enrolled 
in 2 large prospective randomized clinical trials with a uniform treatment protocol. We 
could not confi rm the prognostic relevance of  the immunohistochemical GCB or non-
GCB sub classifi cation in these large cohorts of  patients with a long follow-up of  7 to 
8 years. Differences in the clinical characteristics, including age or being included in a 
specifi c treatment arm were not a likely explanation for this result, since for example, the 
participants in the studies had different median ages in the respective studies.
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Although we could not fi nd a predictive power of  the Hans model in our study, others 
have corroborated this model as being predictive6,7,8,9. Therefore, we have investigated 
different cut-off  levels in attributing classifi ers. We have looked more closely at CD10 
cut-off  levels because it is the principal denominator in this classifi cation system. In 
accordance with other investigators who have used a dichotomous scoring system for 
CD10, variation in cut-off  levels resulting in shifts towards GCB or non-GCB sub types 
did not result in improved or altered outcome prediction. Also, variation in the cut-off  
level of  MUM1 or BCL6 did not infl uence the predictive power. These results indicate 
that the prognostic value of  the Hans algorithm is probably not caused by variations in 
the cut-off  levels of  the individual markers CD10, BCL6 and MUM1. 
 In our study, we have used TMA as a novel approach to standardize staining for 
each antibody and compared this with whole section staining. We found lower scores 
for the antibodies used in the TMA and this has probably resulted in more non-GCB 
cases in our TMA series compared to the whole section series in one of  the studies (the 
HOVON 25 study). Discrepancies in scoring as such were investigated and were found 
not responsible for this effect. 
 A more plausible explanation for our fi ndings using TMA as well as whole tissue 
sections was that variations in tissue processing procedures in the various laboratories 
contributing tissue for these studies have caused the differences in outcome prediction. 
A recent report suggests that the huge variability in laboratory processing and staining 
techniques might ultimately explain the wide variation reported in the literature concerning 
the prognostic impact of  these markers. Variable results and very poor reproducibility 
in scoring for BCL6, MUM1, and BCL2, and to a lesser extent for CD10 have been 
reported10. Concerns regarding the standardization of  the IHC procedures and prognostic 
relevance of  the investigated markers are thus very important and need careful attention. 
 One might argue that these data are from trials conducted in the pre-rituximab 
era. However, the addition of  rituximab to the anthracyclin-based regimens did not 
eliminate the difference between clinical outcome between GCB and non-GCB sub 
types as determined by GEP11. Moreover, controversial results have also been reported 
in R-CHOP treated patients regarding the prognostic relevance of  IHC based cell of  
origin algorithms12,13,14. Other novel markers associated with a GCB profi le such as the 
HGAL protein also did not provide a complete correlation with the GCB and non-
GCB division as defi ned by Hans et al15. Altogether, the need to further determine the 
biological variation of  the protein expression levels and to further study the relevance of  
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prognostic classifi cations based on immunohistochemical algorithms preferably treated in 
prospective clinical trials, is obvious.
Prognostic value of  CB2 in the context of  the GCB vs. non-GCB classifi cation 
system
In an attempt to avoid a possible effect of  technical variations of  tissue processing in 
the various laboratories, we have employed the TMA technique in a retrospective cohort 
of  DLBCL patients of  which tissues were processed in one laboratory using standard 
procedures. Using immunohistochemistry, we have found that the expression of  the 
peripheral cannabinoid receptor CB2 did not defi ne cases with favorable or unfavorable 
clinical outcome. Although CB2 has a GCB-like expression pattern in normal lymph 
nodes, no association with clinical outcome was demonstrated in DLBCLs as a group 
and in the respective subgroups with either a GCB or non-GCB phenotype as defi ned by 
Hans et al. This is a remarkable fi nding, because in this study we could indeed confi rm 
the results of  Hans et al. using CD10, BCL6 and MUM1 in their specifi c algorithm. We 
could also confi rm the improved outcome for CD10 positive cases and a worse outcome 
for BCL-2 positive cases whereas no clinical signifi cance was found for the expression 
of  BCL-6 and MUM1. However, the latter results have to be interpreted with caution, 
because contradicting results have also been reported using the Hans algorithm for which 
the possible causes have already been mentioned. These results may yet represent another 
example of  abnormal CB2 expression in B-cell lymphoma cells. 
Targeting the CB2 receptor as a novel treatment modality in NHL en AML 
We have not been able to demonstrate a correlation between prognosis and CB2 
expression. However, there are indications that targeting this receptor might be useful 
as part of  therapeutic strategies. Expression of  CB2 is absent on normal human myeloid 
bone marrow cells, whereas certain types of  AML highly express this protein. Functional 
assays on myeloid cells showed that stimulation of  Cb2 either induces a neutrophilic 
differentiation block or abnormal migration in a ligand-dependent manner20. Within the 
cohort of  AML samples, the largest group of  patients is classifi ed as intermediate risk 
AML. In this group, an improved OS was detected for the active CB2 receptor using 
the N-terminal CB2 antibody (unpublished observation). It is however obvious that the 
exact role, including the prognostic value, of  CB2 expression on AML remains to be 
investigated. Future research may include analyzing a large cohort of  primary AMLs to 
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detect a potentially clinical impact on outcome and studying the impact on the survival 
of  AML cells in vitro and vivo using ligands to either stimulate of  block the CB2 receptor. 
 Cannabinoid ligands have been described to induce apoptosis in malignant 
cells of  immune origin including lymphomas and leukemia via the caspase and BID 
pathways16, 17,18 . It was demonstrated that human leukemia and lymphoma cell lines such 
as Jurkat cells and Molt-4 expressed CB2 receptors and were susceptible to apoptosis 
induced by cannabinoid ligands18. Further evidence of  CB2 mediated apoptosis was 
shown in murine tumors in which exposure to endocannabinoids such as THC (delta-9-
tetrahydrocannabinol) in vitro and in vivo led to a signifi cant reduction in cell viability and 
an increase in apoptosis19. In human leukemia and lymphoma cell lines (Jurkat, Molt-4, 
and Sup-T1) expressing CB2, apoptosis was induced, by THC, HU-210, anandamide, and 
the CB2-selective agonist JWH-015. This effect was mediated at least in part through the 
CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed 
the THC-induced apoptosis20. Culture of  primary acute lymphoblastic leukemia cells with 
THC in vitro reduced cell viability and induced apoptosis. In functional studies using 
lymphoma cell lines, a CB2 ligand anandamide analog R(+)-methanandamide (R(+)-
MA) induced cell death in mantle cell lymphoma (MCL) cells, which over expressed CB2 
receptors in vivo. Also, treatment with R(+)-MA caused a signifi cant reduction of  tumor 
size and mitotic index in mice xenografted with a human MCL21. These results suggest 
that therapies of  malignant lymphomas (over)expressing CB2 using cannabinoid receptor 
ligands may favorably impact the clinical outcome. 
142 | Chapter 7
REFERENCES
1. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stemcell 
mobilization. Curr Pharm Des. 2010; 16(35):3903-20.
2. Bouaboula, M, D. Dussossoy, and P. Casellas. 1999. Regulation of  peripheral cannabinoid receptor 
CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. 
J Biol Chem. 274:20397.
3. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, Zimmer 
A.A.Immunomodulation by cannabinoids is absent in mice defi cient for the cannabinoid CB(2) 
receptor. Eur J Pharmacol. 2000 May 19;396(2-3):141-9.
4. Carayon P, Marchand J, Dussossoy D, Derocq JM, Jbilo O, Bord A, Bouaboula M, Galiègue S, 
Mondière P, Pénarier G, Fur GL, Defrance T, Casellas P. Modulation and functional involvement of  
CB2 peripheral cannabinoid receptors during B-cell differentiation. Blood. 1998 Nov 15;92(10):3605-
15.
5. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, 
Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, 
Staudt LM, Connors JM, Armitage JO, Chan WC. Confi rmation of  the molecular classifi cation of  
diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004 Jan 
1;103(1):275-82. 
6. van Imhoff  GW, Boerma E-JG, van der Holt B, et al. Prognostic impact of  the germinal center-
associated proteins and chromosomal breakpoints in poor-risk DLBCL. J Clin Oncol, 2006; 24:4135-
42.
7. Sjo LD, Poulsen CB, Hansen M, et al. Profi ling of  diffuse large b-cell lymphoma by immunohistoche
mistry:identifi cation of  prognostic subgroups. Eur J Haematol, 2007; 79:501-7.
8. Muris JJF, Meijer CJLM, Vos W, et al. Immunohistochemical profi ling based on Bcl-2, CD10 and 
MUM1 expression improves risk stratifi cation in patients with primary nodal diffuse large B cell 
lymphoma. J. Pathology, 2006; 208:714-23.
9. Barrans S, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined 
with the International Prognostic Index improves patient risk stratifi cation in diffuse large B-cell 
lymphoma. Blood, 2002; 15:1136-43.
10. de Jong, D, Rosenwald A, Chanabhai M, et al. Immunohistochemical prognostic markers in diffuse 
large B-cell lymphoma: validation of  tissue microarray as a prerequisite for broad clinical applications-
-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol, 2007; 25:805-12.
11. Fu K, Weisenburger DD, Choi WW, et al. Addition of  rituximab to standard chemotherapy improves 
the survival of  both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of  
diffuse large B-cell lymphoma. J Clin Oncol, 2008; 26:4587-94.
12. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of  dose-adjusted EPOCH and rituximab 
in untreated diffuse large B-cell lymphoma with analysis of  germinal center and post-germinal center 
biomarkers. J Clin Oncol, 2008; 26:2717-24.
13. De Paepe P, Achten R, Verhoef  G, et al. Large cleaved immunoblastic lymphoma may represent two 
distinct clinicopathologic entities within the group of  diffuse large B-cell lymphomas. J Clin Oncol, 
2005; 28:7060-8.
Discussion | 143
14. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al. Prognostic impact of  immunohistochemically 
defi ned germinal center phenotype in diffuse large B-cell lymphoma patients treated with 
immunochemotherapy. Blood, 2007; 109:4930-5.
15. Natkunam Y, Lossos IS, Taidi B et al. Expression of  the human germinal center-  associated lymphoma 
(HGAL) protein, a new marker of  germinal center B-cell derivation. Blood, 2005; 105:3979-86.
16. Lombard C, Nagarkatti M, Nagarkatti PS. Targeting cannabinoid receptors to treat leukemia: role of  
cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced 
apoptosis of  Jurkat cells. Leuk Res. 2005 Aug;29(8):915-22. Epub 2005 Mar 2.
17. McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M Cannabidiol-induced 
apoptosis in human leukemia cells: A novel role of  cannabidiol in the regulation of  p22phox and 
Nox4 expression. Mol Pharmacol. 2006 Sep;70(3):897-908. Epub 2006 Jun 5.
18. McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti M. Targeting 
CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 2002 
Jul 15;100(2):627-34.
19. Zhu W, Friedman H, Klein TW. Delta9-tetrahydrocannabinol induces apoptosis in macrophages and 
lymphocytes: involvement of  Bcl-2 and caspase-1. J. Pharmacol Exp Ther. 1998 Aug;286(2):1103-9.
20. Jia W, Hegde VL, Singh NP, Sisco D, Grant S, Nagarkatti M, Nagarkatti PS. Delta9- tetrahydrocannabinol-
induced apoptosis in Jurkat leukemia T cells is regulated by translocation of  Bad to mitochondria. Mol 
Cancer Res. 2006 Aug;4(8):549-62.
21. Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, Christensson B, Flygare J, Sander 
B. Expression of  cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth 
inhibition by receptor activation. Int J Cancer. 2008 Sep 1;123(5):1025-33.

Summary | 145
Summary
Non-Hodgkin lymphomas (NHL) and acute myeloid leukemia’s (AML) are heterogeneous 
groups of  haematological malignancies with a large difference in clinical behavior and 
prognosis. 
 NHLs are malignancies which arise from cells of  the immune system as a result 
of  accumulating genetic aberrations and usually resulting in either B-cell or T-cell 
lymphomas. NHLs usually demonstrate characteristics of  their normal counterpart 
representing the various differentiation stages in the lymph nodes. The B-cell lymphomas 
are the largest group within the group of  NHLs. B-cell NHLs make up for approximately 
85% of  all lymphomas, with diffuse large B-cell lymphomas (DLBCLs) as the largest 
subtype. The most recent WHO classifi cation (2008) distinguishes about 50 different 
clinico-pathological entities. 
 The IPI is one of  the most powerful tools to separate NHL patients with a good 
from those with a poor prognosis. However, it is a clinical classifi cation system which in 
itself  is cannot fully encompass the heterogenic biological behavior of  this malignancy. 
Therefore, biological classifi cation systems have been developed in order to improve 
outcome prediction. For this purpose, DNA micro-array techniques are nowadays widely 
investigated.
 Using gene expression profi ling (GEP), two sub types of  DLBCL were identifi ed 
i.e. a germinal center B-cell (GCB) type with a relatively favorable prognosis and an 
ABC (activated B-cell) type with a relatively unfavorable prognosis. Since GEP is still 
diffi cult to implement in clinical practice, histological sub classifi cation systems using 
immunohistochemistry were designed, which could identify patients with a favorable 
GCB or a non-favorable ABC phenotype. The fi rst of  these systems used 3 antibodies 
(CD10, BCL6 and MUM1). The results regarding clinical outcome correlated surprisingly 
well with those using GEP of  the same tissue samples. However, these fi ndings could 
not always be confi rmed by other investigators, indicating the need for novel prognostic 
markers or improvement of  the technique. 
 This is also the case for AML which is also a heterogeneous disease, characterized 
by a large diversity of  morphologic, cytogenetic, immunophenotypic and molecular 
features. AML is the most common type of  acute leukemia in adults. Analogous to NHL, 
accumulating genetic aberrations lead to maturation and differentiation arrest at the 
various stages of  development resulting in accumulation of  immature cell types in the 
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bone marrow. The underlying correlation with developmental state is partly refl ected by 
the distinct AML subtypes with a different biological and clinical behavior in the latest 
WHO 2008 classifi cation. 
 Methods used to classify myeloid leukemias include morphology, cytochemistry, 
immunophenotyping, cytogenetic and molecular genetic studies. Immuno-
phenotyping separates the various AML entities having widely variable aberrant or 
unusual immunophenotypical characteristics. Additional genetic studies such as gene-
rearrangement analysis by RT-PCR or FISH and mutation detection by gene sequencing 
or allelic PCR may be performed in order to refi ne the classifi cation. This is especially 
important in AML, in which mutation analysis have revealed novel important diagnostic 
and prognostic subtypes. Examples of  mutations in AML which have diagnostic and 
prognostic implication are RAS, JAK2, PTPN11, NMP1, CEBPA, RUNX1, KIT and 
FLT3 and EVI. However, ongoing research is necessary to defi ne novel genes or their 
products to achieve more patient-tailored treatment modalities.
 Cannabinoid receptors are members of  the family of  seven trans membrane 
G-protein-coupled receptors (GPCR). In mice, using retroviral insertional mutagenesis, 
Cb2 was identifi ed as the target gene in the common virus integration site Evi11, 
indicating that Cb2 may act as a proto-oncogene in leukemogenesis. Up till now, two 
cannabinoid receptors have been identifi ed. The human central cannabinoid receptor 
(CB1) is mainly located in the central and peripheral nervous system, whereas the human 
peripheral cannabinoid receptor (CB2) is mainly found on cells of  the immune system. 
Many aspects of  the mechanisms of  CB2 activation and its downstream effects are still 
elusive. It has been reported that cannabinoid receptor ligands may interfere with the 
immune response having an anti-infl ammatory effect by inducing apoptosis, inhibition 
of  proliferation, suppression of  the production of  chemokines and cytokines and 
induction of  regulatory T-cells. They also enhance human B-cell growth at nanomolar 
concentrations and migration of  these cells. In myeloid cells, CB2 enhances migration 
and block of  neutrophilic differentiation. 
 The aim of  this thesis is to investigate the expression of  the Cb2 receptor and its 
potential as a novel diagnostic and/or prognostic marker in hematological malignancies. 
More specifi cally, we have investigated the expression of  the CB2 receptor in normal and 
malignant hematopoietic and immune tissues and its relation with clinical outcome with a 
focus on DLBCL. 
 In chapter 2 we have studied the CB2 expression in normal human bone marrow 
and primary AMLs. We have found that CB2 protein was not detectable on normal 
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myeloid precursors whereas CB2 protein was frequently expressed on AML blasts. In a 
ligand-dependent manner, the receptor either induced a neutrophilic differentiation block 
or conferred abnormal migration properties. 
 In chapter 3 we have found that distinct expression profi les are present on normal 
human B-cells in secondary follicles of  lymph nodes depending on the receptor activation 
status. Using the N-terminal specifi c anti CB2 antibody, we have found that GC-B-cells 
highly express the activated CB2 receptor, whereas using the inactive non-phosphorylated 
anti C-terminal CB2 antibody, the inactive CB2 receptors were mainly detected in areas 
outside the GCs e.g. in the mantle zones and marginal zones of  the secondary follicles. 
The major function of  the CB2 receptor as tested in a human malignant B-cell line 
was migration upon stimulation with the endocannabinoid 2-AG. This migration was 
signifi cantly augmented with co-stimulation using CD40 ligands.
 In chapter 4, we have described the CB2 protein expression in various NHL sub 
types. We have found that various B- and T-cell lymphoma express the active or inactive 
CB2 receptor. Remarkably, the presence or absence of  active CB2 receptors as detected 
by the N-terminal specifi c CB2 antibody, on normal B-cells does not (always) correspond 
with the expression in their malignant counterparts. This suggests that CB2 receptor 
expression may be aberrant in B-cell malignancies. This observation is further supported 
by the fact that in contrast to normal T-cells, frequent CB2 expression was present on 
T-NHL.
 In chapter 5, we have investigated the clinical impact of  known immuno-
histochemical classifi cation systems of  DLBCL in the GCB (germinal center B-cell) and 
non-GCB-cell (ABC-activated B-cell) subtype. We could not demonstrate an impact of  
this classifi cation system on outcome using 2 well defi ned randomized clinical trials in 
which patients received uniform (CHOP) treatment. Also variations in the algorithm 
used for this classifi cation did not infl uence clinical outcome. We hypothesize that this 
outcome is probably caused by non-uniform fi xation techniques in different laboratories. 
 In chapter 6, we have investigated the potential use of  CB2 expression as a 
prognostic factor using TMA and immunohistochemistry in a retrospective study, in which 
patients received an anthracyclin containing regimen. We have not found a correlation 
between the expression of  CB2 and the clinical outcome of  this receptor. However, in 
this study and in contrast to the results described in chapter 4, we have been able to 
demonstrate an improved clinical outcome in patients with the GCB phenotype according 
to the algorithm of  Hans et al. 
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Although we could not demonstrate a correlation between CB2 expression and prognosis 
in DLBCL, our results indicate that CB2 is probably aberrantly expressed on human 
B-and T-cell NHLs and AMLs. This aberrant expression is already being tested in various 
preclinical studies as a potential target in the quest for more patient-tailored therapies.
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Samenvatting
Non-Hodgkin lymfomen (NHL) en acute myeloide leukemieën (AML) kunnen worden 
beschouwd als groepen hematologische maligniteiten waarvan de afzonderlijke entiteiten 
onderling een grote klinische en prognostische verscheidenheid tonen. 
 Non-Hodgkin lymfomen hebben hun oorsprong in het immuun systeem. Hierbij 
leiden genetische aberraties tot het ontstaan van een B-cel of  T-cel lymfoom. Deze 
lymfomen kunnen als een maligne tegenhanger beschouwd worden van de verschillende 
stadia van de ontwikkeling van een naïeve lymfocyt tot een immuun competente cel in 
het lymfoide weefsel. De meest recente WHO classifi catie uit 2008 kent ongeveer 50 
verschillende lymfomen als een klinisch-pathologische entiteit. B-cel lymfomen vormen 
de grootste groep (85%) NHL. Op zijn beurt is het diffuus grootcellig B-cel lymfoom 
(DLBCL) de grootste entiteit binnen de groep van B-cel NHL. 
 De verschillende vormen van het NHL hebben een uiteenlopend klinisch beloop 
variërend van relatief  indolent tot zeer agressief. Grotendeels hiermee samenhangend 
varieert de prognose van relatief  goed tot zeer slecht. De IPI (International Prognostic 
Index) wordt beschouwd als de beste indicator bestaande uit klinische parameters die 
het onderscheid maakt tussen NHL met een relatief  goede dan wel een relatief  slechte 
prognose. De IPI is echter een klinisch classifi catie systeem dat onvoldoende rekening 
houdt met de onderliggende biologische diversiteit, terwijl deze zeker ook van invloed 
is op de prognose. Om deze reden worden ook classifi catie systemen ontwikkeld waarin 
biologische parameters zijn geïncorporeerd om het klinisch beloop beter te kunnen 
voorspellen en vervolgens het therapeutisch beleid hier beter op aan te passen. Een van 
de recent ontwikkelde technieken die hiervoor gebruikt kan worden, is het maken van 
genexpressie profi elen. Door gebruik te maken van deze genexpressie profi elen kunnen 
we twee DLBCL subtypen onderscheiden; de germinal-center B-cel (GCB) subtype met een 
relatief  goede prognose en de non-germinal-center B-cel (non-GCB), ook wel geduid als 
activated-B-cel (ABC) subtype met een relatief  slechte prognose. 
 Het maken van genexpressie profi elen is echter nog steeds niet goed in te passen 
in de klinische praktijk. Daarom worden ook praktisch beter toepasbare histologische/
immunohistochemische sub classifi catie systemen ontwikkeld. In een van de eerste 
immunohistochemische classifi catiesystemen werd gebruik gemaakt van slechts 3 
antilichamen (CD10, BCL6 en MUM1). De resultaten van dit classifi catie systeem blijkt 
voor wat betreft de klinische uitkomsten goed overeen te komen met de resultaten van de 
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genexpressie profi leringstechnieken. Deze bevindingen konden echter niet altijd worden 
bevestigd door andere onderzoekers zodat nieuwe prognostische merkers of  verbetering 
van deze immunohistochemische methoden noodzakelijk zijn.
 AML is de meest voorkomende acute leukemie bij ouderen. Min of  meer analoog 
aan NHL is hierbij door genetische aberraties sprake van een maturatie en differentiatie 
stop tijdens de verscheidene rijpingsstadia van de myeloide cel. Hierdoor treedt accumulatie 
op van de afwijkende onrijpe (leukemische) cellen in het beenmerg. De onderliggende 
samenhang met het ontwikkelingsstadium komt deels ook tot uiting in de verschillende 
AML subtypen in de WHO 2008 classifi catie. Naar analogie met NHL blijkt ook AML 
een zeer heterogene ziekte, waarbij de verschillende subtypen worden gekarakteriseerd 
door sterk uiteenlopende morfologische, cytogenetische, immunologische en moleculaire 
kenmerken. De heterogeniteit van het ziektebeeld blijkt ook uit het vaak voorkomen van 
aberrante of  ongewone immunofenotypische kenmerken binnen de AML subtypen. 
 Om AML te classifi ceren worden verschillende technieken gebruikt. Deze zijn 
cytomorfologische beoordeling, immunofenotypering en karyotypering. Om de initiële 
classifi catie te verfi jnen worden additionele moleculair biologische technieken gebruikt. 
Voorbeelden zijn RT-PCR, FISH, gene sequencing en allelische PCR analyse. Bij AML heeft 
het toepassen van deze technieken geleid tot nieuwe entiteiten op grond van genetische 
afwijkingen, Voorbeelden zijn: RAS, JAK2, PTPN11, NMP1, CEBPA, RUNX1, KIT, 
FLT3 en EVI. Deze genetische afwijkingen leiden tot verschillen in prognose.
 Cannabinoid receptoren behoren tot de familie van zeven transmembraan G-eiwit-
gekoppelde receptoren (GPCR). Cb2 werd in de muis geïdentifi ceerd als het doelwit in de 
common virus integration site Evi11 met de retrovirale insertie mutagenese techniek. Dit wijst 
op een mogelijke rol als een proto-oncogen in de leukemogenese. Er werden tot nu toe 
twee cannabinoid receptoren gevonden. De humane centrale cannabinoid receptor (CB1) 
is voornamelijk gelokaliseerd op cellen in het centrale en perifere zenuwstelsel, terwijl de 
humane perifere cannabinoide receptor (CB2) voornamelijk gevonden wordt op de cellen 
van het immuunsysteem. Veel van het mechanisme van CB2 activatie en de stroomafwaarts 
effecten hiervan in de cel is nog onbekend. Wel zijn effecten van activatie van de CB2 
receptor op het immuunsysteem beschreven. Deze zijn een ontstekingsremmend effect 
door het stimuleren van apoptose, remming van proliferatie, onderdrukking van de 
productie van chemokines en cytokines en stimuleren van de regulatoire T-cellen. Ook 
bevordert de stimulatie van CB2 receptor de groei en migratie van humane B-cellen. Bij 
myeloide cellen bevordert CB2 migratie van de cellen en wordt de neutrofi ele differentiatie 
geblokkeerd.
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In dit proefschrift worden de resultaten beschreven van het onderzoek naar de 
mogelijkheid om de expressie van het cannabinoid receptor type 2 (CB2) te gebruiken als 
nieuwe diagnostische en/of  prognostische merker bij NHL en AML. 
 In hoofdstuk 2 hebben we de CB2 expressie in myeloide cellen in normaal 
humaan beenmerg en in primaire AML onderzocht. Het CB2 eiwit was niet aantoonbaar 
op normale myeloïde voorloper cellen maar wel zeer frequent aantoonbaar op de AML 
blasten. Op een ligand afhankelijke manier induceert de receptor ofwel een blok in 
neutrofi ele differentiatie of  abnormale migratie eigenschappen. 
 In hoofdstuk 3 hebben we aangetoond dat expressie van de CB2 receptor op 
normale humane B-cellen in de lymfklier verschillend is. De mate van expressie lijkt 
te correleren met de activatie status van de receptor. Door gebruik te maken van een 
antilichaam gericht tegen het N-terminus van de CB2 receptor, hebben we aannemelijk 
gemaakt dat de B-cellen in het kiemcentrum de geactiveerde CB2 receptor tot expressie 
brengen. Door gebruik te maken van een antilichaam dat gericht was tegen de C-terminus 
van de CB2 receptor kon ook aannemelijk worden gemaakt dat de inactieve, niet-
gefosforyleerde receptor voornamelijk op B-cellen voor komt die liggen in de gebieden 
buiten het kiemcentrum, namelijk in de mantel- en marginale zone. In een maligne 
humane B (Raji)-cellijn bleek stimulatie van de CB2 receptor met de endocannabinoid 
2-AG migratie te induceren. Deze migratie werd bovendien versterkt door co-stimulatie 
met CD40 ligand. 
 In hoofdstuk 4 werd de CB2 expressie bij de verschillende NHL subtypen 
onderzocht. We vonden dat verschillende B- en T-cel lymfomen de actieve CB2 receptor 
tot expressie brachten terwijl hun normale fysiologische tegenhangers geen actieve CB2 
receptor tot expressie brachten. Deze bevindingen wijzen er op dat de CB2 receptor 
mogelijkerwijs aberrant tot expressie wordt gebracht in humane B-cel en T-cel lymfomen.
 In hoofdstuk 5 werd de betekenis van de immunohistologische classifi catie 
systeem volgens Hans et al. in de klinische praktijk onderzocht. Bij patiënten die in 2 
gerandomiseerde prospectieve klinische trials weren behandeld met CHOP konden wij 
met dit classifi catie systeem geen verschil in prognose aantonen tussen GCB en non-GCB 
subtype DLBCL. Evenzo heeft variëren van de afkappunten in het algoritme die werd 
gebruikt voor dit classifi catie systeem geen invloed op voorspelbaarheid van de prognose 
gehad. Een waarschijnlijke verklaring voor deze bevindingen is dat er niet-uniforme 
fi xatie technieken zijn gebruikt in verschillende laboratoria voor de vervaardiging van de 
paraffi ne blokjes waarvan de coupes op de glaasjes zijn gemaakt of  van waaruit de puncties 
voor TMA zijn genomen. Dit pleit voor verdere standaardisatie van deze technieken. 
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In hoofdstuk 6 werd de mogelijk klinisch voorspellende waarde van CB2 expressie d.m.v. 
immunohistochemische technieken onderzocht. Om de effecten van de verschillende 
fi xatie en weefsel bewerkingstechnieken te minimaliseren hebben we gebruik gemaakt 
van weefselmateriaal dat in één laboratorium was bewerkt. De patiënten van deze 
retrospectieve studie hebben een anthracycline bevattende chemotherapie ontvangen. Het 
al dan niet tot expressie komen van de CB2 receptor bleek niet voorspellend te zijn voor 
de prognose. Overigens bleek in deze studie de sub classifi catie in GCB-en non-GCB wel 
prognostisch van belang te zijn. 
 Wij konden geen correlatie aantonen tussen expressie van de CB2 receptor en de 
prognose bij NHL. We hebben wel aannemelijk gemaakt dat NHL en AML deze receptor 
aberrant tot expressie te brengen. Dit gegeven zou een aangrijpingspunt kunnen vormen 
voor de verdere ontwikkeling van op maat gemaakte behandelingen van deze maligniteiten 
en wordt momenteel in preklinische studies getest.
List of  abbreviations | 153
List of  abbreviations
Ab Antibody
ABC Activated B-cell
ALCL Anaplastic large cell lymphoma
AML Acute myeloid leukemia
CB1 Cannabinoid receptor type / central cannabinoid receptor
CB2 Cannabinoid receptor type 2 /  peripheral cannabinoid receptor
CCR7 chemokine-receptor-7
CD Cluster of  differentiation
CHO Chinese hamster ovary
CR Complete response 
CRE Cyclic AMP responsive element
cVIS Common virus integration site
DFS Disease free survival
DLBCL Diffuse large B-cell lymphoma
EFS Event free survival
EVI Ecotropic virus integration site
FL Follicular lymphoma
GC Germinal center
GCB Germinal center B-cell
GEP Gene expression profi ling
GPCR G-protein coupled receptor
G-CSF Granulocyte colony stimulating factor
GM-CSF Granulocyte macrophage colony stimulating factor
GWAS Genome wide association study
HOVON Hemato-oncologie voor  volwassenen Nederland
IHC Immunohistochemistry
Il Interleukin
IPI International prognostic index
LBL Lymphoblastic B- cell lymphoma
MCL Mantel cell lymphoma
MGZL Marginal zone lymphoma
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NHL Non-Hodgkin’s lymphoma
OS Overall survival
PFS Progression free survival
PTCL Peripheral T-cell lymphoma
PTX Pertussis toxin
R Rituximab
RIM Retroviral insertional mutagenesis
THC Delta-9- tetrahydrocannabinol
TMA Tissue micro array
TNF Tumor necrosis factor
T-NHL T-cell non-Hodgkin’s lymphoma
WHO World health organization
WS Whole section
2-AG 2-arachidonoyl glycerol
7-TM 7-trans membrane
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Nazik Rayman werd geboren op 27 augustus 1975 te Sarıkaya, Turkije. In het kader van 
gezinshereniging kwam zij in 1983 naar Nederland. Haar eerste woorden Nederlands 
heeft zij geleerd op de Hietweide school in Twello. In 1994 behaalde zij haar Gymnasium 
diploma aan het Alexander Hegius Scholengemeenschap te Deventer. In hetzelfde 
jaar begon zij met haar studie Geneeskunde aan de Erasmus Universiteit Rotterdam. 
In 2000 behaalde zij haar artsexamen en ving haar promotie onderzoek aan op de 
afdeling Hematologie (toenmalig hoofd: Prof.dr. B. Löwenberg, huidig hoofd: Prof.dr. P. 
Sonneveld) onder supervisie van Prof.dr. H.R. Delwel. Haar opleiding tot internist volgde 
zij in het Erasmus MC (opleiders Prof. dr. H.A.P Pols en Prof.dr. J.C.L.M van Saase) en 
het Albert Schweitzer Ziekenhuis (opleiders dr. A. van Vliet en dr. E.F.H. van Bommel). 
Op 1 september 2009 begon zij met de opleiding in haar aandachtsgebied Hematologie 
in het Erasmus MC (opleiders Prof.dr. B. Löwenberg en Prof.dr. P. Sonneveld). Op 1 
september 2011 heeft zij zich geregistreerd als internist-hematoloog. Nazik is getrouwd 
met Hayrettin Durdu. Samen hebben zij een zoon Kerim en een dochter Irem.
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Eindelijk is het “boekje” dan af. Het heeft lang geduurd, maar de aanhouder wint. Zonder 
de hulp en vooral de steun van velen was het er niet van gekomen. Ik zal vast vergeten 
enkele mensen te noemen, waarvoor bij voorbaat mijn excuses.
 Ik heb zelfs het voorrecht om 2 promotoren te mogen noemen die mij hebben 
begeleid tijdens mijn promotietraject, een klinische wetenschapper en een hardcore basic 
scientist. 
 Prof.dr.P. Sonneveld, beste Pieter. Hier is het boekje dan. Het was niet gelukt 
zonder jouw onvoorwaardelijke steun en vertrouwen. Het heeft lang geduurd, maar je 
hebt mij nooit het gevoel gegeven dat je niet (meer) in mij geloofde. Op de momenten dat 
het er echt toe deed was je er. Ik denk dat het Erasmus MC trots mag zijn op zijn nieuwe 
afdelingshoofd Hematologie. Dank ook voor de mogelijkheid die je mij hebt geboden om 
opgeleid te worden tot internist-hematoloog.
 Prof.dr. R. Delwel, beste Ruud, je hebt me vanaf  het begin geboeid met je 
enthousiasme voor de wetenschap. Terecht ben jij een van de wetenschappelijke 
steunpilaren van de afdeling, maar wat ik bijzonder vind aan jou, is dat je vooral ook een 
sociaal mens bent. Je hebt altijd een luisterend oor gehad, en ik kon heel veel bespreken 
met jou ook zaken die niets met de wetenschap te maken hadden. Toen ik zware en 
moeilijke tijden doormaakte met mijn zieke vader heb je me volop gesteund. Ik zal dit 
nooit vergeten. Ik bedank je uit het diepst van mijn hart voor alle steun en input tijdens 
mijn promotie periode en tijdens mijn opleiding tot internist. 
 Prof.dr. B. Lowenberg, beste Bob, ik wil je bedanken voor de belangrijke input 
die je hebt geleverd en natuurlijk ook voor de mogelijkheid die je me hebt geboden om 
op jouw afdeling onderzoek te doen en opgeleid te worden tot internist-hematoloog. Je 
oprechte interesse voor de thuissituatie gaf  me telkens een boost om verder te gaan. Ik 
wens je al het goede in je nieuwe carrière na jouw emeritaat.
 Prof.dr. A. Hagenbeek, Prof.dr. H. Hooijkaas en Dr. D. de Jong wil ik danken 
voor het plaatsnemen in de kleine commissie en voor het kritisch beoordelen van het 
proefschrift in zeer korte tijd. Daphne, dit proefschrift was niet in deze vorm tot stand 
gekomen zonder jouw belangrijke bijdrage, zowel voor het ter beschikking stellen van de 
tissue micro arrays als jouw kritische commentaar op de onderzoeksvoorstellen. 
 Dr. K.H. Lam, beste King. En opeens was je gebombardeerd tot co-promotor! Je 
kwam pas echt in beeld tijdens het tweede jaar van mijn onderzoek, maar algauw bleek je 
onmisbaar. Je hebt mij altijd op een positieve manier begeleid en gestimuleerd. Je stuurde 
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me zelfs sms’jes en e-mails (waar blijft de laatste versie?) zelfs midden in de nacht wat 
resulteerde in klusjes klaren midden in de nacht. Je hebt altijd rekening gehouden met 
mijn gezinsleven voor het maken van afspraken. Deze vonden dan ook plaats in de late 
uurtjes, maar het was (bijna!) altijd erg gezellig. Ik moet bekennen dat je een hele geduldige 
man bent, en dat voor een Antilliaan! Je bent een enthousiaste, stimulerende en leergierige 
man. Wellicht kan je later nog andere promovendi begeleiden, daar je mij in ieder geval 
overleefd hebt! Ik bedank jou heel hartelijk voor alle steun, begeleiding en de gezellige 
momenten. Het zal je misschien verbazen, maar ik ga dit alles zeker missen. 
 Dr. L.M. Budel wil ik bedanken voor het meeschrijven van de onderzoeksvoorstellen 
die de basis hebben gevormd voor dit onderzoek. Dr. A. H. Mulder, beste Andries, dank 
voor het bewaren en ter beschikking stellen van de blanco coupes en je gastvrijheid op de 
afdeling Pathologie in het Rijnstate Ziekenhuis.
 Prof.dr. J.L.C.M. van Saase, beste Jan, ik vind het een eer dat je zitting wilt 
nemen in de grote commissie. Ik weet niet of  je erin geloofde dat ook ik uiteindelijk zou 
promoveren (de voorlaatste van de 3 van de afdeling Hematologie die bij de algemene 
interne in opleiding waren), maar hier is dan het bewijs. Ik wil je hartelijk danken voor je 
steun en begeleiding tijdens mijn opleiding tot internist.
 De overige leden van de grote commissie, dr. P. Valk en dr. E. Lugtenburg wil ik 
ook hartelijk bedanken voor hun deelname. Peter, jij hebt met basaal wetenschappelijk 
onderzoek de perifere cannabinoid receptor in beeld gebracht. Ik als clinicus heb dit 
verder met veel plezier mogen uitspitten. Elly, bedankt voor de steun en feedback die je mij 
de afgelopen maanden hebt gegeven tijdens mijn opleiding tot hematoloog.
 Dr. B. van der Holt, beste Ronnie, dank voor al je statistische inspanningen als ik 
weer eens de zoveelste report nodig had van de HOVON studies. Het mag duidelijk zijn 
dat het zonder jou mij niet gelukt was te promoveren. 
 De groep van Ruud Delwel (het is zo lang geleden dat het mij zelfs niet lukt 
om iedereen apart op te noemen) wil ik bedanken voor hun collegialiteit en de gezellige 
momenten, ondanks het feit dat ik vaker op de afdeling Pathologie te vinden was. Meri, 
je was een zeer enthousiaste collega die mede onderzoek deed naar de cannabis receptor 
en je hebt mij menigmaal geholpen met de functionele studies. Muchas gracias. Ik hoop dat 
je in alle opzichten succesvol bent in het buitenland. Sahar, mijn lieve en gepassioneerde 
collega, dank voor jouw collegialiteit en vriendschap tijdens het onderzoek. Ik hoop dat 
alles goed gaat met jou en je familie.
 Buiten de Delwel groep wil ik van de afdeling Hematologie prof.dr. Ivo Touw, 
dr. Marieke von Lindern, Ans Mannens, Stefan en Karola van Rooyen bedanken voor 
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hun hulp en bijdrage. Het transplantatie laboratorium (Peter, Hans, Pia, Hannie, Arie en 
Lianne) wil ik vooral bedanken voor hun hulp bij het opzoeken van de AML monsters en 
het leveren van de humane antilichamen voor de FACS analyses. Ik vond het erg leuk om 
jullie af  en toe op de afdeling te zien bij de autologe stamceltransplantaties. 
 Ineke en de andere medewerkers van de 13e verdieping die ik niet genoemd, 
wil ik verder bedanken voor de prettige samenwerking. Ook wil ik alle collega’s van de 
klinische afdeling Hematologie hartelijk danken voor hun collegialiteit en gezelligheid in 
het afgelopen 2 jaar.
 Ik wil niet vergeten alle analisten van het diagnostisch laboratorium van de afdeling 
Pathologie te noemen. Frieda, Monique, Jeanine, Pieter en Marcel, bedankt voor jullie 
hulp en adviezen bij de immunohistochemische kleuringen. Jullie hebben mij nooit het 
gevoel gegeven dat ik een passagiere gast was op het laboratorium. Ik was daar meer 
een vaste stamgast die altijd welkom was. Nel en Ronald, bedankt voor jullie hulp bij het 
maken van de histologische coupes. Johan, eindelijk heb je je microscoop terug. Bedankt 
voor het geduld. Prof. dr. J.W. Oosterhuis wil ik bedanken voor de mogelijkheid om op de 
afdeling Pathologie onderzoek te mogen doen.
 Alle ex-collega’s van het Albert Schweitzer ziekenhuis en de opleiders (dr. Adrie 
van Vliet, dr. Eric van Bommel, assistenten interne geneeskunde en cardiologie) wil ik 
bij deze ook bedanken voor de leerzame en gezellige periode tijdens mijn opleiding tot 
internist.
 Ook wil ik van de afdeling Interne Geneeskunde van het Erasmus MC, Paula 
van Biezen, dr. Paul van Daele, dr. Jan van Laar en natuurlijk prof.dr. Martin van Hagen 
bedanken voor hun interesse en toewijding om mij de beginselen van het vak Interne 
Geneeskunde bij te brengen. Ik denk nog met veel plezier en weemoed terug aan jullie 
allen.
 En dan nu mijn beide paranimfen: Emine, lang geleden zijn wij samen begonnen 
met het promotie onderzoek, ik heb jou toen beloofd dat jij mijn paranimf  zou worden. 
Ik bedank jou voor je waardevolle vriendschap tijdens de studie geneeskunde en ook in de 
periode erna. Ik hoop dat jij je ambities als stafl id van de afdeling Oogheelkunde verder 
kunt vervullen. Behiye, mijn lieve vriendin, niet alleen zijn wij al heel lang vriendinnen 
maar ook onze Kayseriaanse mannen zijn vrienden geworden. Ik verheug me op vele 
leuke en gezellige momenten samen met onze gezinnen. Emine en Behiye, dank voor 
jullie tomeloze inzet om mijn promotie tot een gedenkvolle dag te maken.
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Mijn andere vrienden wil ik natuurlijk niet vergeten: Caner en Shakib, jullie hebben een 
bijzondere plek in mijn hart. Caner, jij wordt vast een hele goede psychiater, het is jou 
op het lijf  geschreven. Shakib, zorg goed voor Sevilay, zij is denk ik het beste wat jou is 
overkomen. Aysel, jij bent een bijzonder persoon, ik hoop dat je je oprechtheid nooit zult 
verliezen. Dit geldt eveneens voor Yavuz, het was erg prettig om met je samen gewerkt 
te hebben. Nu jij nog over een aantal dagen!! Nuray en Bilge, hoewel we elkaar niet vaak 
meer zien, blijven jullie in mijn vaste vriendenkring. Dank voor de gezellige etentjes en de 
humor. En dan natuurlijk niet te vergeten, mijn lieve vriendin Serpil. Jij hebt altijd voor 
mij klaargestaan in voor-en tegenspoed. Ik zal nooit jouw steun nooit vergeten. Jij hebt 
een gouden hart dat je graag deelt met anderen. Ik dank je dat jij mij waardig vindt om 
te delen. Hatice en Suleyman, jullie zijn onmisbare vrienden voor ons. Wanneer gaan we 
weer naar Zeeland? Matieu, Consuelo, Menno, Andrea en Vernon, jullie zijn niet alleen 
vrienden van mijn man, maar ook mijn onmisbare vrienden. Ik ben blij dat ik jullie heb 
leren kennen. Mijn basis school vriendin Vera, ook jou zie ik niet vaak, maar ik denk wel 
vaak aan jou. Mede dankzij jou ben ik zover gekomen. Juffrouw Irma Koers, mijn eerste 
woorden Nederlands heb ik van jou geleerd. Je bent altijd een groot voorbeeld geweest 
voor mij. 
 Natuurlijk heb ik dit alles niet kunnen bereiken zonder de hulp van mijn familie. 
Annecigim, seni cok seviyorum. Babamin yoklugunu hafi fl ettin hayatimizda. Rabbim sana 
saglikli ve uzun omur versin. Babam belki hissedip benimle gurur duyuyordur. Abi ve 
yengecigim, bana her zaman destek verdiniz, hakkinizi zor odeyecegim. Fadime ve Gamze 
ablam, ve eniştelerim sizinde yardimlariniz ve desteginiz icin cok tesekkur ederim. Sevgili 
Nusret kardesim ve esi Ozlem, bana en yakin sizlersiniz. Kardesim, senin o temiz yuregin 
hic bir zaman kararmasin, Ozlemle ve gelecek ufaklikla aydin bir gelecege yuruyeceksiniz. 
Belki ufaklik bana benzer! Sevgili kardesim Guli ve esin Asgar, hayatinizdaki attiginiz 
her adimda basari, huzur ve saglik dilerim. Sizde yakinda evlenecek ve yuva kuracaksiniz. 
Unutmayin, yaninizda ben varim! Omer, Serif, Semih, Mustafa, Ferzi, Yasin, Semra ve 
Alperen, halaniz/teyzeniz sizleri cok seviyor. Hayatinizda basarili ve azimli olmanizi 
dilerim.
 Van mijn schoonfamilie wil ik allereerst mijn schoonzus Marit en mijn zwager 
Keramettin bedanken. Marit, jij bent niet alleen een schoonzus maar ook een vriendin 
voor mij. Wat er ook gebeurt, ik kan altijd bij jou terecht. Dit geldt ook voor mijn lieve 
zwager Keramettin, abi desteginiz ve yardimlariniz icin cok tesekkur ederim. Ik kan mij 
geen betere schoonfamilie wensen. Ik hoop dat we samen nog mooie dagen gaan beleven 
in onze huizen in Kayseri. Ayse annem, Hasan babam, hersey icin cok tesekkur. Rabbim 
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sizlere agiz tadi ve uzun omur versin. Fatma, Funda ve Sadullah, bana ve aileme sonsuz 
desteginiz icin cok tesekkur ederim. Funda, anne olacaksin, welcome to the club!! En dan 
mijn andere neefjes en nichtjes, Emre, Maside, Sueda, Zahra, Leyli, tante houdt heel veel 
van jullie! 
 En dan mijn woorden voor mijn lieve echtgenoot, Hayrettin. Het valt niet mee om 
een dankwoord voor jou te schrijven, daar mijn gevoelens voor jou zo diep zijn dat het 
voor mij te emotioneel is om alles op papier te zetten. Jij hebt mij altijd gestimuleerd en 
gesteund om het maximale uit mijzelf  te halen. Zonder jouw steun zou alles te zwaar voor 
mij zijn geweest. Dank liefste. Ik hoop dat wij samen onze kinderen een mooie toekomst 
kunnen bieden. 
 Mijn lieve kinderen Kerim en Irem, later als jullie kunnen lezen en Turks hebben 
geleerd, zullen jullie lezen dat mama heel veel van jullie houdt. Benim dunyadaki 
meleklerimsiniz. 
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Color fi gures
CHAPTER 3
Figure 2 | CB2 expression in 
primary follicles of  the human 
spleen. CB2 expression is 
demonstrated using the C-terminal 
(A,*5; B *20) and the N-terminal 
(C, *5; D, *20) anti-CB2 antibodies 
respectively. Specifi city of  the 
C-terminal anti-CB2 antibody was 
confi rmed by pre-incubation with 
a specifi c C-terminal peptide (E; 
5*). Staining with only the 
secondary antibody (F; 5*) served 
as a negative control. P=primary 
follicle; red staining=C-or 
N-terminal CB2 antibody staining; 
blue staining=counterstaining 
with haematoxylin. See page 59
 
Figure 6 | CD40 and CB2 expression in Raji cell line. Intra cellular CB2 protein in permeabilised 
cells (C) was analysed using the N-terminal specifi c anti-CB2 receptor antibody. The green dots 
represent CB2 protein in the cytoplasm; blue counter stain with diamino-2-phenylindole refl ects the 
nuclei of  Raji cells. See page 64.. 
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Figure 3 | Single immunohistochemical analysis in primary and secondary follicles of  the human 
lymph node. C-terminal anti-CB2 antibody staining pattern is depicted in fi gures (A; 1.25*), (B; 
10*) and (C; 20*). N-terminal anti-CB2 antibody staining pattern is shown in fi gures (D; 1.25*), 
(E; 10*) and ((F;20*, insert *40). P= primary follicle; s= secondary follicle; MZ=mantle zone; 
MGZ=marginal zone; GC=germinal centre. Black rectangles represent magnifi cations of  areas 
of  interest. Red staining=C-or N-terminal CB2 staining; blue staining=counterstaining with 
haematoxylin. See page 60.
164 | 
Color fi gures | 165
166 | 
Figure 4 |CB2 coexpression analysis in normal human lymph nodes. Co expression was analysed in 
primary and secondary follicles using the C-terminal anti-CB2 antibody with the pan B-cell marker 
CD79a (A; 10*) or with IgD (B; 20*). Using the N-terminal anti-CB2 antibody, co expression 
of  CD79a expressing cells (C; 10* and 40*), or IgD (D; 10*) expressing cells was also analysed. 
Detailed co expression analysis of  CD79a positive GC cells using the C-terminal anti-CB2 antibody 
is shown in fi gure (E; 10*). Open and fi lled arrows indicate coexpression; red arrows inidcate lack 
of  coexpression. Red staining= C-or N-terminal CB2; blue staining= CD79a (A,C, and E) or IgD 
(B and D); purple staining=coexpression. The fi lled rectangle represents the magnifi cation of  the 
area of  interest. P=primary follicle. See page 62.
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Figure 5 | Coexpression of  CD40 and Ki67 positive GC cells. Coexpression of  CD40 and Ki67 
positive cells in the GCs of  secondary follicles of  lymph nodes using the N-terminal anti-CB2 
antibody (A; 10 and 20* respectively; and B; 20 and 40* respectively). The C-terminal anti-CB2 
antibody was used to determine co expression of  Ki-67 positive GC cells (C; 20 and 40*respectively). 
Open rectangles represent magnifi cations of  areas of  interest. Costaining is indicated by purple 
membrane staining of  CB2 and CD40 (A) or red membrane staining (N-terminal CB2) with blue 
nuclear staining (Ki-67; B). Cells are either highly red (membrane/cytoplasmatic) or blue (nuclear) 
stained when costaining is absent (C). See page 63.
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CHAPTER 4
Figure 1 | CB2/CD3 dual staining of  normal reactive lymph nodes. Dual staining procedures 
using the C-terminal (panel A, C and E) or N-terminal (panel B, D and F) anti-CB2 antibodies (red 
staining) combined with the pan-T-cell marker CD3 (all panels) (blue staining) on normal lymph 
node sections. Note the almost complete separation of  red and blue staining areas. See text for 
further discussion. The following areas in the lymph node are indicated: GC; germinal centre, MZ: 
mantle zone. MGZ: marginal zone, P: para-cortical (T-cell) area. Original object lens magnifi cations: 
A: 1,25x, B: 2.5x, C and D: 10x, E and F: 40x. See page 78.
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Figure 2 | CB2/CD23dual staining of  normal reactive lymph nodes. Dual staining of  secondary 
follicles of  human normal reactive lymph nodes using the C-terminal (A and B) or N-terminal (C 
and D) specifi c anti-CB2 antibodies (red staining) with CD23 (blue staining). Note the reticular 
blue-purple staining pattern in the germinal centre (C and D). Co-staining was absent in the GC 
B-cells (A and B). The following areas in the lymph node are indicated: GC; germinal centre, MZ: 
mantle zone. MGZ: marginal zone, P: para-cortical (T-cell) area. Original object lens magnifi cations: 
A and C: 10x, B and D: 20x. Panels A and B were taken form different germinal centres for technical 
reasons. See page 80.
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Figure 3 | CB2 expression in malignant lymphoma’s. Whole sections of  malignant lymphomas 
were stained with C- and N-terminal CB2 antibodies respectively (brown staining). Representative 
cases showing positive staining with both antibodies including negative controls are shown: A-C: 
T-cell NHL; D-F: FL; G-I: DLBCL; J-L: MCL. Original object lens magnifi cation: 40x (inserts,20x). 
See page 82.
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CHAPTER 6
Figure 4 | CB2 expression in the germinal center B cell (GCB) subtype. A and B : CB2 negative 
case. C and D: CB2 positive case. Original object lens magnifi cations are 10× and 40× respectively. 
See page 128.
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